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ABSTRACT 
Alzheimer’s disease (AD) is a complex neurodegenerative disease determined 
by the combination of environmental and genetic factors. The prevalence of the 
disease is rapidly increasing with the aging of the population in the Western world. 
The main genetic contributors to the disease are still unclear and no cure is available 
yet. The complete picture of the molecular pathologic mechanisms involved in the 
disease are also not resolved yet. The current hypothesis is that the disease is caused 
by accumulation of a toxic fragment of amyloid precursor protein (APP) called Aβ in 
the neurons. This accumulation causes synaptic dysfunction and neuronal death. 
Our study aims at investigating the role of TrkB in modulating APP 
metabolism. TrkB is a receptor expressed on neurons and important in synaptic 
function, neuronal survival and long-term potentiation. This receptor has a functional 
relevance in AD and a genetic relevance since some studies associated single 
nucleotide polymorphisms on this gene to AD. We hypothesized that TrkB isoforms 
can affect APP metabolism in different ways and we tested this hypothesis in 
different human cell lines.  
We found that TrkB isoforms can alter APP glycosylation and processing and 
that the TrkB isoforms can interact with each other and alter their effect on APP. We 
also showed for the first time that TrkB SHC, one of the TrkB truncated isoforms, 
regulates the full-length isoform differently from TrkB T.   
Our work demonstrates the potential importance of TrkB in AD pathogenesis 
and lays ground for designing better AD therapies based on the natural TrkB ligand 
BDNF (Brain Derived Neurotrophic Factor).   
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1. CHAPTER 1: INTRODUCTION 
 
Alzheimer’s disease (AD) is a complex neurodegenerative disease determined 
by the combination of environmental and genetic factors. The prevalence of the 
disease is rapidly increasing with the aging of the population in the Western world. 
The environmental factors that contribute to the incidence of this disease are common 
to pathologies: age, lifestyle components, such as diet and exercise regime (Maslow, 
2010). These factors generally affect the health state of an individual and are not 
surprisingly related to AD as well. Education levels are also important in determining 
susceptibility to this disease (Maslow, 2010) suggesting that brain function depends 
on more than just a healthy body state. Recommendations on healthier life styles 
might be useful to prevent the occurrence of the disease at earlier age. Nevertheless 
the main genetic contributors to the disease are still unclear and no cure is available 
yet. The complete picture of the molecular pathologic mechanisms involved in the 
disease are also not resolved yet. The current hypothesis is that the disease is caused 
by accumulation of a toxic fragment of amyloid precursor protein (APP) called Aβ in 
the neurons. This accumulation causes synaptic dysfunction and neuronal death. 
Current studies are aimed at gaining better understanding of AD. The focuses 
of AD research are:  
1. The investigation of genetic factors associated with the disease (genetic 
association studies, genome wide association studies, family based studies).  
 - 2 - 
2. The identification of molecular interactors and modulators of amyloid 
precursor protein involved in synaptic function and neuronal metabolism.  
3. The identification of markers for early detection of AD and of appropriate 
therapeutic targets.  
Obviously all these aspects are interrelated and important.  
Our study aims at investigating the role of TrkB in modulating APP 
metabolism. TrkB is a receptor expressed on neurons and important in synaptic 
function, neuronal survival and long-term potentiation. This receptor has a functional 
relevance in AD and a genetic relevance since some studies associated single 
nucleotide polymorphisms on this gene to AD.  
The introduction that follows establishes the rationale for our study and 
provides an overview of the current knowledge on TrkB receptor function in relation 
to APP.    
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1.1 NTRK2 and Alzheimer’s Disease 
 
1.1.1 Genetic Association of NTRK2 with Alzheimer’s Disease 
 
The major risk factor for late onset AD is age while the respective 
contributions of environmental and genetic factors remain elusive (Maslow, 2010). 
Studies on twins have suggested a greater influence of genotype rather than 
environmental factors for the development of the AD (Pedersen et al., 2004; Gatz et 
al., 2006). Despite this, the majority of the risk-associated genes remain to be 
confirmed (Bertram and Tanzi, 2008). To date, the only genetic factor that has been 
consistently implicated with increased AD risk is the APOE-ε4 allele (Lehmann et al., 
2001; Bertram and Tanzi, 2008). 
In an attempt to identify genes associated with AD many researchers are 
conducting case-control studies that compare the genotypes of AD subjects with those 
of age-matched controls. Comparisons might regard polymorphisms and alleles in 
specific genes or the whole genome (Genome-Wide Association Studies) to assess 
association of genes with the diseased phenotype (Bertram and Tanzi, 2008). These 
studies often lead to contrasting findings regarding the same gene or significant 
associations that are difficult to replicate (Lehmann et al., 2001; Bertram et al., 
2007a). Defining association of a gene with AD is difficult because: each genetic 
study is based on samples of subjects that can be limited in size and stratification. 
Moreover, environmental factors are still an important component in AD and 
dissecting the interaction between genes and environment is particularly challenging. 
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Finally, some genetic risk factors might be detectable by genetic association studies 
only when present in combination with another gene. Also they can be in linkage 
disequilibrium with other possible genetic risk factors thus complicating the 
repeatability of case-control studies (Lehmann et al., 2001). Therefore meta-analysis 
studies that utilize data pooled from each individual case-control study prove useful 
in defining or negating associations in a manner more relevant to the general 
population (Bertram et al., 2007b; Bertram et al., 2007a).        
Genetic association studies indicate that the region 9q22 on the long arm of 
chromosome 9 shows a “suggestive association” with AD (Blacker et al., 2003). 
Some studies show even a stronger association when subsets of the population studied 
are removed from the analysis (Kehoe et al., 1999; Pericak-Vance et al., 2000; Myers 
et al., 2002) and when heterogeneity in the population is accounted for (Blacker et al., 
2003). A study on the National Institute of Aging Late Onset families found two 
polymorphisms significantly associated with AD. The first, rs1143025 is located on 
9p22.3 and is in an intronic region of a zing finger transcription factor ZDHHC21. 
The second, rs720974, is not associated with a gene and is found on the short arm of 
chromosome 9 therefore outside of our locus of interest (Lee et al., 2008b).  
A genome-wide study involving more subjects, found again a suggestive 
evidence for association of the locus 9q22 with AD (Hamshere et al., 2007). The 
same 9q22 locus has been significantly associated with AD (Perry et al., 2007) even 
when taking into account the linkage that is dependent on the gene UBQL1, which 
has been significantly and repeatedly associated with AD (Chuo et al.; Bertram et al., 
2005; Kamboh et al., 2006; Slifer et al., 2006). In this genomic region, there is 
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evidence for at least one more significantly associated locus. A possible candidate to 
explain the additional association is NTRK2 (localized at approximately 87.3 CM). 
NTRK2 encodes the tyrosine kinase receptor TrkB that is the Brain Derived 
Neurotrophic Factor (BNDF) receptor and is important for neuronal differentiation 
and function. The receptor is present in humans in at least three splicing isoforms 
(Ferrer et al., 1999; Stoilov et al., 2002; Hartmann et al., 2004; Webster et al., 2006).  
Based on the previous results that SNPs on NTRK2 display a trend of 
association with late onset AD (p=0.06) (Perry et al., 2007), Chen et al. systematically 
analyzed SNPs within the NTRK2 candidate gene. The purpose was to narrow down 
the chromosome locus that is genetically associated with AD (Chen et al., 2008). The 
authors used as a sample population a group of 796 individuals belonging to 203 of 
the NIMH-ADGI families (National Institute of Mental Health-Alzheimer’s Disease 
Genetics Initiative). Chen et al. found a significant association of some SNPs in the 
NTRK2 gene even when correction for ApoE-ε4 and gender was applied. Also these 
SNPs did not seem to be in linkage disequilibrium with a causative gene. It must be 
noted that 5 families which were not Caucasian, like the remaining samples, had to be 
included in the analysis to increase sample numbers, even if excluding these from the 
analysis did not significantly alter the results (Chen et al., 2008). This would suggest 
that ethnic background does not affect the frequency of the polymorphisms. No single 
SNP was found to be significantly associated with the disease but significance was 
achieved when the SNPs were grouped together with adjacent ones. When SNPs 
rs1624327 (SNP 4) and rs1443445 (SNP 5) were clustered they showed association 
(p=0.012) with AD. The same was true for SNPs rs1443445 (SNP 5) and rs3780645 
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(SNP 6) (p=0.038). Stronger association was found when clustering SNPs 4,5 and 6 
(p=0.009) and marginal association was found for the cluster 5,6 and 7 (rs6559840, 
p=0.045)(Chen et al., 2008). The significant association observed could be explained 
by the position of the analyzed SNPs in sequences potentially important for splicing 
regulation. In particular, SNP 4 is located close to exonic splicing enhancers (ESE) 
but SNPs 5 and 6 are located several thousands of base pairs from any splicing site. 
SNP 5, though, is located in a CpG island, generally associated with gene 
transcription regulation. An alternative explanation is that these SNPs are in linkage 
disequilibrium with other SNPs that are found in proximal intronic regions and that 
might be involved in splicing regulation (Chen et al., 2008). For example SNP 6 was 
found to be in linkage disequilibrium with a SNP, rs2289658, located in a sequence 6 
bp distal from the junction of intron 19 and exon 20 (Chen et al., 2008). Exon 20 is 
the first encoding the tyrosine kinase intracellular domain in the TrkB FL transcript. 
The SNPs analyzed are mainly found in intronic regions, suggesting that more work 
is necessary to identify the role of TrkB isoforms, generated by alternative splicing, in 
AD. In particular, the relative abundance of the transcripts could be compared in AD 
patients and control. Splicing regulation of NTRK2 might be important in the 
pathology of AD. The work of Chen et al. suggests that the SNPs on NTRK2 should 
be tested for association with AD by haplotypes since they tend to segregate together 
and show significant association when tested that way. A stronger association of 
individual SNPs in NTRK2 with LOAD might be dependent on the sample 
population. In fact a non-haplotype study has found significant association between 
SNP rs2289656 in NTRK2 and LOAD (Cozza et al., 2008). This SNP is located at the 
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intron 17 exon 16 junction. Interestingly, exon 16 encodes for the terminal part of the 
TrkB truncated isoform and is only present in that isoform. This study adds to the 
evidence suggesting the importance of alternative splicing regulation of TrkB 
isoforms in the pathogenesis of AD.  
Other studies attempting to establish a correlation between SNPs in NTRK2 
and AD have investigated SNPs in other regions of the gene. SNP rs1212171 in the 5’ 
UTR of the gene, was not found to be significantly associated with AD both in a 
Finnish study including 375 AD patients and 460 control subjects (Vepsalainen et al., 
2005) and by a study on 418 AD patients and 249 controls sharing the same family 
environment but not genetically related, from the United Kingdom (Li et al., 2008). 
While the non-association result is consistent between two different large populations 
that do not overlap, it would be interesting to see if a non-Caucasian population 
would yield different results. In fact, SNPs in the 5’ UTR are more likely to be 
associated with general stability of the NTRK2 RNA transcript rather than regulation 
of alternative splicing and the latter does not seem to differ between non-Caucasians 
and Caucasians. Expression levels of TrkB protein influenced by RNA transcript 
stability might differ in different ethnic backgrounds and partially explain the ethnic-
based susceptibility to AD. The Finnish study also investigated association of 2 other 
SNPs, in the 5’ UTR region, failing to find a significant association (Vepsalainen et 
al., 2005; Li et al., 2008). Li et al. instead, investigated the association of SNPs in the 
intronic regions intercalating exons that are found in the TrkB FL isoform, the only 
one that has tyrosine kinase activity. They did not find association between SNPs in 
introns 19, 20 and 22.    
 - 8 - 
 The importance of SNPs in the non-translated regions of NTRK2 might be 
dependent on the alteration of microRNA target sites. Also in this case it might be 
more apparent when microRNAs show ethnic-based differential expression levels. 
NTRK2 full-length isoforms contain putative target sites for several microRNAs: 
200b/c, 521, 429, 298, 888, 93624, 199a, 215, 551a 551b (MirBase Database).  
Significant genetic association between intronic SNPs in the gene UBQLN1 
and LOAD has been established (Bertram et al., 2005). Therefore it is reasonable to 
think that SNPs in intronic sequences of other genes might be significantly involved 
in AD by altering the splicing and/or transcriptional regulation.  
Alteration of RNA transcripts stability and levels, both microRNA dependent 
and independent, probably reflects in TrkB protein level alteration and possibly in 
different isoforms ratio. It remains to be determined how these proteins influence the 
main pathogenic mechanisms of AD. TrkB isoforms levels could cause 
developmental alterations contributing to AD risk later in life or could directly affect 
Amyloid Precursor Protein metabolism or other proteins, such as Tau, that have been 
established to be causative in AD pathogenesis. Recently, a genome wide association 
study suggested that proteins involved in protein cellular trafficking like TOMM40 
are major genetic contributors in AD (Hong et al., 2010). This suggests that 
trafficking could be an important mechanism of AD pathogenesis. Our results suggest 
that TrkB might be involved in APP trafficking and glycosylation pointing to a 
possible mechanism of action of this receptor in AD.  
After performing genetic association studies, it becomes necessary to show the 
biological relevance of the suggested associated genes with the pathology. This can 
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be done at two different levels. The first is through in vitro and in vivo laboratory 
experiments exploring the molecular mechanisms responsible for the observed 
association. This approach can help identifying new therapeutic targets and also be 
useful to test drugs. The second approach, is the observation of the relationship 
between the genetic variables under study and phenotypic characteristics of AD 
patients. In this case, the phenotypic markers can be used for diagnositic purposes 
(Biffi et al., 2010).  
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Table 1.1: NTRK2 SNPs that have been studied for association with late-onset AD. 
MCC: Multiple Comparison Correction; NS: Non Significant; *: Initially used to 
establish the importance of studying genetic association of NTRK2 SNPs with AD.    
Numbers in parenthesis (For example (1)) indicate the denomination of the SNPs in 
the original study that is being cited. **: Haplotype analysis study. ---: SNPs analyzed 
as haplotype. 
 
SNPs Bp change Location/Intron p-value Isoform Reference 
 
rs4412435 C/T 22 0.06 FL 
Not specified  5 NS  
(Perry et al., 2007) 
rs1212171 A/G (C/T in 
NCBI) 
5’ UTR NS  
rs1187326 A/G 5’ UTR NS  
rs1187327 A/G 5’ UTR NS  
 
(Vepsalainen et al., 
2005) 
 
rs1212171 G/G G/A A/A 5’ UTR NS  
rs1443445 C/C C/T T/T 19 NS SHC 
(Reiman et al., 
2007) 
rs1212171 G/G G/A A/A 5’ UTR NS  
rs1443445 C/C C/T T/T 19 NS SHC 
rs3780645 T/T T/C C/C 20 NS FL 
rs4578034 C/C C/T T/T 22 NS FL 
 
(Li et al., 2008) 
rs1047856 T/T T/A A/A Exon 8 (extracell 
domain) 
NS ALL 
rs2289656 T/T T/C C/C Boundary exon 
16 intron 17 
0.0036 T 
 
(Cozza et al., 2008) 
rs893584 (1)* A/G 5 ~0.05 ALL 
rs1778931 (2) A/G 8 NS ALL 
rs7048278 (3) A/G 14 NS ALL 
rs1624327 (4) C/T 16 0.009 T 
rs1443445 (5) C/T 19 0.009 SHC 
rs3780645 (6) C/T 20 0.009 FL 
rs6559840 (7) C/T 22 NS FL 
rs4412435 (8)* C/T 22 0.06 FL 
rs4578034 (9) C/T 22 NS FL 
rs12001219 (10) C/T 22 NS FL 
rs11795386 (11) C/T 22 NS FL 
rs10512159  (12) C/T 22 NS FL 
rs4142909  (13) C/T 22 NS FL 
rs17418241 (14) C/T 22 NS FL 
 
 
 
 
 
 
(Chen et al., 
2008)** 
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1.1.2 TrkB/BDNF signaling regulation during development, aging and 
disease 
 
Expression of NTRK2 has been found to be localized to the central nervous 
system during embryonic development and in adult mice (Klein et al., 1990b). In the 
mammalian brain TrkB and TrkB T are developmentally regulated: strong expression 
of TrkB is observed during rat embryonic development and TrkB T is elevated in the 
post-natal period when the majority of the inter neuronal connections are formed 
(Fryer et al., 1996). TrkB FL and TrkB T expression decreases with age in human 
hippocampus while TrkB T remains at constant levels through life in the temporal 
cortex. The TrkB ligand, BDNF, shows the opposite trend: remains constant in the 
hippocampus but decreases in the temporal cortex (Webster et al., 2006). TrkB shows 
higher expression levels in the hippocampus in infants rather than in adults while 
BDNF levels do not significantly differ (Tang et al.).  
All trans-retinoic acid (ATRA) regulates TrkB expression during embryonic 
development and is also involved in the maintenance of adult brain functions (Lane 
and Bailey, 2005). Retinoic acid receptors are expressed in discrete parts of the brain 
and are important for memory formation in the hippocampus and adult neurogenesis 
in the dentate gyrus (Katsuki et al., 2009). ATRA can activate transcription not only 
of TrkB but also of PS1, PS2 and APP (Lane and Bailey, 2005). ATRA also increases 
expression of the ADAM10 gene (Prinzen et al., 2005). Interestingly, up-regulation of 
the presenilins and APP is generally associated with increased degeneration while 
ADAM10 is protective. Since ATRA treatment results in beneficial effects in AD 
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context, it has been tested as a therapy in AD models. The pathways mediated by 
ATRA activation must be over-all protective.  
Activation of the retinoic acid receptors causes increase in BDNF/TrkB 
mediated signaling that decreases inflammation in a mouse model of Parkinson 
disease when the dopaminergic neurons are subjected to injury or inflammatory 
challenge (Katsuki et al., 2009). Treatment of Alzheimer’s disease mice with retinoic 
acid decreased Aβ load and improved cognitive function. The effect seemed to be 
related to a decreased activation of glial cells and decreased inflammation (Ding et 
al., 2008).  ATRA has also been shown to decrease iNOS synthesis and production of 
pro-inflammatory cytokines in activated microglia (Katsuki et al., 2009). Therefore, 
in AD, up-regulation of TrkB expression via ATRA treatment or RARs agonists (like 
Am80) could improve neuro-degeneration by decreasing the inflammatory response. 
It remains to be determined if this effect is at least partially mediated by TrkB 
signaling. The effect of RAR agonists seems to be specific for RAR-α and β 
receptors and not general RXRs, moreover, expression of RAR-α and β is prevalent 
in neurons while only few microglial cells show RAR-β expression, astroglial cells 
do not show expression of either RAR α or β (Katsuki et al., 2009). It is known that 
TrkB isoforms are differentially expressed on neurons and glial cells. In particular 
TrkB FL is mainly expressed in neurons while TrkB T is mainly expressed on glial 
cells. If ATRA increases the transcription of the NTRK2 gene, it will do so not-
specifically in all these cell types and the splicing regulation that yields different 
TrkB isoforms protein levels will allow up-regulation of TrkB FL in neurons but not 
in glial cells. It is possible that ATRA mediated up-regulation of TrkB FL in neurons 
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enhances their survival and that other signaling pathways regulate the anti-
inflammatory activity of ATRA. If pro-inflammatory activity of glial cells is partially 
mediated by TrkB T expression and signaling, when TrkB FL is up-regulated on 
neurons, BDNF will bind on neuronal cells and not on glial cells. This could result in 
inhibition of glial cell pro-inflammatory pathways.     
The developmental regulation of ATRA and TrkB and their importance in neuronal 
functions suggests that the mechanisms activated by their signaling might be 
important in AD and possible therapies.   
Post-mortem analysis of TrkB full length and BDNF expression in AD versus 
age matched controls revealed that both TrkB FL and BDNF levels are decreased in 
AD tissues while TrkB T is increased in AD versus non AD controls. Interestingly, 
neurons with higher numbers of neurofibrillary tangles showed lower expression of 
TrkB (Ferrer et al., 1999). On the contrary, TrkB T expression was found to be higher 
in AD brains than in controls, especially in the reactive glial cells (Allen et al., 1999; 
Ferrer et al., 1999). This finding is in agreement with the possible previously 
described role of TrkB signaling in inflammation. More recently, another study has 
shown that TrkB expression levels decrease as cognitive impairment increases in AD 
patients brains (Ginsberg et al., 2006). This study showed that, in the basal nuclei, 
TrkB FL expression levels were higher in non-demented and mildly cognitive 
impaired patients but much reduced in severely cognitive impaired patients. Another 
study showed that Aβ generation in Tg2576 mice impairs BDNF-TrkB mediated 
axonal transport in neurons (Poon et al., 2009). Moreover Aβ42 accumulation in 
neurons that are over-expressing APPSwe has been shown to decrease the BDNF 
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mediated degradation of TrkB receptor (Almeida et al., 2006).  These data suggest 
that Aβ can negatively affect TrkB FL signaling. On the other hand, interruption of 
NGF/BDNF signaling in primary neurons induces an increase in Aβ production and 
increased PS1 levels (Matrone et al., 2008). 
In contrast with these findings, one report does not find a significant difference in 
TrkB FL mRNAs expression levels among AD or control brains. BDNF and TrkB 
mRNA levels were measured in laser-captured neurons from AD brains or controls. 
There was also no significant reduction in TrkB immuno-reactivity in neurons that 
showed Aβ immuno-reactivity (Fujimura et al., 2009). The fact that this report is in 
disagreement with previous studies might depend on the sampling of the neurons by 
laser capture and also by the lack of discrimination between TrkB FL and TrkB T 
mRNA. Total TrkB levels might remain stable but isoform levels might explain 
neurologic dysfunctions. 
All these results suggest that TrkB FL signaling is generally down-regulated in AD 
context.  
Consistent with these observations, increased TrkB FL/BDNF signaling and 
pharmacological treatments or life styles, like an healthy diet and exercise, that 
increase TrkB expression and BDNF production seem to be beneficial in AD context 
(Peng et al., 2007; Nichol et al., 2009) (Cho et al.; Ding et al., 2008; Komulainen et 
al., 2008; Bousquet et al., 2009; Katsuki et al., 2009; Nichol et al., 2009). Expression 
of BDNF is increased by omega 3 fatty acids in the diet and the increased levels of 
BDNF cause an increase in TrkB expression and mRNA levels (Bousquet et al., 
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2009). TrkB and BDNF also protect cells from apoptosis by decreasing caspase 3 
activation in cells that receive cytotoxic insults (Nguyen et al., 2009).   
The levels of BDNF in AD patients have also been measured in different 
studies. Some groups report an increase in BDNF levels in AD or mildly cognitive 
impaired patients compared to controls (Angelucci et al.). Others report a decrease in 
BDNF levels caused by Aβ aggregates (Peng et al., 2009). Whatever the cause of 
these contrasting reports, a role for TrkB isoforms in the pathogenesis could be 
supported in either case. If increased BDNF levels are found concomitantly with 
decreased TrkB FL and increased TrkB T levels, then the signaling activated will be 
mainly mediated by TrkB truncated isoforms. These isoforms are located on glial 
cells, which can mediate inflammation. If BDNF decreased levels are associated with 
normal TrkB FL/T levels the BDNF mediated signaling necessary for neuronal 
function could be insufficient due to the lower ligand levels.  
 In conclusion, TrkB plays an important role during development and in the 
adult brain and alterations in TrkB/BDNF signaling seem to be involved in AD 
pathology. Therefore elucidation of the mechanisms underlying the role of TrkB in 
AD will be important to design therapeutic strategies.   
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1.2 NTRK2 gene and TrkB protein 
 
1.2.1 TrkB isoforms structure and functions 
 
TrkB (tyrosine receptor kinase B) was first identified in 1989 for homology 
with the already known TrkA, the receptor of Nerve Growth Factor (NGF) (Klein et 
al., 1989). Expression levels of this receptor where found to be high in the central 
nervous system and many primary transcripts were isolated suggesting the presence 
of different isoforms. Soon after, another isoform, TrkB T, lacking the tyrosine kinase 
activity, was isolated (Klein et al., 1990a). The third isoform, TrkB SHC was 
identified much later (Stoilov et al., 2002). More isoforms have been identified 
recently (Luberg et al., 2010) but our work will focus on the three aforementioned 
isoforms.   
NTRK2, the gene encoding TrkB, has a complex genomic organization and it is 
expressed in 3 different splicing isoforms in rat and mouse (Kumanogoh et al., 2008) 
and at least five isoforms in humans (Stoilov et al., 2002; Luberg et al., 2010). The 
numerous TrkB isoforms expressed in the human brain differ for short sequences but 
can be grouped, based on their intra-cellular domains, in two full-length isoforms 
(TrkB FL), two intermediate isoforms (TrkB SHC) and one truncated isoform (TrkB 
T). Each of these can bind BDNF in the conserved extra-cellular domain (encoded by 
exons 5-15) but differ in the cytoplasmic domain (Figure 1.1). BDNF binds to the IgG 
like domains of the TrkB receptors on the extra-cellular portion. Isoforms that lack 
the leucine-rich region in the extra-cellular portion have also been recently identified 
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(Luberg et al., 2010). These N-truncated isoforms are probably not transported to the 
cell surface lacking the signal sequence but include all the intracellular functional 
domains of their non N-truncated counterparts (Luberg et al., 2010). We are 
interested in investigating the role of the intracellular functional domains. The longest 
TrkB isoforms, TrkB FL (822-838 amino acids in length) contain a tyrosine kinase, a 
SHC binding, and a PLC-γ binding domain in the cytoplasmic portion. The 
intermediate length isoforms, TrkB SHC (537-553 amino acids in length) contain 
only a SHC binding domain (located on exon 19) while the truncated TrkB isoform, 
TrkB T (477 amino acids in length) does not contain any known functional domains 
in the cytoplasmic domain that is encoded by exon 16 (Figure 1.1) (Klein et al., 
1990a; Middlemas et al., 1991; Stoilov et al., 2002) 
.  
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic representation of TrkB isoforms highlighting the 
differences in the intracellular domains.  
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In the central nervous system, TrkB regulates synaptic plasticity, neuronal 
differentiation, neuronal proliferation and development (Dechant and Barde, 2002; 
Nagappan and Lu, 2005; Reichardt, 2006; Minichiello, 2009). The importance of 
TrkB in neuronal development is underlined by the fact that mice with a targeted 
disruption of the NTRK2 locus develop until birth but die at P1 (Klein et al., 1993). 
They have dramatic deficits in the sensory and motor systems which affect their 
feeding behavior (Klein et al., 1993). Mice lacking BDNF display major movement 
and balance defects caused by major neuronal loss in the vestibular ganglion, many 
do not survive past the second post-natal week (Ernfors et al., 1994).  
During development TrkB isoform expression has different roles: TrkB T seems to 
promote synapse destruction while phosphorylated TrkB FL promotes synaptic 
formation. Correct balancing of these isoforms allows the correct innervation and 
synaptic connections to be formed during brain development (Sherrard et al., 2009). 
TrkB is important in cancer as an oncogene. Up-regulation of TrkB FL and its 
ligand, BDNF, is related to increased cell proliferation. TrkB is a marker of high 
malignancy and chemotherapy resistance in neuroblastomas while TrkA is associated 
with more positive outcomes (Thiele et al., 2009). It is probably for this reason that 
activated TrkB FL levels at the cell surface are tightly regulated. After binding to its 
ligand TrkB FL is rapidly endocytosed and degraded through the proteosome 
(Sommerfeld et al., 2000). The rapid decrease in TrkB FL surface levels is mediated 
by a juxta-membrane domain in the protein and is not observed in TrkA after binding 
of NGF (Sommerfeld et al., 2000). Instead, the truncated, non-catalytically active, 
TrkB T, it is not subjected to the same rapid degradation.  
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TrkB is subjected to different regulation and has different functions that do not over 
lap with TrkA despite the very similar structure of the two receptors.  
  
1.2.2 TrkB full-length functions and signaling pathways 
 
TrkB FL is the only isoform with a tyrosine kinase domain. Upon binding to BDNF it 
dimerizes and auto-phosphorylates. There are several phosphorylation sites in the 
intracellular domain some of which act as a docking site for adaptor proteins and 
effector proteins (Reichardt, 2006). The activated receptor can trigger intracellular 
signaling through several pathways (Figure 1.2).  
Binding of SHC on tyrosine 515 mediates activation of PI3K/AKT survival pathways 
and activates transcription through ERK down-stream signaling targets (Figure 1.2) 
(Minichiello, 2009). Since SHC contains both PTB (phospho tyrosine binding) and 
SH domains it is also possible that binding of SHC occurs on the non-phosphorylated 
docking site through the SH domains. The SHC binding site is important for the 
activation of MEK/IP3K that signal downstream and activate ERK1/ERK2 pathways, 
which mediate survival and axonal growth (Atwal et al., 2000). This pathway is 
mediated by Ras. The PLC-γ binding site is not required for these functions (Atwal et 
al., 2000). Signaling downstream of SHC binding to TrkB FL mediates the formation 
of conditional fear in mice (Musumeci et al., 2009).     
A PLC-γ binding site is located on tyrosine 816. Phosphorylation of the receptor on 
that residue is necessary since PLC-γ employs only PTB domains for binding. PLC-γ 
signaling is mediated by IP3 (Inositol-tri-Phosphate) and DAG (diacyl glycerol). IP3 
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allows release of intracellular Ca2+ and activates calmodulin and calmodulin 
dependent kinases, which can then activate transcription via CREB phosphorylation. 
DAG activates PKC (phospho kinase C) that can phosphorylate many substrates 
(Figure 1.2) (Minichiello, 2009).     
Trks can also undergo a neurotrophin independent activation. In this case the trans-
activation can be dependent on a G-protein coupled receptor (Rajagopal et al., 2004). 
Once the G-protein coupled receptor is activated by its ligand (for example the 
neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP)(Lee et al., 
2002), adenosine or synthetic adenosine agonists (Lee and Chao, 2001). The 
activation of TrkA through this alternative route triggers phosphorylation of the same 
residues that are phosphorylated by the neurotrophin binding but happens on a longer 
timescale (over an hour versus seconds of neurotrophin stimulation). The active 
receptors, also, are found associated to the Golgi membrane and are immature (non 
completely glycosylated). Fully glycosylated receptors do not get activated by GPCR 
agonists. Disruption of the Golgi via Brefeldin A treatment abolished the activation of 
this pool of activated immature receptors. These experiments were performed both in 
PC12 cells and primary neurons. Transactivation of the TrkA receptor through this 
pathway causes activation of PI3K but not of MAPK pathway (Rajagopal et al., 
2004). Activation of Trks independent of neurotrophin binding has been observed 
even when the receptors are ectopically over-expressed. Over-expression of the TrkB 
receptor in HEK293 cells can cause auto-activation of the receptor in the Golgi 
(Schecterson et al.). This auto-activation causes Golgi fragmentation impeding 
complete glycosylation of the receptor and of other proteins (Schecterson et al.). 
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These observations are very similar to the ones made with GPCR-mediated activation 
of Trks and were dependent on the tyrosine kinase activity of the receptor 
(Schecterson et al., 2010). Interestingly ectopic expression of TrkB FL in MDCK 
cells showed that, while TrkB T was uniformly distributed in the cells, TrkB FL was 
not present on the apical side of the cells (Kryl et al., 1999). This suggests that 
localization of the TrkB isoforms is different and might be dependent on TrkB FL 
auto-activation and residency in the Golgi.     
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Figure 1.2: TrkB FL signaling pathways elicited by BDNF binding of the 
receptor. The figure is from Minichiello 2009. Note that BDNF mediated activation 
of TrkB FL occurs in 15 seconds and involves surface receptors. BDNF independent 
activation of TrkB FL occurs in hours and engages receptors localized inside cellular 
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compartments such as the Golgi (see text for references and details) (Minichiello, 
2009). Figure used with permission granted by Nature Publishing Group.   
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1.2.3 TrkB truncated functions and signaling pathways 
 
In humans there is only one isoform of TrkB truncated, TrkB T,  (homologous 
of TrkB T1 in mouse and rat), the other non-catalytically active TrkB isoform is TrkB 
SHC that contains a SHC binding site (Stoilov et al., 2002).      
In mouse and rat there are two TrkB truncated isoforms, TrkB T1 and T2, both 
expressed in neurons. TrkB T1 and T2 have 12 amino acids of their short intracellular 
domains in common with TrkB FL while 11 and 9 amino acids respectively are 
isoform specific (Baxter et al., 1997). The two short non-conserved domains are 
necessary for BDNF induced intracellular signaling of the two truncated isoforms in 
cell lines (Baxter et al., 1997). This intracellular signaling is probably dependent on 
kinases since it can be prevented by kinase inhibitors (Baxter et al., 1997). TrkB T1 
displays a largely non over-lapping patter of expression with TrkB FL while TrkB T2 
is expressed in the same central nervous system regions and motor neurons as TrkB 
FL suggesting a regulatory role of this isoform on TrkB FL. TrkB T1 is mainly 
expressed on the glial cells (Armanini et al., 1995). Interestingly, both TrkB T1 and 
T2 were able to promote dendritic filopodia growth in hippocampal neurons 
(Hartmann et al., 2004). 
Co-culture experiments of SH-SY5Y neuroblastoma cells with 3T3 NIH 
fibroblasts over-expressing TrkB T1 suggested that TrkB T1 could act as a BDNF 
scavenger and thus reduce neurite sprouting on the TrkB FL expressing neurons 
(Fryer et al., 1997). This possible mechanism of action suggests that TrkB T 
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expression on non-neuronal cells could obstacle neuronal regeneration in 
neurodegenerative diseases.  
TrkB T co-expressed in PC12 cells expressing TrkB FL, was found to inhibit 
cell survival probably by inhibiting TrkB FL signaling via dimerization (Haapasalo et 
al., 2001). TrkB T was also shown to mediate BDNF independent neurite outgrow in 
N2a neuronal cells and 3T3 fibroblasts (Haapasalo et al., 1999). The authors find that 
deletion of the extra-cellular domain eliminates this effect while deletion of the 
intracellular domain of the TrkB T receptor does not. It has to be noted that the 
deletion mutant used eliminates the IgG like domains that have been shown to 
mediate binding of the neurotrophin (Arevalo et al., 2001). Moreover co-expression 
of TrkB FL antagonized the TrkB T process sprouting via a tyrosine kinase dependent 
mechanism (Haapasalo et al., 1999). Another study also found the same TrkB T 
mediated, BDNF independent, process sprouting effect in hippocampal neurons 
(Hartmann et al., 2004). These two studies both demonstrate that some TrkB T effects 
are independent of BDNF signaling. Hartman et al. also found that p75 was necessary 
for TrkB T mediated process growth. In p75-/- neurons or neurons co-expressing p75 
without its intracellular domain the TrkB T induced filopodia outgrowth was 
inhibited (Hartmann et al., 2004).  
TrkB T can activate intracellular Ca2+ currents in glial cells independently 
from TrkB FL but upon BDNF stimulation. TrkB T was found to be expressed mainly 
on glial cells that were able to generate Ca2+ currents upon BDNF stimulation (Rose 
et al., 2003). Interestingly, these responses were dependent on PLC-γ activation but 
not on tyrosine kinase activity. Glial cells from mutant mice TrkB FL-/- were still 
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able to generate the Ca2+ currents demonstrating that TrkB T functions independently 
of TrkB FL (Figure 1.3). The effect seemed to be dependent on activation of a G-
protein upstream of PLC-γ. Treatment with a G-protein agonist was able to sustain 
the Ca2+ evoked currents after the first application of BDNF or ATP but this effect 
could not be blocked by conventional antagonists of G-proteins. The authors conclude 
that the G-protein mediating the signal is insensitive to the blockers used (Figure 1.3). 
Confirming these findings that TrkB is able to elicit signaling pathways, further 
studies demonstrated that TrkB T can promote proliferation of neuronal progenitors 
in neurospheres (Tervonen et al., 2006) and direct the differentiation of neuronal stem 
cells to glial differentiation through PLC-γ and protein G mediated signaling (Cheng 
et al., 2007). Moreover the TrkB T isoform has been shown to regulate TrkB FL 
kinase activity in vivo. Mice lacking TrkB T but not TrkB FL display increased 
aggression and weight gain compared to control littermates, even if learning and 
memory are not affected. The dendritic arborization of some neuronal populations is 
affected as well (Carim-Todd et al., 2009).  
TrkB T has also been demonstrated to bind a 61KDa protein that was named TrkB 
Truncated Interacting Protein (TTIP) the physiologic function of this protein is still 
unknown (Kryl and Barker, 2000).  
In summary, several physiological roles have been proposed for TrkB T: 
molecular scavenger of BDNF limiting its availability to TrkB FL (Fryer et al., 1997), 
dominant negative dimer partner of TrkB FL (Haapasalo et al., 2001), independent 
activator of intracellular signaling pathways that regulate TrkB FL signaling for 
example to control neurite sprouting and neuronal proliferation (Haapasalo et al., 
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1999; Haapasalo et al., 2002; Rose et al., 2003; Hartmann et al., 2004; Tervonen et 
al., 2006; Cheng et al., 2007). All these data suggests that TrkB T homodimers have 
an independent signaling function or maybe that BDNF mediates binding of TrkB T 
with p75 as observed (Hartmann et al., 2004).    
 
1.2.4 TrkB SHC functions and signaling pathways 
 
The TrkB SHC truncated isoform of TrkB has been recently identified in 
human cells (Stoilov et al., 2002), there are no homologous counterparts in rodents. 
Surprisingly, this isoform has not been widely investigated. There is only one study 
which investigated the cellular distribution of TrkB SHC, TrkB FL and T in N2a 
neuroblastoma cells (Haapasalo et al., 2002). This study shows that while TrkB FL is 
distributed mainly on proximal processes, soma, granular structures and to a lower 
extent on the membrane, TrkB T is distributed on the membrane and on the distal 
processes (Haapasalo et al., 2002). TrkB SHC co-localizes with TrkB FL in the soma 
and granular structures but is also found in distal processes and on the membrane, 
displaying a distribution that is intermediate between the other two isoforms 
(Haapasalo et al., 2002). The TrkB T isoform was able to reduce TrkB FL surface 
levels while TrkB SHC and a TrkB FL kinase inactive mutant were able to increase 
those levels (Haapasalo et al., 2002). This suggests that TrkB SHC and T have 
different regulatory roles on TrkB FL, which are probably mediated by the SHC 
binding site (Figure 1.3).     
 
 - 28 - 
 
 
Figure 1.3: Established and hypothesized signaling pathways activated by the 
three TrkB isoforms. Note that the TrkB FL activates many signaling pathways that 
have been confirmed by different studies. TrkB SHC contains a SHC binding site that 
could mediate the activation of MEK/ERK and Akt pathways. These relationships 
have not been established or investigated. TrkB T has been shown to activate 
intracellular Ca2+ current even if the exact mechanism is not clear; a G-Protein seems 
to be involved in this pathway. TrkB binds to Truncated TrkB Interacting Protein but 
the role of this interaction has not been elucidated. Solid lines indicate established 
pathways; dashed lines indicate hypothesized or not fully understood pathways. 
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1.3 TrkB and APP: established and possible interactions 
 
1.3.1 Amyloid hypothesis and Alzheimer’s Disease molecular pathogenesis 
 
The Amyloid Precursor Protein (APP) is a glycosylated type I trans-
membrane protein ubiquitously expressed in three isoforms: APP770, APP751 and the 
neuronal specific APP695. The primary function of this protein has not been identified 
to date but APP is implicated in many cellular processes: cell adhesion, 
differentiation, proliferation and intracellular signaling (De Strooper and Annaert, 
2000). The proteolytic cleavage of APP is considered the main pathological event in 
AD (Figure 1.4). APP is mainly cleaved by α-secretases, β-secretases and γ-
secretases  (multiprotein complexes) (Figure 1.4). The α-secretases activity is 
attributed to Alpha-disintegrin and metalloproteinases family members (ADAM9, 10 
µand 17). The β-secretase, BACE1 (Beta APP Cleaving Enzyme1) is responsible for 
production of the neurotoxic Aβ fragment. Both α and β secretases produce soluble 
N-terminal fragments (sAPPα and sAPPβ) that are released in the extra-cellular space 
and membrane bound C-terminal fragments (C83 and C99) that are subsequently cut 
by γ-secretases (Figure 1.4). The γ-secretase activity, PSEN1 and PSEN2 (Presenilin 
1 and 2) releases the p3 fragment from the α-CT stub and the Aβ peptide from the β-
CT. At the same time intracellular fragments are released that have nuclear signaling 
functions (De Strooper and Annaert, 2000). During AD pathogenesis APP cleavage is 
shifted towards the production of the Aβ42 fragment that is lipophilic and aggregates 
forming oligomeric species that are highly toxic (Ma and Nussinov, 2002; 
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Mamikonyan et al., 2007). Aggregation of the Aβ peptide starts inside neurons, glial 
and endothelial cells and eventually spreads to the extra-cellular environment. Here, 
Aβ accumulates in the characteristics amyloid plaques that are found in AD brains 
(Turner et al., 2004). In EOAD Aβ peptide formation is increased by mutations in 
APP (for example the Swedish mutation: K595N and M596L) or in the presenilins 
(Turner et al., 2004).  
Stimulation of α-secretase cleavage of APP is considered a therapeutic 
approach because it prevents the formation of the Aβ peptide (Fahrenholz and 
Postina, 2006). 
 
 
 
Figure 1.4: Schematic representation of the main proteolytic processing of 
Amyloid Precursor Protein. 
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1.3.2 TrkB as modulator of APP transcription 
 
Treatment of SH-SY5Y neuroblastoma cells with retinoic acid (RA) promotes 
their differentiation to neuronal phenotype with process sprouting (Ruiz-Leon and 
Pascual, 2003). RA treatment induced up-regulation of TrkB and also increased the 
levels of APP, interestingly, BDNF treatment of SH-SY5Y cells further increased 
APP levels (Ruiz-Leon and Pascual, 2003). These transcriptional effects occurred in 
48 hours suggesting an indirect effect of BDNF/TrkB signaling on APP promoter 
activity but were blocked by K252a the tyrosine kinase inhibitor suggesting the 
importance of the tyrosine kinase activity of the receptor in mediating transcriptional 
activation (Ruiz-Leon and Pascual, 2003). The use of site directed mutants of TrkB 
FL indicated that the APP transcriptional effect is due to activation of the Ras/MAPK 
and PI3K/Akt pathways downstream of the SHC binding and tyrosine kinase activity 
of the receptor respectively (Figure 1.5) (Ruiz-Leon and Pascual, 2004). Importantly 
these effects were independent of AP-1 transcription factor activation, which has 
binding sites on the APP promoter (Ruiz-Leon and Pascual, 2001).         
 
1.3.4 TrkB as modulator of APP processing, ADAM10 and BACE 
 
Consistent with these findings, RA induced TrkB up-regulation and BDNF 
stimulation of the TrkB receptor in SH-SY5Y cells. RA and BDNF treatments of 
these cells increase APP production and shift the APP cleavage pathway towards α-
secretase, as demonstrated by quantification of sAPP-α (Figure 1.5) (Holback et al., 
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2005). In addition, impairment of O-glycosylation of APLP1, a protein that is 
homologous of APP, was observed in cells treated with BDNF (Holback et al., 2005). 
The increase in sAPP-α levels seems to be dependent on both increased APP 
transcription and increased α-secretase processing of APP, in fact C99 levels were 
decreased (Holback et al., 2005). It could be hypothesized that, TrkB activation of 
PLC-γ producing DAG, which is the endogenous agonist of PKC, increases the 
amount of active ADAM that cleaves APP (Figure 1.5). This mechanism of action 
has not been demonstrated yet and the previously mentioned studies did not elucidate 
a mechanism of action by measuring levels of ADAM10 or BACE.  
The regulation of APP main processing enzymes, BACE and ADAM10, is a 
possible way in which TrkB could affect APP processing. There are several possible 
regulation mechanisms of the secretases: transcriptional, glycosylation and 
trafficking. TrkB has been shown to affect other proteins at all these different levels. 
TrkB affects transcription (Ruiz-Leon and Pascual, 2001; Groth and Mermelstein, 
2003), glycosylation of proteins (Schecterson et al., 2010) and trafficking (Cassens et 
al.; Colley et al., 2009) and the secretases could be included in the list of proteins 
affected. Below we briefly review the secretases metabolic pathways that could be 
affected by TrkB.  
Many transcription factors are downstream of BDNF/TrkB FL signaling. For 
example CREB and AP-1 both bind the BACE promoter (Sambamurti et al., 2004) 
and are both activated by TrkB.  NFAT4c (also known as NFAT3), the neuronal-
specific form of the nuclear factor of activated T-cells, has also been shown to be 
activated downstream of PLC-γ activation through IP3 and PKC mediated signaling 
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(Groth and Mermelstein, 2003). Interestingly, while the activation of NFAT1 through 
ionomycin has been related to increased BACE1 levels, NFAT4 (also known as 
NFAT3c) was not affected by this treatment (Cho et al., 2008). This suggests that 
TrkB FL signaling could be specifically activating pathways that do not lead to 
increased β-secretase cleavage of APP. The ADAM10 promoter is responsive to 
retinoids but it does not contain any binding site for transcription factors down-stream 
of TrkB (Prinzen et al., 2005).   
ADAM10 and BACE are both N-glycosylated and the proteolytic activity has 
been related to the glycosylation state (Capell et al., 2000; Walter et al., 2001; 
Escrevente et al., 2008; Vanoni et al., 2008).  
BACE1 fully glycosylated migrates at 66KDa while the holo protein migrates 
at 46KDa. BACE1 that resides in the endoplasmic reticulum is 58KDa showing only 
partial glycosylation (Huse et al., 2000). BACE is a highly stable protein with a half 
life of 16 hours and matures to the fully glycosylated form in only thirty minutes 
(Huse et al., 2000). It localizes to the endosomes and cell surface, not to lysosomes. 
The signal sequence needed to localize BACE at the endosomes is DDXXLL, when 
this is disrupted BACE1 localizes mainly to the cell surface. BACE can be active 
even if not glycosylated (Vanoni et al., 2008). Finally, BACE is synthesized as a pro-
protein displaying a peptide of 24 amino acids that is necessary for its transport 
outside the ER and gets cleaved in the Golgi but does not seem to significantly inhibit 
its enzymatic activity (Benjannet et al., 2001).  
In conclusion, BACE1 mediated APP cleavage could be modulated mainly by TrkB 
trafficking effects since neither glycosylation/cleavage are fundamental in 
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determining BACE1 activity. Therefore, localization of BACE1 is probably going to 
be the main determinant of APP processing modulation by TrkB. In fact, BACE1 is 
only active in the endosomes. Also, since its half-life is long, the only limiting factor 
in generating APP fragments is the co-localization of BACE1 and APP. Supporting 
the importance of BACE1 localization, siRNA mediated knock-down of SHC, that 
binds to TrkB, and Fe65 was able to reduce CTFs and Aβ production (Xie et al., 
2007). While SHC knock-down also decreased BACE1 levels, Fe65 knock-down did 
not affect BACE levels (Xie et al., 2007). The authors suggest that the reduced APP 
processing observed is mainly due to altered APP trafficking within the cells.  
ADAM10, ADAM17 and ADAM9 have been implicated in the α-secretase 
cleavage of APP (Allinson et al., 2003). They are integral glycoproteins membrane 
type I. In addition to transcriptional and translational regulation, there are three main 
ways of ADAMs activity regulation: first the conversion of the zymogens to the 
active form (maturation process). This process requires proprotein-convertases that 
are Ca2+ dependent endoproteinases (Endres et al., 2003). Second, the 
phosphorylation and the activation of signaling pathways mediated by adaptors at the 
intracellular domain. Third the intra-cellular trafficking. 
ADAMs intracellular domain can be phosphorylated or have binding sites for 
adaptor proteins like SHC3 (Allinson et al., 2003). ADAM9 and ADAM10 display 
constitutive and regulated (PKC induced) α-secretase activity while ADAM17 only 
displays regulated activity (Endres et al., 2003).  α-secretase cleavage can be 
increased by DAG activation of PKC by binding to its C1b domain (Endres et al., 
2003). ADAM17 (TACE: Tumor Necrosis Factor α Converting Enzyme): is 
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converted to its mature from by furin and PC7 both substrates of PKC (Endres et al., 
2003). ADAM10 is regarded as the main α-secretase activity involved in processing 
of APP in AD.  ADAM10 activity depends on the pro-domain but not on the 
disintegrin domain (Fahrenholz et al., 2000). Trafficking and sub-cellular localization 
of ADAMs are important for ADAMs activity and therefore APP processing (Borroto 
et al., 2003; Marcello et al., 2007). In conclusion, TrkB could modulate ADAM 
activity by a PLC-γ mediated pathway leading to PKC activation and by trafficking 
effects. 
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Figure 1.5: Some of the interactions between TrkB isoforms and APP. Aβ is 
known to down-regulate TrkB/BDNF signaling and TrkB/BDNF signaling 
stimulation is generally associated with beneficial outcomes in Alzheimer’s disease. 
The role of the truncated isoforms is not well established. TrkB T seems to promote 
degeneration while the role of TrkB SHC is unknown. Red arrows/boxes indicate 
factors that promote degeneration while green labeled objects are associated with 
beneficial factors.   
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1.3.4 TrkB as modulator of APP trafficking/maturation 
 
1.3.4.1 Trafficking of TrkB isoforms to the cell surface and degradation 
 
Trafficking of TrkB receptor at the cell surface is regulated by many 
mechanisms and probably regulates trafficking of neighboring proteins as well. The 
TrkB isoforms display different surface levels and their trafficking is probably 
differently regulated.    
Expression of TrkB receptor at neurites with rapid kinetics is regulated by Ca2+ influx 
and membrane potential. Phosphorylation of the receptor at Ser 478 by Cdk5 and the 
juxtamembrane domain of TrkB are essential for activity dependent membrane 
localization of TrkB (Zhao et al., 2009).  
TrkB T is present on the surface of the neurons when the neurons are unstimulated 
while TrkB FL is greatly up-regulated when cells are stimulated by an electric 
current. Blockers of membrane potential are able to prevent the differences (Du et al., 
2000). The process is dependent on the activity of Ca2+/calmodulin dependent kinase 
II. In agreement with these findings, it has been shown that surface expression of 
TrkB isoforms is regulated by BDNF. A 15 seconds treatment of primary 
hippocampal neurons with BDNF caused a rapid increase in cell surface levels of 
TrkB FL suggesting that there is an intracellular pool of receptors that is stored in 
vesicles inside the cells and is released to the surface when BDNF bound receptor is 
internalized. TrkB receptors that lack the tyrosine kinase activity can regulate TrkB 
FL surface expression: TrkB T decreases the surface levels of TrkB FL while TrkB 
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SHC increases it (Haapasalo et al., 2002). This suggests that isoform interactions are 
important in regulating surface levels of the receptor and also a role for the SHC 
binding site in the trafficking of TrkB. It is interesting to see how the two different 
truncated isoforms can affect differently TrkB FL. These results underline the 
importance of defining the roles of the truncated isoforms as they can have very 
different effects on the TrkB FL. Moreover the fact that TrkB isoforms can regulate 
each other expression at the surface suggests that they might regulate the surface 
transport and trafficking of other proteins as well. For example, SHC has been shown 
to mediate TrkB induced transport of the channel Kv1.3 without BDNF mediated 
activation of the TrkB receptor (Colley et al., 2009). Interestingly APP has binding 
sites for SHC as well (Tarr et al., 2002). Recently, TrkB has also been shown to 
modulate surface levels of the inwardly rectifying K (+) channel Kir3.3 via NCAM 
interaction (Kleene et al.). This suggests that not only adaptor proteins could be 
involved in TrkB mediated APP trafficking, but that even a direct APP TrkB 
interaction should be tested. Based on the aforementioned data, we therefore 
hypothesized that TrkB might modulate APP trafficking and that TrkB isoforms 
might do so in different ways. 
Previous research on tyrosine kinase receptors has shown that internalized 
receptors are transported to multi-vesicular bodies (MVB) and, depending on their 
tyrosine kinase activity, are localized in the vesicles in the lumen portion of the MVB 
or at its periphery on the membrane. The different localization in the MVB 
corresponds to a different recycling pattern: the tyrosine kinase deficient receptors are 
transported back to the plasma membrane while the tyrosine kinase active receptors 
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are transported to lysosomes and degraded (Ullrich and Schlessinger, 1990). The 
hypothesis for this difference in sorting of the receptor is that the tyrosine kinase 
active receptors can interact with sorting proteins, maybe by phosphorylating them. 
The inactive receptors, instead, do not interact with other proteins and are then 
segregated from the degradation pathway.  
A recent microarray study on the C1 hippocampal region of AD and non 
demented control brains has shown that early endosomal markers such as Rab5/7 are 
up-regulated in AD while they are not in controls. They also found a down-regulation 
of both TrkB T and FL in the same brain region that was a consequence of the 
endosomal markers up-regulation. In fact, over-expression of rab5 in fibroblasts was 
able to reduce TrkB levels as measured by both Western blot and qPCR. There was 
no regulation of TrkB on rab5 expression levels (Ginsberg et al., 2010). Rab5 was 
also found in vesicles transporting APP from endosomes to the TGN. This retrograde 
trafficking decreases Aβ production and increases N-O-glycosylated APP half-life in 
the cells (Vieira et al.). An APP mutant mimicking T655 phosphorylation is 
preferentially retrogradely transported from the endosomes to the TGN showing that 
this trafficking is phosphorylation mediated (Vieira et al.). Phosphorylation of APP 
has been previously involved in regulating APP processing (Lee et al., 2003). TrkB 
has been shown to bind and phosphorylate NCAM on tyr734 after being activated by 
its ligand BDNF (Cassens et al.). This demonstrates that TrkB can phosphorylate in 
trans intramembrane proteins and could theoretically do the same on APP even if this 
has never been shown. Moreover it is intriguing that rab5 is associated with both 
TrkB and APP containing vesicles, it is possible that trafficking of these proteins is 
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regulated by the same mechanisms and maybe is partially dependent on their 
interaction.   
 
1.3.4.2 Trafficking and intracellular processing of APP 
 
TrkB trafficking regulation is complex and involves specific compartments, 
APP trafficking regulation is also complex and very important in the pathogenesis of 
AD. APP retention at the cell surface via a dynamine dominant negative that blocks 
efficient endocytosis, increased both the production of C83/99 and sAPP-α/Aβ 
demonstrating that APP trafficking is very important in determining levels of its 
processing products (Chyung and Selkoe, 2003). As detailed below, there are 
overlapping patterns between TrkB and APP intracellular trafficking. These over-laps 
suggest that TrkB and APP might regulate each other trafficking or at least be 
regulated by the same factors. Elucidation of these interactions and factors is going to 
be fundamental in furthering the knowledge of APP biology.     
It was initially postulated that APP cleavage only occurs when APP, fully 
glycosylated, is transported to the cell periphery in neurons but recent evidence shows 
that APP epitopes containing the N-terminal or C-terminal domains are segregated in 
different cellular compartments (Muresan et al., 2009). This finding suggests that 
APP cleavage occurs in different cell compartments and the localization of the 
fragments is tightly controlled. Fragments containing the N-terminus of APP 
localized preferentially at the tip of the neurites while the C-terminus containing 
fragments localized in the cell soma. The Aβ containing fragments also labeled 
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mainly the cell soma. Further study of the vesicles showed that Aβ containing 
fragments were for the majority not co-localized with CTFs containing fragments 
(Muresan et al., 2009). Phosphorylated species of APP preferentially localize at the 
neurites (in particular at the center of the growth cone of neurites) and are mainly 
CTFs and not full length APP (Muresan et al., 2009). The phosphorylated forms of 
APP also localized at the periphery of the growth cone while the non–phosphorylated, 
probably APP FL and N-terminal fragments, localized to vesicles at the center of the 
growth cone and acetylated microtubules (Muresan et al., 2009). From an interactome 
study it is clear that different fragments of APP, localized to different cellular 
compartments interact with proteins that are specific to the cytoplasm, the membrane 
or the extra-cellular space (Bai et al., 2008)   
APP CTFs and AICD are collected in the intra luminal vesicles of multi-vesicular 
bodies and exocytosed in exosomes. Treatment with alkalizing agents impedes 
degradation of these APP fragments in late endosomes and allows their accumulation 
(Vingtdeux et al., 2007). Interestingly, the experiments showing that alkalizing agents 
allow accumulation of CTFs and AICD in exosomes were performed in SH-SY5Y 
cells differentiated with retinoic acid. Retinoic acid induces TrkB up-regulation in 
SY5Y cells and TrkB FL has been shown to be associated with multivescicular 
bodies after BDNF stimulation (SH-SY5Y cells produce basal levels of BDNF). In 
particular, tyrosine kinase active receptors are found inside the luminal vesicles (just 
as APP CTFs and AICD) while the tyrosine inactive receptors are associated with the 
membrane of the multi-vesicular bodies and recycled to the cell surface. These 
findings suggest that APP and TrkB are found in the same cellular compartments and 
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this co-localization might be, at least partially, regulated by TrkB isoforms expression 
levels and activation.  
The fact that TrkB can interact with several membrane and adaptor proteins, 
suggests that it might affect APP indirectly. For example, the expression of SORL1 
has been shown to be increased by BDNF treatment in primary mouse neurons (Rohe 
et al., 2009) while in AD patients SORL1 expression is decreased. The SORL1 gene 
encodes for the SORLA (sortilin related) receptor. This belongs to the family of the 
vacuolar sorting domain-containing receptor proteins 10, the LDLR family and the 
fibronectin type III repeats protein. Polymorphisms in this gene have been associated 
with late onset AD in several populations. SORLA controls the trafficking of APP 
from the trans-Golgi network and early endosomes. Over-expression of SORLA 
decreases APP processing by localizing APP to the Golgi (Andersen et al., 2005). 
BDNF treatment of primary neurons increases SORLA expression levels and 
decreases Aβ formation (Rohe et al., 2009). The SORLA-mediated effect on APP is 
not observed in SORLA deficient mouse primary neurons demonstrating that the 
TrkB/BDNF effect is SORLA dependent. It is interesting to notice how in SORLA 
deficient animals TrkB T has lower levels of expression while it has higher levels in 
BDNF treated SORLA+ cells. The effects on APP do not seem to be mediated by the 
downstream signaling of the receptor (Akt and ERK do not differ between SORLA+ 
or – cells). 
Enzymatic complexes that process APP are also subjected to trafficking 
regulation and can regulate APP trafficking. The γ-secretase complex has been shown 
to be targeted to the cells surface (Kaether et al., 2002). At the same time, impaired γ-
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secretase cleavage of APP decreased APP re-internalization without affecting β-
secretase expression levels at the cell surface (Kaether et al., 2002). This data suggest 
that processing enzymes can affect APP trafficking through the cleavage itself. It 
remains to be determined what exactly causes the observed effect. It might be a 
feedback mechanism regulation due to the APP cleavage products.   
 
1.3.4.3 APP glycosylation: role in trafficking and intracellular processing 
 
APP is both O- and to a lower extent, N-glycosylated. O-glycosylation 
accounts for the majority of the gel shift, from 91KDa to 110KDa, that is observed 
between non-glycosylated APP and N-O glycosylated APP (Weidemann et al., 1989). 
O-glycosylation of APP occurs in the Golgi compartment (Tomita et al., 1998). N- 
and O-glycosylated APP695 over-expressed in SH-SY5Y neuroblastoma cells is 
found on the surface of the cells and in the trans-Golgi and post-Golgi compartments. 
N-glycosylated forms are found in the endoplasmic reticulum and in the cis-Golgi 
compartment (Tomita et al., 1998). Glycosylation of APP is important for its 
processing and surface transport. There can be several ways in which glycosylation of 
APP can be modified. The most obvious include altering its trafficking between the 
compartments where the glycosylation occurs (both with interacting proteins or 
chemicals) and disruption of the Golgi structure. Other less characterized mechanisms 
include molecules involved in synaptic activity. We report some examples for these 
different mechanisms below.   
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Over-expression of wild type syntaxin 1A abolished glycosylation of APP and 
inhibition of α and β processing as measured by dramatically decreased levels of C99 
and C83 (CTFs) (Khvotchev and Sudhof, 2004). Further analysis of APP 
glycosylation, in presence of the different syntaxins, showed that wild type syntaxin 
induces impairment of APP N- and more dramatically, of O-glycosylation. 
Interestingly, when BACE1 was co-expressed with APP and truncated syntaxin, there 
was an increase in CTFs levels while this increase was not observed when wild type 
syntaxin 1A was expressed. Moreover, analysis of Aβ, revealed that in wild type 
syntaxin transfected cells, Aβ intracellular levels were lower when BACE1 was co-
expressed and there was no increase in Aβ levels in the conditioned media 
(Khvotchev and Sudhof, 2004). This result underlines what already stated earlier: 
increased BACE1 levels do not necessarily correlate to increased APP processing. In 
fact, if APP and BACE1 are physically separated processing cannot occur. While 
having opposite effects on CTFs production, syntaxin and its truncated mutant both 
eliminated sAPP from the culture media (Khvotchev and Sudhof, 2004). Another 
example of a protein affecting APP glycosylation is TMEM59, a trans-membrane 
protein that is resident in the Golgi. TMEM59 over-expression results in APP 
retention in the Golgi (even if no direct interaction with APP was observed) and 
impaired N- and O-glycosylation of APP (Ullrich et al.). TMEM59 seems to act as a 
general inhibitor of glycosylation since it was also able to inhibit N-glycosylation of 
BACE1 and the prion protein. The authors do not describe any effects on C83/C99 
production but observe a decrease in α and β sAPP levels that was not due to loss of 
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BACE1 or ADAM10 activity suggesting, once again, a trafficking mediated effect 
(Ullrich et al.). 
Brefeldin A (a molecule that inhibits APP O-glycosylation by disrupting the 
Golgi) treatment increased Aβ generation in the ER compartment. Moreover, APP 
was not properly localized to the cell surface (Chyung et al., 1997). This study 
underlines once again how APP glycosylation, trafficking and processing are 
intimately related and influence each other. 
NMDA receptor activation increases APP α-secretase processing while 
decreasing Aβ40 intracellular and extracellular levels (Hoey et al., 2009). The over-
expression of the NMDA receptor also caused decreased APP O-glycosylation (Hoey 
et al., 2009). These results are interesting because they relate receptors involved in 
synaptic transmission to APP processing. Moreover, they show that proteins with a 
specific physiologic role that is unrelated to glycosylation, can affect APP 
glycosylation. 
Auto-activation of the TrkB receptors in the Golgi has been shown to cause 
both an accumulation of immature (not fully glycosylated) forms of the receptor and 
at the same time a decreased glycosylation of other proteins. The proteins that are not 
fully glycosylated are then not localized at the cell surface (Schecterson et al.).  
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2. CHAPTER 2: TrkB isoforms differentially 
affect AICD production through their 
intracellular functional domains 
 
Abstract 
 
We report that NTRK2, the gene encoding for the TrkB receptor, can regulate 
APP metabolism, specifically AICD levels.  
Using the human neuroblastoma cell line SH-SY5Y, we characterized the 
effect of three TrkB isoforms (FL, SHC, T) on APP metabolism by knock down and 
over-expression.  
We found that TrkB FL increases AICD mediated transcription and APP 
levels while it decreases sAPP levels. These effects were mainly mediated by the 
tyrosine kinase activity of the receptor and partially by the PLC-γ and SHC binding 
sites. The TrkB T truncated isoform did not have significant effects on APP 
metabolism when transfected alone, while the TrkB SHC decreased AICD mediated 
transcription. TrkB T abolished TrkB FL effects on APP metabolism when co-
transfected with it while TrkB SHC co-transfected with TrkB FL still showed 
increased APP levels.  
In conclusion we demonstrated that TrkB isoforms have differential effects on 
APP metabolism. 
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2.1 Introduction 
 
Alzheimer’s Disease (AD) is a neurodegenerative disorder that will affect 15 
million people in the US alone in the next ten years (Wancata et al., 2003; 
Alzheimer's, 2010). The most common form of the disease is the late onset (LOAD) 
that affects people older than 65. LOAD is caused by a complex interaction of risk 
factors including age, genetics and environmental factors, such as level of education, 
diet and physical activity (Munoz and Feldman, 2000; Khvotchev and Sudhof, 2004; 
Gatz et al., 2006; Scarmeas et al., 2009; Ramesh et al., 2010). To date, the ApoE-ε4 
allele is the only genetic allele that has been unequivocally associated to increased 
risk of late onset AD (Corder et al., 1993; Bertram et al., 2007a; Bertram et al., 2010). 
The majority of the genetic risk factors for AD are still unknown. Genetic linkage, 
association and genome wide association studies are underway to identify genes and 
genomic loci involved in AD pathogenesis (Carrasquillo et al.; Jun et al.; Lipinski et 
al.; Naj et al.; Zetzsche et al.; Myers et al., 2000; Hardy and Selkoe, 2002; Blacker et 
al., 2003; Bertram and Tanzi, 2005; Bertram et al., 2007a; Rogaeva et al., 2007; Lee 
et al., 2008a; Brown et al., 2010; Hong et al., 2010; Reitz et al., 2010). The hope is 
that these studies will provide a further understanding of the disease processes, new 
early diagnosis markers and possible ways of therapeutic intervention.   
We used a previously described cell-based functional screen (Zhang et al., 
2007) to identify putative Amyloid Precursor Protein (APP) metabolism regulators on 
chromosome 9q22. This locus has been genetically linked to AD (Hamshere et al., 
2007). One of the genes on this locus, NTRK2, has been here investigated as a 
potential modulator of APP metabolism. 
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NTRK2 encodes the Tropomyosin Related Kinase B or Tyrosine Receptor 
Kinase B (TrkB), which is the specific receptor of the Brain Derived Neurotrophic 
Factor (BDNF) (Middlemas et al., 1991). There are three major TrkB isoforms 
derived by alternative splicing (Figure 2.1) (Stoilov et al., 2002; Luberg et al., 2010). 
All the isoforms we investigated share an extra-cellular BDNF binding domain and 
differ in their cytoplasmic domain (Figure 2.1) (Stoilov et al., 2002). Two splice 
variants encode full length receptors, TrkB full length (FL), that contain a tyrosine 
kinase domain, a SHC binding domain and a PLC-γ binding domain in the intra-
cellular portion (Middlemas et al., 1991; Atwal et al., 2000). Two are shorter 
receptors, TrkB SHC, that contain only a SHC binding site in the intracellular portion 
and the remaining isoform is a truncated receptor, TrkB T, that does not have any 
known intracellular functional domain (Figure 2.1). Recently, isoforms differing in 
the extra-cellular domain have also been identified (Luberg et al., 2010).    
It is known that TrkB can affect APP metabolism. In fact, TrkB FL increases 
APP promoter transactivation and promotes accumulation of sAPP-α in the media of 
TrkB expressing cells (Ruiz-Leon and Pascual, 2001, 2003, 2004; Holback et al., 
2005). Conversely, Aβ has been found to reduce TrkB FL/BDNF levels and to impair 
TrkB mediated signaling (Olivieri et al., 2003; Tong et al., 2004; Poon et al., 2009; 
Zeng et al., 2010). These results suggest a dynamic and mutual influence of 
TrkB/BDNF signaling and APP. The three neurotrophin receptors TrkA, TrkB and 
TrkC but not p75NTR are down regulated in AD brain samples (Ginsberg et al., 2006). 
Moreover, Trks down regulation seemed to be a good marker of progressively severe 
cognitive impairment (Ginsberg et al., 2006). Finally TrkB T knock-down in a mouse 
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model of Down syndrome, which also displays AD symptoms, rescued neuronal 
death (Carrasquillo et al.). However, case control and genome-wide association 
studies of NTRK2 single nucleotide polymorphisms (SNPs) found no significant 
association with AD (Vepsalainen et al., 2005; Perry et al., 2007; Reiman et al., 2007; 
Chen et al., 2008; Cozza et al., 2008; Li et al., 2008). Only one family based study 
found genetic association of NTRK2 haplotypes and AD (Chen et al., 2008). 
All these results suggest that TrkB and its isoforms affect APP metabolism and could 
play a role in the pathogenesis of AD.  Nevertheless, the effects of TrkB on APP 
metabolism have not been widely investigated, especially the role of the different 
TrkB isoforms.  
We hypothesized that the TrkB truncated isoforms would have different 
effects on APP metabolism dependent on the ability of binding SHC of the TrkB SHC 
isoform. We also hypothesized that the different functional domains on the TrkB FL 
cytoplasmic region would be responsible for some of the previously described APP 
metabolism effects. In particular, we hypothesized that TrkB FL activation and 
binding to PLC-γ activates PKC and therefore increases ADAM10 activity.  
To test these hypothesis, we used a SH-SY5Y neuroblastoma cell line over-
expressing APP as a fusion protein with the yeast transcription factor Gal-4 (Zhang et 
al., 2007). This cell line expresses low endogenous levels of TrkB and BDNF. To 
characterize the role of TrkB FL and truncated isoforms we knocked down and over-
expressed the isoforms and measured APP FL levels and proteolytic products using 
Western blots and luciferase assays. We found that TrkB FL increases AICD-Gal4 
mediated luciferase activity. TrkB T does not alter the luciferase activity while TrkB 
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SHC decreases the luciferase activity compared to control. For the first time we show 
a different effect of the TrkB isoforms on APP. We determined that the functional 
domain responsible for this effect on TrkB FL is the tyrosine kinase domain and that 
the SHC binding and PLC-γ binding domains also contribute to increase the AICD 
mediated luciferase activity in combination with an active tyrosine kinase site. We 
also found that the SHC binding site on TrkB SHC is responsible for the decreased 
AICD mediated luciferase activity. BDNF stimulation of the TrkB exogenously 
expressed receptors amplified the APP metabolism effects and co-transfection of the 
TrkB truncated isoforms with TrkB FL alters its effect on APP metabolism.  
 
2.2 Materials and Methods 
 
2.2.1 Constructs and site directed mutagenesis 
 
Four shRNA containing plasmids specific for NTRK2 were obtained from the 
pSM2 retroviral Library of the Drexel RNAi Resource Center purchased from 
OpenBiosystems. The constructs ID numbers are: NTRK2.1: 1920; NTRK2.2: 2295; 
NTRK2.3: 29734; NTRK2.4: 30795. We also used APP (ID 39147) and luciferase 
targeting shRNA (RHS1705) as positive controls and a scrambled shRNA sequence 
(non-silencing, NS, RHS1707) as a negative control. The TrkB full length and 
truncated GFP fusion constructs and the GFP-F control over-expression plasmid were 
kindly donated by Dr. Eero Castren (University of Helsinki, Finland) and were 
previously described (Haapasalo et al., 1999; Haapasalo et al., 2002). Site-directed 
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mutagenesis (Stratagene, Quikchange mutagenesis kit) was utilized to generate point 
mutants on the TrkB full length receptor functional domains. The mutant amino acid 
indicated refers to the amino-acidic sequence of TrkB. Therefore TrkB FL K571M 
indicates the tyrosine kinase dead receptor since it is mutated on the ATP binding 
site; TrkB FL Y515F indicates the receptor mutated on the SHC binding site; TrkB 
FL Y816F indicates the receptor mutated on the PLC-γ binding site (Minichiello, 
2009). Note that in some literature the TrkB mutants are referred to with the 
numbering of the amino-acidic sequence of TrkA, the NGF receptor, that has 
functional sites in common with TrkB and therefore are referred to as K560M, Y490F 
and Y785F respectively (Middlemas et al., 1991; Atwal et al., 2000). TrkB SHC 
indicates the other human truncated isoform (isoform d and e, NCBI Gene 
NM_001018064+2 and NM_001018066+2). TrkB SHC was obtained by insertion of 
the exon 19 followed by a STOP codon after the SHC binding site on the TrkB FL 
constructs. After obtaining the TrkB SHC isoform by insertion, the SHC binding site 
was mutated on that isoforms using the same primer sequence employed for the TrkB 
FL mutant on the SHC binding site (TrkB Y515F).     
Mutagenesis was carried out according to manufacturer’s instructions and the 
primers employed are reported in the table below (the bolded sequences represent the 
mutations/insertion):  
 
Table 2.1: Primer sequences used to obtain the point mutations and the sequence 
insertion on the TrkB FL receptor. The mutated bases are represented in bold.  
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Primers Sequence 5' to 3' 
TrkB.Y515F.F GTCATTGAAAACCCCCAGTTCTTCGGTATCACCAACAG 
TrkB.Y515F.R CTGTTGGTGATACCGAAGAACTGGGGGTTTTCAATGAC 
TrkB.Y816F.F GCGTCGCCCGTCTTCCTGGACATCCTAG  
TrkB.Y816F.R CGCAGCGGGCAGAAGGACCTGTAGGATC 
TrkB.Shc.F CTCAAGCCGGACACATGGCCCAGAGGTTCCCCCAAGACCGCCTGATAGTAATTTGTTCAGCACATC 
TrkB.Shc.R GATGTGCTGAACAAATTACTATCAGGCGGTCTTGGGGGAACCTCTGGGCCATGTGTCCGGCTTGAG 
TrkB_K571M.F GGTGGCCGTGATGACGCTGAAGG 
TrkB_K571M.R CCTTCAGCGTCATCACGGCCACC 
TrkB.SHC.  GTCATTGAAAACCCCCAGTTCTTCGGTATCACCAACAG 
TrkB.SHC. CTGTTGGTGATACCGAAGAACTGGGGGTTTTCAATGAC 
 
 
Successful mutations were identified by sequencing and one clone per 
construct was transformed in E.coli (DH5-α competent cells, InVitrogen). 
Transformed bacteria were selected on 100 µg/ml ampicillin LB-agar plates and 
liquid cultures were grown overnight at 37 °C. Bacterial cultures were miniprepped 
(MiniPrep Kit, Quiagen) and used for transfection after DNA quantification. 
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2.2.2 Cell culture and transfection 
 
SH-SY5Y cells stably transfected with UAS-Luciferase and APP-Gal4 
described before (Zhang et al., 2007) were maintained in DMEM (Gibco) 
supplemented with 10% FBS, penicillin-streptomycin and 200 µg/ml G418 (Gibco).   
To assess the effects of TrkB knock-down or over-expression on AICD-Gal 4 
mediated luciferase we used the following transfection protocol previously described 
(Zhang et al., 2007). Briefly, one day before transfection cells were plated in 96-wells 
plates at approximately 40-50% confluency. The day of transfection media was 
removed from the cells and replaced with transfection media: 100 µl of serum free 
DMEM media containing 2 µg/well Arrest-In (Open Biosystems) and 0.2 µg/well 
plasmid DNA. The pSM2 plasmids referred to as NTRK2.1 through 4 were 
transfected in the cells. Cells were also transfected with shRNA targeting APP, 
luciferase and a control shRNA that contains a scrambled sequence that does not 
target any human gene. In addition a mock transfection, containing only Arrest-In 
was performed to control for selection effectiveness. 6 replicate wells per shRNA 
constructs and mock control transfection were set up for each independent 
experiment. The transfection media was left on the cells for 8 hours and then replaced 
with complete media. 48 hours after transfection, transfected cells were selected with 
4 µg/ml puromycin (Sigma) in 10% FBS DMEM with 200 µg/ml G418. Puromycin 
selection was used to preserve transiently transfected cells. The media was changed 
every 48 hours and cell death was monitored and compared to the mock-transfected 
control. Once all the cells in the mock control wells were dead, surviving cells, in the 
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shRNA transfected wells, were split and transferred to another 96-well plate and a 24 
well plate. Cell lysates were collected from 60-80% confluent 96-wells 11-13 days 
after transfection in 100 µl Glo Lysis Buffer per well (Promega). Lysates were used 
immediately post collection or frozen prior to performing Steady Glo luciferase 
assays (Promega). The luciferase assays were performed as per manufactures’ 
instructions. ShRNA mediated knock-down effectiveness was monitored by 
comparing the luciferase signal of the non-silencing control shRNA with the APP 
targeting shRNA. After assessing successful knock-down, luciferase data for the 
experimental shRNA targeting NTRK2 was collected and analyzed. In parallel 24-
well plates and 12-well plates were seeded with the same cells that had been assayed 
for luciferase signal, and collected for Western Blot analysis.  
The same transfection procedure was followed for the over-expression 
experiments but lysates were collected 48 hours after transfection and transfection 
efficiency was monitored in fluorescence microscopy, no antibiotic selection was 
performed in this case.   
 
2.2.3 Western Blotting Procedures 
 
Conditioned media was collected from the cells (48 hours after transfection) 
in eppendorf tubes and centrifuged at 14,000 rpm for 10 minutes at 4 °C (Beckman 
Coulter, Microfuge 22R). The resulting supernatant was collected and 142 µl were 
mixed with 33 µl of 4X Reducing loading buffer (InVitrogen) supplemented with 
0.4% β-mercapto-ethanol (Sigma). These samples were heated at 70 °C for 10 
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minutes. The remaining conditioned media was stored frozen at -20 °C for later 
Western Blot analysis.  
Whole cell lysates were collected (48 hours post transfection) by lysing the cells with 
ice-cold radio immuno-precipitation (RIPA) buffer (150mM NaCl, 1% NP40, 0.5% 
DOC, 1% SDS, 50mM Tris, pH 8.0) supplemented with Halt cocktail of protease and 
phosphatase inhibitors (ThermoScientific). Cell lysates were sonicated in an ice-cold 
water bath sonicator for 6 minutes then centrifuged 20 minutes at 4 °C at 14,000 rpm. 
The resulting supernatants were collected and protein concentration measured with a 
BCA protein concentration kit (Pierce) according to manufacturer’s instructions.  
Western blot samples were prepared at a final concentration of 1-2 µg/µl in 4X 
reducing loading buffer (InVitrogen) and heated at 70 °C for 10 minutes. 15-25 µg of 
total protein/well were separated on 4-12% Tris-Glycine midi gels (InVitrogen) in 
MES-SDS running buffer (InVitrogen) and run at 190 mVolts for 45 minutes. The 
separated proteins were transferred to PVDF FL membranes (Millipore) in a Semi-
Dry transfer apparatus (AA Hoefer TE77X) for 3 hours at 125 milli Amp per gel.  
Membranes were blocked one hour at room temperature using Licor blocking buffer 
then probed overnight with primary antibodies diluted in Licor blocking buffer at 4-
25 °C. Membranes were then washed for 5 minutes 4 times with 0.1% Tween 
(Sigma) in PBS. One last wash was performed with PBS to rinse off the detergent. 
After washing, membranes were incubated in the dark with the appropriate secondary 
antibody IRDye (Licor) diluted in Licor blocking buffer for one hour. Again 
membranes were washed as above and finally rinsed with PBS. Membranes were 
scanned on an Odyssey InfraRed scanner (Licor) at appropriate intensities and images 
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acquired. Band intensities were quantified with the provided in-built software (Licor) 
and always normalized to the actin loading control. When conditioned media was 
analyzed the signals were normalized to the protein concentration of the 
corresponding lysates.  
 
2.2.4 Antibodies 
 
Detection of TrkB-GFP tagged constructs utilized mouse anti GFP antibody 
(1:1000, Living Colors, Clontech); detection of APP full length and C- terminal 
fragments utilized A8717 rabbit antibody (1:2000, Rb, Sigma); detection of sAPP 
22C11 utilized mouse antibody (1:1000, Millipore); detection of sAPP-α 6E10 
utilized mouse antibody (1:1000, Covance); detection of actin A5441 utilized mouse 
antibody (1:15,000, Sigma). The secondary antibodies: IRDye700 anti mouse 
antibody (1:15,000) and IRDye800 anti rabbit antibody (1:15,000) were obtained by 
Licor.       
 
2.3 Results 
 
2.3.1 NTRK2 knock-down decreases AICD-mediated luciferase activity 
 
We applied our functional screening method (Zhang et al., 2007) to all the 
genes in the linkage region on chromosome 9 that displays a high likelihood of 
disease score for AD (Blacker et al., 2003). This screening is conducted in SH-SY5Y 
cells stably transfected with a luciferase reporter driven by the yeast UAS promoter 
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and APP fused to Gal4. When APP is cleaved by the secretases the AICD-Gal4 
domain is released and can activate the transcription of the luciferase reporter. 
Variations in AICD mediated luciferase activity are measured. Since changes in 
AICD-mediated luciferase activity can occur through a variety of mechanisms 
affecting APP, this is an effective and general way of identifying regulators of APP 
metabolism (Zhang et al., 2007). We targeted NTRK2 with 4 different shRNA 
constructs. Three shRNAs targeted all the TrkB isoforms (NTRK2.1-3) and one 
(NTRK2.4) targeted all the isoforms except the TrkB T. We also transfected a non-
silencing scrambled shRNA (CTRL) that does not target any human gene as a 
negative control and a shRNA targeting APP as a positive control. Of the four 
transfected constructs NTRK2.1-3 decreased AICD-mediated luciferase to the same 
extent of the APP targeting shRNA compared to the CTRL shRNA (Figure 2.2A). 
The fourth construct, NTRK2.4 targeting all TrkB isoforms except TrkB T, 
consistently caused cell death (data not shown). This result suggests that NTRK2 can 
affect APP metabolism and that the isoforms have different roles since down-
regulation of all the isoforms except TrkB T was lethal. Therefore we investigated the 
effect of the single isoforms in the same experimental model.  
We transiently transfected individual TrkB isoform over-expression constructs 
in the cells and measured AICD-mediated luciferase activity. We found that there was 
no difference in AICD-mediated luciferase activity between TrkB T and the GFP-
control while TrkB FL significantly increased luciferase activity (p=0.01) and TrkB 
SHC significantly decreased it (p=0.01) (Figure 2.2B). These results demonstrate that 
TrkB isoforms have different effects on APP metabolism. Moreover we show that 
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there is a difference between the isoforms TrkB SHC and TrkB T even if both of 
them lack the tyrosine kinase activity. 
 
2.3.2 Two functional domains of TrkB FL (tyrosine kinase and PLC-γ  
binding domains) and the SHC binding domain on TrkB SHC determine 
the effect on AICD mediated luciferase activity 
 
TrkB T did not alter AICD-mediated luciferase activity compared to the GFP-
F control, while TrkB SHC decreased it and TrkB FL increased it. We hypothesized 
that the intracellular domains of the TrkB SHC and TrkB FL are responsible for the 
effects observed. To determine which domain was responsible for this effect, we 
mutated each cytoplasmic functional domain individually.  
We generated a mutant of the TrkB SHC isoform that cannot bind SHC 
(Y515F). We transfected this mutant and the other TrkB wild type isoforms, in SH-
SY5Y-APP-Gal4 cells and measured AICD-mediated luciferase activity. We 
observed that TrkB FL Y515F (SHC binding site mutant) does not significantly alter 
luciferase activity compared to TrkB T but significantly increased it compared to the 
TrkB SHC wild type isoform (p<0.001) (Figure 2.3A). Therefore, disrupting the SHC 
binding site on the TrkB SHC isoform impairs its ability to decrease AICD-mediated 
luciferase activity. 
We then generated mutants on the three functional sites of the TrkB FL. We 
mutated the SHC binding site (Y515F) to generate a mutant that cannot bind SHC. 
Then we mutated the ATP binding site (K571M) to generate a TrkB FL tyrosine 
kinase inactive receptor (Middlemas et al., 1991; Atwal et al., 2000). Similarly, we 
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disrupted the PLC-γ binding site by introducing the mutation Y816F. We also 
generated a double mutant that is tyrosine kinase inactive and does not bind SHC 
(TrkB Y515F/K571M). We then transfected these TrkB FL mutant constructs in SH-
SY5Y-APP-Gal4 cells. We measured the AICD mediated luciferase activity and 
compared it to TrkB FL wild type (Figure 2.3B).       
The TrkB Y515F mutant (preventing SHC binding) did not significantly alter 
AICD-mediated luciferase activity compared to TrkB FL (Figure 2.3B). The TrkB FL 
K571M (tyrosine kinase inactive) significantly decreased luciferase activity compared 
to TrkB FL (p=0.0006). TrkB FL Y816F, (preventing PLC-γ binding) also 
significantly decreases luciferase activity compared to TrkB FL (p<0.0002). The 
double mutant TrkB Y515F/K571M (preventing SHC binding and tyrosine kinase 
inactive) significantly decreased luciferase compared to TrkB FL (p<0.002) but did 
not differ from the tyrosine kinase inactive TrkB K571M (Figure 2.3B).  
In summary, the TrkB FL mediated increase on luciferase activity is mainly 
dependent on the tyrosine kinase activity and PLC-γ binding, while the decrease 
caused by the TrkB SHC isoform is dependent on the SHC binding site. In fact, either 
inactivation of the tyrosine kinase activity (TrkB K571M) or prevention of PLC-γ 
binding (TrkB Y816F), decreased AICD mediate luciferase signal approximately to 
the same extent of TrkB T, 50-70% compared to TrkB FL (Figure 2.2B and Figure 
2.3B). While TrkB SHC decreased AICD-mediated luciferase activity about 90% 
compared to TrkB FL, its mutant, TrkB SHC Y515F, only decreased it to the extent 
of TrkB T, about 70% (Figure 2.3A).    
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2.3.3 NTRK2 knock-down decreases APP FL levels 
 
The effects we observe on AICD-mediated luciferase activity can occur 
through many different mechanisms: decreased APP transcription, increased APP 
degradation, decreased APP cleavage, destabilization of AICD and trafficking that 
affects APP localization. Anything that decreases AICD levels will be reflected in a 
decrease in luciferase activity. The most immediate way of decreasing AICD levels is 
to decrease APP levels. To determine if NTRK2 knock-down decreased APP levels, 
we tested if APP levels were altered. We transfected the NTRK2 targeting shRNA, a 
CTRL shRNA, and an APP targeting shRNA as a positive control. As an additional 
control we used shRNA targeting the luciferase gene: this construct accounts for 
over-expression of shRNA that have to be processed by the endogenous RNAi 
machinery. We then measured APP protein levels by Western blot (Figure 2.4A). We 
found that knock-down of all the TrkB isoforms causes a significant decrease in APP 
FL levels (p<0.05) (Figure 2.4B) and we concluded that decreased APP levels might 
be at least partially responsible for the observed reduction in luciferase activity.   
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2.3.4 TrkB FL over-expression increases APP FL levels and AICD Gal4 
levels 
 
Based on the previous knock-down results, we then hypothesized that over-
expression of TrkB FL causes increased AICD-mediated luciferase activity by 
increasing APP FL levels. We transfected the TrkB isoforms in the cells, performed 
Western blot analysis and quantified APP FL levels in cell lysates. Transfection of 
TrkB FL significantly increased APP FL levels compared to TrkB T (p=0.03) and 
TrkB SHC transfections (p=0.008) (Figure 2.5A). There was no difference in APP 
levels between TrkB T and TrkB SHC transfected cells (Figure 2.5A). 
We then verified that AICD-Gal4 levels in TrkB FL transfected cells correlated to the 
observed increase in luciferase activity. AICD-Gal4 is the intracellular domain of 
APP that is generated by γ-secretase cleavage, translocates to the nucleolus and 
activates transcription. We found that, as expected, TrkB FL showed increased 
AICD-Gal4 levels compared to TrkB T. TrkB SHC, instead, caused an expected 
decrease in AICD-Gal4 levels compared to TrkB T (Figure 2.5B). Interestingly, we 
consistently observed TrkB FL lower levels compared to TrkB T and TrkB SHC in 
our Western blot analysis (Figure 2.5A). 
 
2.3.5 TrkB FL over-expression decreases sAPP levels without altering C83 
levels 
 
To assess changes in APP proteolysis we measured APP C-terminal fragments 
(CTFs) and sAPP levels upon TrkB transfection. CTFs include both C83 and C99. 
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C83 and C99 are generated by the cleavage of APP by α-secretase and β-secretase 
respectively. In our cell line we measure C83-Gal4 and C99-Gal4 levels since APP 
over-expressed is a fusion protein with Gal4. These fragments are the precursors of 
AICD that is released in the cytoplasm by γ-secretase cleavage (Kamenetz et al., 
2003; Cao and Sudhof, 2004). While C83 and C99 are membrane bound fragments of 
APP, the soluble N-terminal fragment of APP, sAPP, generated by α/β-secretase 
cleavage is released in the extra-cellular environment. In SH-SY5Y cells, the β-
secretase cleavage occurs at a lower extent than α-secretase cleavage. Therefore, the 
majority of the luciferase signal observed is due to AICD-Gal4 generated from C83-
Gal4 γ-secretase cleavage. If the AICD-Gal4 fragment levels are increased, as 
measured by luciferase and Western blot, then the levels of its precursor C83-Gal4 
should also be increased.  
We then tested the hypothesis that C83-Gal4 and sAPP levels are increased by 
TrkB FL over-expression and decreased by TrkB SHC. However we could not detect 
a difference in C83-Gal4 levels among the cells transfected with the different TrkB 
isoforms (Figure 2.5C).  
Since C83-Gal4 levels did not differ upon transfection of the different 
isoforms, we hypothesized that sAPP levels should also be constant. We tested this 
hypothesis by measuring sAPP levels in the conditioned media of the cells and 
normalizing it to the total APP levels of the corresponding cell lysates. Surprisingly, 
TrkB FL decreased sAPP levels compared to TrkB T (p=0.01). TrkB SHC showed a 
non-significant difference in sAPP levels compared to TrkB T (Figure 2.5D). We 
hypothesized that the decrease in sAPP levels mediated by TrkB FL might be due to a 
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decrease in APP glycosylation, which is fundamental to allow APP transport to the 
cell surface, where the majority of sAPP is generated. We then measured the ratio of 
APP glycosylated (mature, APPm) to APP non-glycosylated (immature, APPim) in 
cells transfected with the different isoforms and we noticed an unexpected increase in 
APP mature to immature ratio in cells transfected with TrkB FL compared to TrkB T 
(Figure 2.5E, p=0.03). TrkB SHC did not significantly alter APPm/im ratio compared 
to TrkB T. 
 
2.3.6 γ-secretase inhibition increases sAPP levels independent of TrkB 
isoforms 
 
 The effects seen on sAPP levels and APP glycosylation suggest that TrkB 
isoforms might be involved in altering APP trafficking and therefore its cleavage. It is 
known that APP γ-secretase cleavage affects its trafficking and viceversa. In 
particular, decreased γ-secretase cleavage increases sAPP levels (Kaether et al., 
2002). We then tested if TrkB isoforms effects on sAPP levels were affected by γ-
secretase impaired cleavage. We found that TrkB isoforms had the same effects on 
sAPP levels in both L-685 or vehicle treated cells (Figure 2.6A and 2.6B). TrkB FL 
caused a significant decrease in sAPP levels compared to TrkB T while TrkB SHC 
did not alter sAPP levels compared to TrkB T.  Then we checked if γ-secretase 
impaired cleavage was able to increase sAPP levels independently of TrkB isoform 
transfected. We found that γ-secretase inhibition was able to increase sAPP levels 
independent of TrkB isoform transfected (p=0.0002, Figure 2.6C). Therefore the 
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effects on sAPP levels caused by TrkB isoforms and γ-secretase activity impairment 
are independent of each other.       
 - 65 - 
2.3.7 BDNF treatment of TrkB isoforms does not significantly alter their 
effects on APP metabolism 
 
All three TrkB isoforms studied here can bind BDNF (Reichardt, 2006).  Moreover it 
has been previously shown that TrkB FL BDNF-mediated intra-cellular signaling can 
alter APP metabolism (Ruiz-Leon and Pascual, 2001, 2003, 2004; Holback et al., 
2005). We hypothesized that application of exogenous BDNF would stimulate the 
TrkB FL mediated effects on APP FL and proteolytic products levels. We then tested 
this hypothesis applying BDNF to cells transfected with TrkB isoforms and measured 
the levels of APP FL by Western blot. We found that short term (10 minutes) BDNF 
application increases APP FL levels in cells transfected with the TrkB T or TrkB 
SHC isoforms and to a greater degree in cells that had been transfected with TrkB FL 
(Figure 2.7). Longer BDNF application on TrkB FL transfected cells did not increase 
APP FL levels. 
 
2.3.8 Co-transfection of the TrkB isoforms modulates TrkB FL mediated 
effects on APP metabolism 
 
It had been previously shown that TrkB T has a dominant negative effect on 
TrkB FL (Haapasalo et al., 2001). We hypothesized that co-transfection of TrkB T 
with TrkB FL would eliminate the TrkB FL effects on APP metabolism observed 
when we transfect TrkB FL alone. Moreover we hypothesized that co-transfection of 
the TrkB SHC with TrkB FL would also have dominant negative effect on TrkB FL. 
Finally we hypothesized that co-transfection of TrkB FL with TrkB Y515F or TrkB 
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Y816F would not significantly alter the effects seen on APP since they seem to be 
primarily mediated by the tyrosine kinase domain and not by the SHC binding 
domain. For this reason we also hypothesized that co-transfection of TrkB FL with 
TrkB K571M (TrkB FL/K571M) would have the same effect as the co-transfection of 
TrkB FL and TrkB T (TrkB FL/T).  
Consistent with our hypothesis, TrkB FL/T co-transfection did not increase 
APP FL levels, nor did co-transfection of TrkB FL/K571M, the tyrosine kinase 
inactive mutant (Figure 2.8). Also as expected there was very little difference 
between the APP FL levels in cells transfected with TrkB FL/Y515F, TrkB 
FL/Y816F and TrkB FL/FL. Surprisingly, co-transfection of TrkB FL/SHC increased 
APP FL levels compared to TrkB FL/T co-transfection but not compared to TrkB 
FL/FL (Figure 2.8).  
We also hypothesized that BDNF treatment of the co-transfected cells would 
affect the effects on APP of the transfected isoforms. Surprisingly BDNF treatment 
did not significantly alter the effects of the co-transfected TrkB receptors.  
In summary both truncated isoforms were able to decrease APP FL levels compared 
to TrkB FL/FL transfection; TrkB T to a greater extent than TrkB SHC. The tyrosine 
kinase inactive receptor decreased APP FL levels to the same extent of TrkB FL/ T 
co-transfection while TrkB FL/Y515F and TrkB FL/Y816F co-transfection did not 
alter APP FL levels compared to TrkB FL/FL.  
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2.4 Discussion 
 
TrkB is a neurotrophic receptor that is involved in synaptic plasticity and long 
term potentiation (Minichiello, 2009; Thiele et al., 2009; Yoshii and Constantine-
Paton, 2010). Interestingly, APP transcription is up-regulated by TrkB and Aβ 
impairs TrkB/BDNF signaling (Ruiz-Leon and Pascual, 2001, 2003, 2004; Holback et 
al., 2005). This evidence is only based on the TrkB FL receptor and there is no 
investigation of the two additional TrkB splicing isoforms encoded by the NTRK2 
gene. Some single nucleotide polymorphisms on NTRK2 that might be associated 
with AD, are mainly found in proximity of splicing regulating regions suggesting that 
alternative splicing of the gene might be important in AD pathogenesis (Chen et al., 
2008).  TrkB T, the shortest isoform, has been shown to mediate neuronal cell death 
in a mouse model of trisomy 21 which develops AD symptoms (Dorsey et al., 2006). 
This experimental evidence points to a possible role of the TrkB isoforms in AD 
pathogenesis. The TrkB SHC isoform has not been extensively studied. We therefore 
investigated the role of the TrkB isoforms on APP metabolism in SH-SY5Y cells 
over-expressing an APP-Gal-4 fusion protein that can transactivate a luciferase 
reporter gene. This system monitors changes in APP metabolism that are reflected in 
altered AICD-mediated transcription of the luciferase gene (Zhang et al., 2007).  
We found that knock-down of all TrkB isoforms in SH-SY5Y-APP-Gal4 cells 
caused a decrease in AICD-mediated luciferase activity. This decrease is probably due 
to a decrease in APP levels observed in cells with NTRK2 knock-down. We 
hypothesize that decreased APP levels in this system are mainly due to increased APP 
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degradation caused by altered trafficking in absence of TrkB. Transcriptional down-
regulation of APP might be partially responsible for the decreased signal observed in 
the Western Blot but that is only possible for the endogenous APP. In fact the 
endogenous APP gene is under the physiologic transcriptional regulation while the 
APP-Gal4 over-expressed is under CMV promoter regulation. A general increase in 
transcription caused by TrkB FL should be accounted for by the normalization to the 
other transfected reporter, renilla luciferase. In agreement with the knock-down data, 
over-expression of TrkB FL increased APP full length levels compared to TrkB T 
while TrkB SHC did not affect APP levels. This suggests that the modulation of APP 
full length levels is due to the tyrosine kinase active receptor and not to the truncated 
isoforms.    
Knock-down of all the TrkB isoforms except the TrkB T lead to cell death and 
this is consistent with the finding that TrkB T is one of the causes of neuronal death 
in a mouse model of trisomy 21 (Dorsey et al., 2006). 
To discriminate between the effects of the different isoforms, we over-
expressed one isoform at a time and measured the resulting AICD-mediated 
luciferase activity. As a control, we employed a GFP expression vector (GFP-F) that 
includes a farnesylation sequence that targets GFP to the cell membrane. This is a 
better control for a membrane bound receptor than a cytoplasmic GFP. Interestingly, 
we observed a different effect of the isoforms: as expected TrkB FL increased 
luciferase activity, while no difference was observed between TrkB T and GFP-F 
control transfected cells. TrkB SHC induced a decrease in AICD-mediated luciferase 
activity. We hypothesize that the decrease in AICD-mediated luciferase activity 
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induced by TrkB SHC might be mediated by binding of SHC adaptor proteins. 
Binding of adaptor proteins to TrkB and possibly to APP, might decrease the 
endocytosis of APP decreasing its β-secretase cleavage (Lichtenthaler, 2006). The 
luciferase assay described here has been found to be particularly sensitive in detecting 
decreased β-secretase processing (Hoey et al., 2009) and that can be the cause of the 
decrease in luciferase activity that we observe, at least with co-transfection of the 
TrkB SHC isoform.  
Western blot analysis of the cell lysates showed, in agreement with the 
luciferase findings, an increase and AICD-Gal4 levels in cells transfected with TrkB 
FL and a decrease in cells transfected with TrkB SHC compared to TrkB T. We did 
not find a correspondent increase in C83-Gal4, the precursor of AICD-Gal4. This 
discrepancy could be due to the different half life of these fragments and to the low 
sensitivity of Western blots as a detection system. sAPP levels were instead decreased 
by TrkB FL transfection while we expected an increase, or no change, like we 
detected for C83-Gal4. This finding suggests that altered trafficking of APP might be 
also contributing to affect the APP fragment levels. In fact, APP cleavage is strongly 
dependent on its localization. Supporting this hypothesis, is the fact that TrkB 
isoforms differently affect the APPm/im ratio. APP glycosylation is dependent on the 
correct trafficking between endoplasmic reticulum and Golgi apparatus and can affect 
APP processing as well. Therefore if TrkB isoforms affect glycosylation and/or 
trafficking of APP they might cause different APP cleavage patterns. APP trafficking 
and processing are tightly linked in fact impaired γ-secretase cleavage can increase 
surface APP cleavage (Kaether et al., 2002). TrkB isoforms are affecting these 
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processes.  Inhibition of γ-secretase cleavage of APP did not change the effects on 
sAPP levels of the TrkB isoforms but was still able to increase sAPP levels, when 
compared to control, independent of TrkB isoform transfected. This shows that APP 
trafficking is still regulated through common mechanisms independent from the TrkB 
isoform transfected.    
Our data demonstrates differential effects of the TrkB isoforms on AICD-
mediated transcription and APP showing that TrkB SHC behaves differently from 
both TrkB FL and TrkB T. It has been previously demonstrated that BDNF 
application does not improve the cognitive function in a trisomy 21 mouse model 
because TrkB T is up-regulated. Knock-down of TrkB T rescues neuronal death 
suggesting that TrkB T contributes to this phenotype possibly by inhibiting binding of 
BDNF to TrkB FL (Dorsey et al., 2002; Dorsey et al., 2006). Since the three isoforms 
are co-expressed on neurons, the binding of BDNF to TrkB FL will be limited by the 
levels of the truncated TrkB T and TrkB SHC. Therefore, a better understanding of 
the individual TrkB isoforms and their signaling role will improve the therapeutic 
potential of BDNF or BDNF agonists.  
Experimentally, we found that the detected protein levels of TrkB FL were 
much lower than TrkB T and TrkB SHC levels. We can exclude effects due to 
plasmid copy number in the cells since we used equimolar amounts of plasmid DNA 
that account for differences in plasmid size. We can also exclude differences in 
transcription levels due to plasmid promoters since the TrkB SHC plasmid was 
obtained from the TrkB FL encoding construct by insertion mutagenesis. The 
difference in expression levels of the TrkB isoforms is highly reproducible suggesting 
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that there might be a tight regulation of the expression levels of the TrkB FL. TrkB 
FL is stored in intracellular vesicles that rapidly fuse to the cell membrane upon 
BDNF stimulation of the cells (Haapasalo et al., 2002). This causes a fast BDNF 
mediated phosphorylation of the receptor and initiates intracellular signaling (Du et 
al., 2003). After this spike of activity TrkB/BDNF complexes are rapidly endocytosed 
and degraded (Sommerfeld et al., 2000). TrkB FL high expression levels increase 
malignancy in neuroblastomas reinforcing the idea that regulatory mechanisms of 
TrkB expression and signaling are necessary to maintain homeostasis (Douma et al., 
2004; Thiele et al., 2009). TrkB FL expression is also decreased by chronic BDNF 
stimulation of H4 neuroblastoma cells while TrkB T levels remain almost constant 
(Rohe et al., 2009). We therefore hypothesize that, in our model system, TrkB FL 
levels are controlled by mechanisms that cannot be overcome by TrkB FL over-
expression and that BDNF expressed by the cell line might be one of the causes of 
this down-regulation.         
           To determine which functional domain and pathway was mediating the TrkB 
effect, we over-expressed the TrkB isoforms in the same cell line and monitored 
AICD-mediated luciferase activity. We found that the tyrosine kinase domain of TrkB 
FL was responsible for the increased luciferase effect because a mutation of the ATP 
binding site (K571M) in the tyrosine kinase domain abrogated the luciferase activity 
increase. The mutation of the PLC-γ site (Y816F) also induced a significant decrease 
in luciferase activity. We hypothesize that this effect is due to lack of PLC-γ 
activation which produces DAG (Diacyl Glycerol) that is an activator of PKC, a 
protein that mediates ADAM10 activation (Lammich et al., 1999). Moreover, PLC-γ 
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mediates release of Ca2+ from intracellular storage and this might activate some 
transcription factors increasing overall APP levels. The fact that there is a difference 
between the TrkB K571M mutant and the TrkB Y816F PLC-γ binding site mutant 
suggests that not all the effect is due to lack of PLC-γ activation (Figure 2.3B). 
The SHC binding site on the TrkB FL receptor did not seem to be involved in 
mediating increased AICD luciferase activity since the TrkB Y515F mutant did not 
differ from the TrkB FL isoform in increasing AICD-mediated luciferase activity. 
Also the AICD-mediated luciferase signal in cells transfected with the double mutant 
TrkB K571M/Y515F did not differ from the cells transfected with the TrkB K571M 
mutant suggesting that there is no additive effect in eliminating both signaling 
pathways. This does not completely exclude a role for the SHC binding domain. In 
fact, the binding of SHC might occur more efficiently when the site is phosphorylated 
so that, when phosphorylation is prevented, the small change in luciferase signal is 
not detectable in our experimental system. Supporting this hypothesis is a non-
significant decrease of AICD-mediated activity caused by the TrkB Y515F mutant 
compared to TrkB FL.  
We find a significant effect of the elimination of the SHC binding site on the 
TrkB SHC isoform, this mutant induces the same luciferase activity signal of the 
TrkB T. This finding suggests that binding of SHC to the TrkB SHC isoform might 
mediate signaling pathways independently of phosphorylation. Importantly, we 
demonstrate that there is a difference in signal transduction between the two truncated 
TrkB isoforms and that they act on APP mediated transcription. Moreover, we 
identify the SHC binding domain as responsible for the difference in signaling 
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mechanism between TrkB T and SHC. Mutation of the binding site for SHC adaptor 
proteins on the truncated TrkB SHC isoform increases AICD-mediated luciferase 
signal while the same site mutated on the TrkB FL is involved in a decreased 
luciferase signal. This contrasting result suggests that interaction between the same 
proteins and specific TrkB isoforms mediates different signaling pathways.  
The cell line used, SH-SY5Y, expresses basal levels of TrkB receptors and 
BDNF (Stoilov et al., 2002), the endogenously expressed BDNF can promote 
dimerization and activation of the over-expressed receptors. Also, BDNF independent 
activation of TrkB FL receptors has been previously demonstrated (Schecterson et al., 
2010) and we hypothesize that both BDNF independent and dependent activation co-
exist in our experimental system.  Endogenous TrkB receptors might also be up-
regulated or down-regulated in response to exogenous TrkB expression.  
To assess the effect of TrkB BDNF dependent activation we added exogenous 
BDNF on the transfected cells. BDNF is hypothesized to activate the receptors by 
mediating their dimerization (Reichardt, 2006). In our experimental system BDNF 
treatment did not significantly alter the effects of the TrkB isoforms on APP FL 
levels. It has been observed before that TrkB FL over-expression can cause receptor 
auto-activation (Schecterson et al., 2010). Our data suggests that a similar mechanism 
occurs in our experimental system. The close proximity of the over-expressed 
receptors on the membrane probably allows dimerization and activation of the 
receptors independently from BDNF so that even when BDNF is added to the system 
any additional effect on TrkB activation is not detectable.    
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We mentioned above that SH-SY5Y cells express basal levels of the TrkB 
receptors. To investigate the role of TrkB isoforms interaction on TrkB FL mediated 
signaling, we co-expressed exogenous TrkB FL with truncated isoforms and mutated 
variants. Co-transfection of the TrkB FL with the truncated T and SHC isoforms or 
the tyrosine kinase inactive mutant abrogated the increase in APP FL levels induced 
by TrkB FL. Interestingly TrkB FL/SHC co-transfection had higher APP FL levels 
than TrkB FL/T co-transfection. This result points to a possible difference between 
the two TrkB truncated isoforms in the regulation of the TrkB FL catalytic receptor. 
The fact that in the co-transfection experiments TrkB FL/SHC showed increased APP 
FL levels compared to TrkB FL/T also suggests TrkB SHC does not have a dominant 
negative effect on TrkB FL. Maybe this is due to recruitment of SHC adaptor protein 
on its binding site in TrkB FL/SHC heterodimers since the SHC binding site of TrkB 
SHC could be phosphorylated in trans by TrkB FL. Interestingly, TrkB K571M, 
functions, likewise TrkB T, as a dominant negative suggesting that even if the SHC 
binding site is not affected, two tyrosine kinase sites are necessary to induce the 
observed effects, at least on a TrkB FL isoform.  Supporting this, co-transfection of 
TrkB FL/Y515F had similar effects on APP FL to TrkB FL/FL co-transfection. TrkB 
Y515F was less effective in inducing an increase in APP FL levels than TrkB FL. 
This suggests that the tyrosine kinase activity of the receptor is very important in 
increasing APP levels but that two functional SHC binding sites in a heterodimer are 
more efficient than one. TrkB FL/Y816F co-transfection was indistinguishable from 
TrkB FL single transfection suggesting that PLC-γ signaling is not crucial in 
determining increased APP FL levels.  BDNF treatment of the co-transfected cells 
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seemed to accentuate the effect of TrkB FL on APP FL levels. For example it 
increased APP FL in cells co-transfected with TrkB FL/T but not in cells co-
transfected with TrkB FL/K571M. On the contrary, TrkB FL/Y515F co-transfection 
seemed to cause lower APP FL levels when BDNF was applied.  It is intriguing to 
think that when TrkB isoforms are all represented in the cell, like in this experimental 
setting, BDNF might promote homodimerization versus heterodimerization. The issue 
of preferential homo versus hetero interaction of TrkB isoforms has not been 
investigated so far and it would be important to address.    
 
Conclusions 
 
This work demonstrates the difference between TrkB truncated isoforms and 
TrkB FL in affecting APP processing and APP levels. Not only do the truncated 
isoforms have a different effect when transfected alone, they were also able to modify 
the TrkB FL effects when co-transected with it. This finding points to the importance 
of the TrkB isoforms in the pathogenesis of AD. In fact all the isoforms are present 
on neurons and other cell types of the CNS. The proportion of TrkB FL to TrkB T 
and TrkB SHC is then important to determine signal transduction. Since all the 
isoforms bind BDNF in the extra-cellular domain, a therapeutic approach that uses 
BDNF biomimetic drugs might not be as effective as if only TrkB FL was expressed. 
This is assuming that only TrkB FL mediates the beneficial effects in AD context. In 
fact, truncated isoforms could scavenge the drugs, activate alternative non-beneficial 
signaling pathways, decrease the benefit of engaging TrkB FL triggered pathways and 
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also inhibit the TrkB FL effects. Depending on the relative amounts of the TrkB 
receptors on the cells, BDNF-mimetic drugs could cause an over-all worsening of the 
conditions (Dorsey et al., 2002) by, for example, increasing the inflammation 
response. It will be important in the future to dissect the contributions of the TrkB 
isoforms to BDNF dependent and independent signaling pathways in the context of 
AD to better understand which ones are beneficial and which ones are not.       
 
 
2.5 Figure Legends: 
 
Figure 2.1: TrkB isoforms structure and functional domains. The extra-cellular 
portion of the receptor is conserved. The intracellular domain differs among the 
isoforms. TrkB FL contains a tyrosine kinase domain a SHC binding domain and a 
PLC-γ binding domain. TrkB SHC contains a SHC binding domain and TrkB T does 
not have any functional domain. The colored boxed areas represent the domains that 
have been mutated. The amino acid in red is the wilt type residue and the one in blue 
the mutation inserted.  
 
Figure 2.2: AICD-mediated Luciferase activity in SH-SY5Y-APP-Gal4 cells with 
TrkB knock-down or TrkB over-expression. (A) ShRNA mediated NTRK2 knock-
down: luciferase activity is decreased by NTRK2 knock-down compared to non-
silencing control (p=0.03). There is no significant difference between luciferase 
activity in NTRK2 knock-down and APP knock-down cells. ShRNA constructs: 
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negative control, non -silencing, scrambled shRNA sequence; positive control, APP, 
shRNA targeting APP; experimental shRNA, NTRK2.1-3, shRNA constructs 
targeting all TrkB isoforms. The experiment was repeated four times independently 
and each time with six replicates. (B) TrkB isoform over-expression. Luciferase 
activity was not altered by TrkB T compared to GFP control. Luciferase activity was 
increased by TrkB FL (p=0.01) and decreased by TrkB SHC (p=0.01) compared to a 
GFP-control vector. The experiment was repeated 3 to 6 times independently with 6 
replicates each.  
The y-axis represents the arbitrary light units of firefly luciferase normalized to cell 
number (A) or transfection efficiency (B). Error bars=SEM. Statistical analysis: 
ANOVA and student t-test with Bonferroni correction where applicable.    
 
Figure 2.3: TrkB FL mutants on the intracellular functional domains change the 
effect on AICD-mediated luciferase activity. (A) The TrkB SHC isoform 
significantly decreases luciferase activity when compared to TrkB T (p=0.001). The 
TrkB SHC Y515F mutant, unable to bind SHC, increases luciferase activity 
compared to TrkB SHC (p<0.001) and does not significantly alter luciferase activity 
compared to TrkB T (p=0.1).  (B) TrkB Y515F (no SHC binding) does not 
significantly alter luciferase activity compared to TrkB FL. TrkB K571M with an 
inactive tyrosine kinase domain significantly decreases luciferase activity compared 
to TrkB FL (p=0.0006); TrkB Y515F/K571M significantly decreases luciferase 
activity compared to TrkB FL (p=0.002) but not to a greater extent of TrkB K571M. 
TrkB Y816F that does not bind PLC-γ also significantly decreases luciferase activity 
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compared to TrkB FL (p=0.0002). 4-8 independent experiments with 6 replicates 
each, error bars SEM. 4-6 independent experiments with 6 replicates each, error bars 
SEM. Statistical analysis: student t-test with Bonferroni correction.    
 
Figure 2.4: NTRK2 knock-down decreases APP full-length levels. (A) 
Representative Western Blot of APP full length and actin as a loading control in 
lysates from cells transfected with shRNA constructs targeting APP, luciferase 
(LUC), NTRK2 and a negative, non silencing (CTRL), control. (B) Average 
quantification of APP full-length levels from four independent Western Blot analyses 
conducted on independent transfections. Within each transfection APP FL 
densitometry was normalized to the APP FL densitometry of the cell lysate obtained 
from cells transfected with CTRL shRNA. A statistically significant difference was 
observed between CTRL and the APP or NTRK2 shRNA targeting constructs 
(p<0.05). The experiment was repeated four times independently with three replicates 
each, error bars indicate SEM. Statistical analysis: ANOVA.    
 
Figure 2.5: TrkB isoform over-expression affects APP FL levels and APP 
processing. (A) TrkB FL increases APP FL levels compared to TrkB T (p=0.03) and 
TrkB SHC isoforms (p=0.008). 5 independent experiments in duplicate, error bars 
indicate SEM. (B) TrkB FL increases AICD levels compared to TrkB T and TrkB 
SHC decreases AICD levels. (C) TrkB FL, TrkB T and TrkB SHC do not alter C83 
levels. (D) sAPP levels in conditioned media. TrkB FL significantly decreases sAPP 
levels compared to TrkB T (p=0.003). (E) APPm/im ratio is increased by TrkB FL 
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(p=0.03) but not altered by TrkB SHC compared to TrkB T. The Western blot shows 
a representation of APP full length in its fully glycosylated form (APPm= mature) 
and partially glycosylated form (APPim= immature). Below the blot, the 
quantification of the APPm/im ratio (1, 1.4 and 0.9) is reported to facilitate the 
identification of the differences that are not readily apparent in the picture. The bar 
graph represents quantification of 4 independent experiments normalized to APPm/im 
values obtained with TrkB T transfection. The experiment was repeated four times 
independently in duplicate. Error bars indicate SEM. Statistical analysis: student t-test 
with Bonferroni correction. 
 
Figure 2.6: γ-secretase inhibition increases sAPP levels independent of TrkB 
isoforms. (A) Representative Western blot showing sAPP levels in conditioned 
media of SH-SY5Y APP-Gal4 cells transfected with the different TrkB isoforms and 
treated with vehicle (DMSO) or L-685. (B) Quantification of 4 to five independent 
experiments. sAPP levels are normalized to the protein concentration of the 
corresponding cell lysates to normalize for cell number. The sAPP levels are then 
divided for the corresponding sAPP levels in TrkB T transfected cells within 
independent experiments and within treatments. TrkB T then has value 1 and all the 
statistical comparisons are made to TrkB T. TrkB FL induces a decrease in sAPP 
levels in both DMSO and L-685 treatments while TrkB SHC does not affect sAPP 
levels. (C) sAPP levels were normalized to the sAPP levels obtained in TrkB T 
transfected cells within independent experiments. This normalization method allows 
identifying differences induced by γ-secretase cleavage impairment (L-685 treatment) 
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in cells transfected with TrkB isoforms. L-685 treatment induced a significant 
increase in sAPP levels independently of TrkB isoforms (p=0.0002). Statistical 
analysis and comparisons performed are reported to the left of the bar graphs.  
      
Figure 2.7: Short term or long term BDNF treatment of TrkB isoforms 
transfected cells. APP full length (FL) levels are increased by a 10 minutes BDNF 
treatment of TrkB FL transfected cells while a 24 hours treatment shows lower APP 
FL levels. TrkB T and TrkB SHC transfected cells are not significantly affected by 
short term or long term BDNF treatment.  
 
Figure 2.8: Co-transfection of TrkB FL with isoforms and mutants alters the 
TrkB FL effects on APP full length. TrkB FL transfection increases APP FL levels 
compared to when TrkB FL is co-transfected with TrkB T, TrkB SHC or TrkB 
K571M. APP FL levels did not significantly differ between TrkB FL transfected cells 
and TrkB FL co-transfection with TrkB Y515F or TrkB Y816F. 24 hours BDNF 
treatment of co-transfected cells did not significantly alter APP FL levels compared to 
co-transfected but non-treated cells. 
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3. CHAPTER 3: TrkB isoforms differentially 
regulate amyloid precursor protein Swedish 
mutant glycosylation and processing 
 
Abstract 
 
Alzheimer’s Disease (AD) is a neurodegenerative disease that causes progressive 
memory loss which mainly affects people older than 65. At the molecular level, the 
main pathological mechanism of AD is the accumulation of Aβ, a cleavage product of 
Amyloid Precursor Protein (APP), which causes synaptic dysfunction and contributes 
to neuronal death. Age, environmental factors and genetic factors all contribute to 
determine susceptibility to AD. Polymorphisms in the NTRK2 gene are among the 
genetic factors associated with increased AD risk. NTRK2 encodes the neurotrophin 
receptor TrkB. Alternative splicing of the NTRK2 mRNA results in at least three 
major receptor isoforms, TrkB FL, TrkB SHC and TrkB T. All of these bind the same 
ligand, Brain Derived Neurotrophic Factor (BDNF). While TrkB FL has been shown 
to regulate APP expression levels and processing, the exact role of TrkB FL in an AD 
context has not been defined. In addition, the effects of the TrkB SHC and TrkB T 
isoforms on APP metabolism have not been investigated. We tested the hypothesis 
that the TrkB isoforms differentially regulate APP metabolism. We found that TrkB 
FL increased APP FL levels, decreased APP glycosylation and decreased C99/C83 
levels compared to the truncated isoforms. These effects were BDNF independent but 
dependent on the tyrosine kinase activity of the FL receptor. We also found that co-
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expression of the TrkB FL receptor with the truncated isoforms can modulate its 
effect on APP. In particular TrkB T completely eliminated the effects of TrkB FL 
while TrkB SHC did not. These results demonstrate that TrkB isoforms differentially 
regulate APP metabolism. All these isoforms are co-expressed in neurons, it is 
important to understand the combinatorial and isoform-specific signaling in the 
context of AD. Especially, since TrkB FL/BDNF signaling has been shown to be 
beneficial in ameliorating cognitive deficits.  
 
3. 1 Introduction 
 
 Late onset Alzheimer’s Disease (LOAD) is the most common cause of dementia 
in Europe and the USA (Wancata et al., 2003). Since there is no current cure for AD 
and the number of cases is projected to triple in the next ten years (Wancata et al., 
2003), the caregivers, the national health systems and the society are challenged to 
find an efficient, cost effective therapy (Maslow, 2010{Sloane, 2002 #143)}.  
 A major challenge in developing effective AD therapies is the lack of 
understanding of the causative pathological mechanism. The dominant mutations 
causing early onset AD (EOAD) are well characterized and located in three genes: 
amyloid precursor protein (APP) and presenilin 1 and 2 that are involved in APP 
proteolytic cleavage. APP cleavage is the most important pathologic mechanism 
underlying AD: α-secretase cleavage products (C83, p3 and sAPP-α) are non-toxic 
and generally protective while one of the β-secretase products (C99, Aβ and sAPP-β) 
Aβ, leads to synaptic dysfunction and eventually neuro-degeneration (De Strooper 
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and Annaert, 2000; Kamenetz et al., 2003; Oddo et al., 2003). Mutations in APP that 
increase the β-secretase over α-secretase processing cause EO heritable AD (Citron et 
al., 1992; Mullan et al., 1992). Studies on twins suggest that the genotype of 
individuals is a more important risk factor than environment even in the development 
of LOAD (Pedersen et al., 2004; Gatz et al., 2006). Therefore to further 
understanding the causes of LOAD is fundamental to focus the research on the genes 
that might affect APP metabolism.   
 To find putative APP metabolism regulators, we performed a cell-based 
functional screen (Zhang et al., 2007) of genes located between 80-120 cM of 
chromosome 9 since this region displays significant linkage to AD in multiple 
samples (Blacker et al., 2003; Bertram et al., 2007a; Perry et al., 2007). We identified 
genes that affect APP metabolism as possible genetic risk factors for AD and 
potential therapeutic targets (Ansaloni, Zhang, Khandelwal and Saunders, 
unpublished observations). One of these genes was NTRK2, the gene encoding for 
TrkB (Tropomyosin Related Kinase B) which is a receptor for Brain Derived 
Neurotrophic Factor (BDNF) (Soppet et al., 1991; Ansaloni et al., 2010).  
 Our data implicating TrkB in AD pathogenesis is supported by a number of other 
observations. Single nucleotide polymorphisms (SNPs) within the NTRK2 gene have 
been significantly associated with AD in some genetic association studies (Chen et 
al., 2008; Cozza et al., 2008) but not in others (Vepsalainen et al., 2005; Bertram et 
al., 2007a). TrkB signaling via PI3K increases APP expression levels (Ruiz-Leon and 
Pascual, 2001, 2004). Moreover sAPP-α has been shown to increase when full-length 
TrkB is up-regulated by retinoic acid treatment in cell lines and when it is stimulated 
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by Brain Derived Neurotrophic Factor (BDNF) (Holback et al., 2005). The pathways 
that increase the production of BDNF and TrkB full length receptor, like an healthy 
diet and exercise, are generally protective in a AD setting (Ding et al., 2008; 
Komulainen et al., 2008; Schobel et al., 2008; Bousquet et al., 2009; Katsuki et al., 
2009; Nichol et al., 2009). Conversely Aβ has been found to reduce TrkB FL/BDNF 
levels and to impair TrkB mediated signaling (Olivieri et al., 2003; Tong et al., 2004; 
Poon et al., 2009). Decreased levels of TrkB FL and BDNF are observed in AD brain 
tissue when compared to controls (Ginsberg et al., 2006). Interestingly, the lowest 
TrkB FL levels are found in brain samples of AD patients displaying the lowest 
global cognitive score (GCS) and mini-mental state examination score (MMSE) while 
higher TrkB FL levels are found in samples from patients displaying higher scores 
(Ginsberg et al., 2006).  
  TrkB is expressed in the human brain as three major splice variants.  Each of 
these can bind BDNF in the conserved extra-cellular domain but differ in the 
cytoplasmic domain (Figure 3.1). The longest isoforms, full-length TrkB (TrkB FL; 
822-838 amino acids in length) contain tyrosine kinase, SHC binding, and PLC-γ 
binding domains in the cytoplasmic portion. The intermediate length isoform (TrkB 
SHC; 537-553 amino acids in length) contains only a SHC binding domain while the 
truncated TrkB isoform (TrkB T; 477 amino acids in length) does not contain any 
known functional domains in the cytoplasmic domain (Klein et al., 1990a; Middlemas 
et al., 1991; Stoilov et al., 2002). Upon ligand binding, the TrkB FL receptors 
dimerize and auto-phosphorylate triggering intracellular signaling cascades such as 
MAK/ERK signaling, IP3K and IP3/DAG signaling (Eide et al., 1996; Reichardt, 
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2006). The intracellular domain of TrkB T is highly conserved and is important for 
mediating the receptor intra-cellular signaling (Armanini et al., 1995; Baxter et al., 
1997; Rose et al., 2003). TrkB T seems to have a dominant negative effect on TrkB 
FL in neurons (Eide et al., 1996; Ninkina et al., 1996; Haapasalo et al., 2001). The 
antagonistic effect of TrkB T on TrkB FL signaling is evident since knock-down of 
TrkB T in mice with three copies of APP, which develop Alzheimer’s like symptoms, 
improves cognitive decline (Dorsey et al., 2006). The role of the TrkB SHC isoform 
on TrkB FL regulation has not been characterized. 
 These isoforms are expressed at different levels in glia and neurons. TrkB T is 
expressed at higher levels in glial cells than neurons but its expression levels in 
neurons can change as a consequence of TrkB FL signaling (Armanini et al., 1995). 
During development and aging there is a decrease in the expression levels of TrkB FL 
receptors and an increase in the expression of TrkB T and SHC isoforms 
(Allendoerfer et al., 1994; Luberg et al., 2010). This suggests that TrkB truncated 
receptors might play an important role in Alzheimer’s disease if we consider AD as a 
developmental disorder. The higher levels of expression of these isoforms on glial 
cells (Rose et al., 2003) compared to neurons also point to a possible role of TrkB 
truncated receptors in mediating inflammatory response which is central in AD.  
 Signaling of auto-activated TrkB receptor has been demonstrated in absence of 
BDNF (Rajagopal et al., 2004; Mojsilovic-Petrovic et al., 2006; Wiese et al., 2007; 
Jeanneteau et al., 2008; Schecterson et al., 2010). Since BDNF levels are decreased in 
AD patients (Peng et al., 2009), while the levels of TrkB truncated isoforms are 
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increased or unaltered (Allendoerfer et al., 1994; Luberg et al., 2010) BDNF 
independent activation of the TrkB signaling might have an important role in AD.  
 Our study aimed at characterizing the BDNF independent effects of the different 
TrkB receptor isoforms on the metabolism of APP. We used HEK293 cells over-
expressing APP containing the Swedish mutation (APPSwe; K670N and M671L) that 
causes EOAD in humans. We found that TrkB FL over-expression decreased the 
levels of N-O glycosylated APP and altered APP proteolysis leading to decreased 
ratio of C99/C83 fragments. These effects were dependent on the tyrosine kinase 
activity of the receptor. The TrkB FL mediated effects were altered when TrkB FL 
was co-expressed with the other isoforms. TrkB T or the TrkB FL tyrosine kinase 
activity deficient receptors eliminated the effect on APP maturation and processing 
while TrkB SHC did not. This demonstrates that truncated TrkB isoforms 
differentially regulate TrkB FL signaling. Moreover, BDNF application did not alter 
the observed effects suggesting that TrkB receptors can regulate APP metabolism 
through a BDNF independent mechanism.  
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3.2 Materials and Methods 
 
3.2.1 Constructs and site directed mutagenesis 
 
The TrkB full length and truncated GFP fusion constructs were a generous gift of 
Dr. Eero Castren (University of Helsinki, Finland). Site-directed mutagenesis 
(Stratagene Quikchange mutagenesis kit) of the TrkB full-length receptor was utilized 
to generate point mutants on the main functional domains. Here we refer to the 
mutants according to the TrkB sequence: TrkB Y515F, does not bind SHC, (TrkB FL 
Y515F); TrkB K571M, tyrosine kinase inactive (TrkB FL K571M) and TrkB Y816F, 
does not bind PLC-γ (TrkB FL Y816F). While in the literature the numbering of the 
mutant amino acid often refers to the analogous position in the TrkA receptor that 
shares the same functional domains of TrkB. Therefore TrkB FL K560M indicates 
the tyrosine kinase dead receptor since it is mutated on the ATP binding site; TrkB 
FL Y490F indicates the receptor mutated on the SHC binding site; TrkB FL Y785F 
indicates the receptor mutated on the PLC-γ binding site (Middlemas et al., 1991; 
Atwal et al., 2000). TrkB SHC indicates the other major human truncated isoform 
(isoform d and e, NCBI Gene NM_001018064+2 and NM_001018066+2). TrkB SHC 
was obtained by insertion of the exon 19 after the SHC binding site on the original 
TrkB FL construct followed by a stop codon. Mutagenesis was carried out according 
to manufacturer’s instructions and the primers employed are reported in the table 
below (the bolded sequences represent the mutations/insertion):  
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Primers Sequence 5' to 3' 
TrkB.rat.Y515F.F GTCATTGAAAACCCCCAGTTCTTCGGTATCACCAACAG 
TrkB.rat.Y515F.R CTGTTGGTGATACCGAAGAACTGGGGGTTTTCAATGAC 
TrkB.rat.Y816F.F GCGTCGCCCGTCTTCCTGGACATCCTAG  
TrkB.rat.Y816F.R CGCAGCGGGCAGAAGGACCTGTAGGATC 
TrkB.rat.Shc.F CTCAAGCCGGACACATGGCCCAGAGGTTCCCCCAAGACCGCCTGATAGTAATTTGTTCAGCACATC 
TrkB.rat.Shc.R GATGTGCTGAACAAATTACTATCAGGCGGTCTTGGGGGAACCTCTGGGCCATGTGTCCGGCTTGAG 
TrkB_Rat_K571M.F GGTGGCCGTGATGACGCTGAAGG 
TrkB_Rat_K571M.R CCTTCAGCGTCATCACGGCCACC 
 
Table 3.1: Primer sequences used to obtain the point mutations and the sequence 
insertion on the TrkB FL receptor. The mutated bases are represented in bold.  
 
 Successful mutations were identified by sequencing and one clone per construct 
was transformed in E.coli (DH5-α competent cells, InVitrogen). Transformed 
bacteria were selected on 100 µg/ml ampicillin LB-agar plates and liquid cultures 
were grown overnight at 37 °C. Bacterial cultures were miniprepped (MiniPrep Kit, 
Quiagen) and used for transfection after DNA quantification.    
 
3.2.2 Cell culture, transfections and drug treatments 
 
293HEK stably expressing human APPSwe were cultured in DMEM media (Gibco) 
supplemented with 10% FBS (Gibco) with penicillin/streptomycin and 200 µg/ml of 
G418 as selection antibiotic. Cells were maintained at 37 °C in 5% CO2. Twenty-four 
hours before transfection cells were split at approximately 60% confluency in 6-wells 
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plates or 12-wells plates. Cells were transfected for 6 hours in serum free media with 
Arrest-In transfection reagent (Open Biosystems) according to manufacturer’s 
instructions. Plasmids were transfected in equimolar concentrations: 2 µg of the 
longest plasmid (TrkB FL and mutants) were used per well of a six-well plate and 
1µg/well of a 12-well plate. Amounts in µg of the other plasmids were calculated 
accordingly based on base pair number. Two replicate wells per construct, per 
treatment were set up in each experiment and experiments were independently 
repeated at least three times. Six hours post-transfection, the media was changed to 
complete media (see above). The day after transfection, the cells were observed by 
fluorescence microscopy to assess transfection efficiency since all TrkB transfected 
constructs were expressed as GFP fusion proteins. Twelve to fourteen hours before 
collection the cells were treated with L-685,458 (Sigma) at 2.5 µg/ml final 
concentration in DMSO (0.5% concentration) or with 0.5% DMSO (Sigma) as a 
vehicle control. BDNF (Gemini, West Sacramento, CA) was prepared as a stock 
solution in sterile water at 0.1 mg/ml and stored at -20 °C. The final concentration in 
cell media was 50 ng/ml. 
 
3.2.3 Western Blotting 
 
 To assess secreted APP products, sAPP and Aβ, conditioned media was collected 
in eppendorf tubes, centrifuged at 14,000 rpm for 10 minutes at 4 °C in a table-top 
centrifuge (Beckman Coulter, Microfuge 22R). The resulting supernatant was 
collected and 142 µl were mixed with 33 µl of 4X Reducing loading buffer 
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(InVitrogen) with 0.4% β-mercapto-ethanol (Sigma). These samples were mixed and 
heated at 70 °C for 10 minutes. The remaining conditioned media was stored frozen 
at -20 °C for later Western Blot or ELISA analysis. Whole cell lysates were prepared 
by lysing cells in the plate with ice cold radio immuno-precipitation buffer (150mM 
NaCl, 1% NP40, 0.5% DOC, 1% SDS, 50mM Tris, pH 8.0) supplemented with Halt 
cocktail of protease and phosphatase inhibitors (ThermoFisher). Cell lysates were 
sonicated in an ice-cold water bath sonicator for 6 minutes then centrifuged 20 
minutes at 4 °C at 14,000 rpm. The resulting supernatants were collected and protein 
concentration measured with the BCA protein concentration kit (Pierce) according to 
manufacturer’s instructions. Western blot samples were prepared at a final 
concentration of 1-2 µg/µl in 4X reducing loading buffer (InVitrogen) and heated at 
70 °C for 10 minutes. 15-25 µg of total protein/well from the cell lysates were 
separated on 4-12% Tris-Glycine midi gels (InVitrogen) in MES-SDS running buffer 
(InVitrogen) and run at 190 mVolts for 45 minutes. The separated proteins were 
transferred to PVDF FL membranes (Millipore) using a Semi-Dry transfer apparatus 
(AA Hoefer TE77X) for 3 hours at 125 mAmp per gel. Membranes were blocked one 
hour at room temperature using Licor blocking buffer then probed overnight with 
primary antibodies diluted in Licor blocking buffer at 4-25 °C. Membranes were then 
washed for 5 minutes 4 times with 0.1% Tween (Sigma) in PBS. After washing, 
membranes were incubated in the dark with the appropriate secondary antibody 
IRDye (Licor) diluted in Licor blocking buffer for one hour. Again membranes were 
washed as above and finally rinsed with PBS. Membranes were scanned on an 
Odyssey InfraRed scanner (Licor) at appropriate intensities and images acquired at 
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159 µm resolution. Band intensities were quantified with the provided built-in 
software (Licor) and always normalized to the actin loading control. When 
conditioned media was analyzed the signals were normalized to the protein 
concentration of the corresponding lysates.  
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3.2.4 Antibodies 
 
  Detection of TrkB-GFP tagged constructs utilized mouse anti GFP antibody 
(1:1000, Living Colors, Clontech); detection of APP full length and C- terminal 
Fragments utilized A8717 rabbit antibody (1:2000, Rb, Sigma); detection of sAPP 
22C11 utilized mouse antibody (1:1000, Millipore); detection of sAPP-α utilized 
6E10 mouse antibody (1:1000, Covance); detection of actin A5441 utilized mouse 
antibody (1:15,000, Sigma); detection of TrkB phosphorylated on the SHC binding 
site utilized Phospho-TrkA (Tyr490) rabbit antibody (1:1000, Cell Signaling 
Technology Inc.). The secondary antibodies: IRDye700 anti mouse antibody 
(1:15,000) and IRDye800 anti rabbit antibody (1:15,000) were obtained from Licor.       
 
3.2.5 Surface biotinylation 
 
  Forty-eight hours post-transfection, cells in a 6-well plate were washed in cold 
PBS twice then incubated 15 minutes in PBS at 4 °C with mild shaking. The PBS was 
removed and 700 µl/well 0.5 mg/ml EZ-Link Sulfo-NHS-LC-LC-Biotin solution 
(ThermoScientific) was slowly added to each well. Plates were incubated 30 minutes 
at 4 °C with mild shaking. The biotin solution was then aspirated and replaced with 2 
ml/well of 0.1 M ice-cold glycine (EBM) solution to quench the remaining biotin 
reagent. Each well was then washed two more times with glycine. Finally the plates 
were incubated for 20 minutes at 4 °C in mild shaking with 2 ml/well of glycine 
solution. The glycine solution was then removed and cells were washed with PBS 
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three times. The PBS was aspirated and cells were lysed with RIPA as described 
above. Protein concentration was determined using a BCA assay (Pierce). 
Neutravidin agarose beads (High Capacity, #29202, Thermo Scientific) were washed 
according to manufacturer’s instructions. 200 µg of total protein per sample were 
added to 50 µl of resuspended neutravidin agarose beads in 1.5 ml eppendorf tubes, 
the volume was adjusted to 200 µl with PBS. The tubes were then incubated in strong 
shaking for 1 hour at room temperature and centrifuged at 3000 rpm at 4 °C. The 
supernatant was removed and the beads washed three times in 200 µl cold PBS. The 
last wash was discarded. The pellet of beads was added with 40 µl of loading buffer 
(125µl 4X Dye InVitrogen, 25 µl β-mercapto-ethanol, 350 µl H2O) and heated 10 
minutes at 95 °C, then 12 µl of 4X Dye + 20% β-mercapto-ethanol were added to 
each sample. The samples were then spun for 5 minutes at 14,000 rpm and the 
supernatant recovered. All of the supernatant was loaded on the gel together with the 
corresponding lysates as a control.  
 
3.2.6 Aβ  1-40 ELISA Assay 
 
  An Aβ 1-40 specific ELISA kit was purchased from Covance (Cat. No. SIG-
38951-kit). Manufacture’s instructions were followed to set up the assay. Conditioned 
media previously stored at -20 °C was thawed and 30 µl were diluted in 90 µl freshly 
made working buffer (provided with the kit). 100 µl of the diluted sample was loaded 
in each well of the plate. Aβ standards were run in duplicates. As a background 
control, conditioned media from a plate of HEK293APPSwe cells that had been 
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transfected with TrkB T and treated with L-685, 458 for 12 hours was used. This 
treatment eliminates Aβ production. After overnight incubation at 4 °C, the plate was 
washed six times with 250 µl of washing buffer (provided with the kit). Every wash 
was performed in an automatic shaker at maximum speed for 20 seconds. The plate 
was read in a Top-Count Luminometer. Light emission was acquired for 1 second per 
well with no delay and the values recorded in an excel spreadsheet. The values in 
Arbitrary Luminescence Units (ALU) were divided by the protein concentration to 
normalize for cell number in the different wells (µg/ml).    
 
3.2.7 Normalization and Statistical Analysis 
  
 Quantification of the Western Blot membranes was performed with the Odyssey 
System (Licor) analysis software. All the bands of interest were normalized to actin 
when whole cell lysate was used as a sample. When conditioned media was used, 
bands were normalized to protein concentration of the corresponding lysates. In each 
independent transfection involving the TrkB isoforms we normalized bands to the 
samples transfected with TrkB T because we have found no difference between the 
effect of TrkB T and a control GFP plasmid on APP (data not shown). Normalizing to 
TrkB T allowed us to take in account the variation among independent experiments 
and to run statistical analysis on all the data collected. When we co-transfected two 
TrkB constructs we normalized the values obtained within each experiment to the co-
transfection of TrkB FL alone. The F-max test was used to test significant differences 
in variances and the Bonferroni correction for multiple comparisons was used to set 
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the appropriate α value (level of significance). ANOVA was used when the variances 
were equal among treatment groups followed by a post hoc t-test.  
 
3.3 Results 
 
3.3.1 TrkB FL alters full-length APP levels and APP glycosylation 
 
 Given our preliminary data that TrkB alters APP metabolism and the fact that 
increased APP levels can cause AD (Zigman and Lott, 2007; Ansaloni et al., 2010), 
we first tested whether TrkB isoforms modulate full-length APP levels. Over-
expression of TrkB FL significantly increased APP levels, by ~ 50%, compared to 
TrkB T and TrkB SHC over-expression (Figure 3.2A and 3.2B). We also observed 
that TrkB FL over-expression altered APP glycosylation. Specifically, TrkB FL 
caused the accumulation of an intermediate APP glycosylation form, decreasing the 
ratio of fully glycosylated, mature APP to the partially glycosylated, immature APP 
(APPm/APPim) (Figure 3.2A and 3.2C). Over-expression of TrkB T or TrkB SHC 
had no effect on this ratio (Figure 3.2C) compared to a GFP vector control (data not 
shown). TrkB T and TrkB SHC transfected cells had a ratio of APP mature to 
immature close to one, TrkB FL transfected cells had a ratio of ~ 0.6 (Figure 3.2C).  
Since APP levels were altered in cells transfected with the TrkB isoforms, we 
investigated if any of the TrkB isoforms also alters the levels of APP cleavage 
products. First we quantified the APP products of α- and β-secretase activity in whole 
cell lysates after treating the cells with L-685,458, a γ-secretase inhibitor. This drug 
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treatment allows the accumulation of the two membrane associated fragments C83 
and C99, products of the α-secretase and β-secretase activities respectively (Figure 
3.2A). We observed only modest effects of the TrkB isoforms on the C99 and C83 
individual production. In fact, neither C99 levels nor C83 levels are significantly 
affected by transfection of the TrkB isoforms (not shown). However, we found that 
TrkB FL significantly decreases the C99/C83 ratio compared to TrkB T while TrkB 
SHC does not significantly alter the C99/C83 ratio compared to TrkB T, even if it 
shows a decreased average value (Figure 3.2D).  
To further investigate changes in APP proteolysis, we analyzed the 
conditioned media of TrkB transfected cells to measure secreted APP levels, (sAPP). 
sAPP is comprised of the products of α and β secretases cleavage, sAPP-α and sAPP-
β respectively. These N-terminal fragments of APP are released into the cell culture 
media. sAPP-α is mainly generated at the cell surface (Lichtenthaler, 2006; Schobel 
et al., 2008). We found no difference in sAPP levels in the conditioned media of cells 
transfected with the different TrkB isoforms (Figure 3.3A and 3.3B). We then 
compared the levels of sAPP-α and observed a trend in increase of sAPP-α levels as 
a result of TrkB FL over-expression (Figure 3.3A and 3.3C). Interestingly, TrkB FL 
is also the construct for which we find a significant decrease in C99/C83 ratio.   
 Secreted Aβ levels were then determined using ELISA. We observed a trend 
towards decreased Aβ40 levels comparing TrkB SHC over-expression to TrkB T over-
expression (Figure 3.3D; p=0.07). Consistent with the increase in sAPP-α levels, we 
observed a decrease, albeit non statistically significant, in Aβ40 levels in TrkB FL 
over-expressing cells. 
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  In conclusion, TrkB FL increased APP FL levels and decreased the APPm/im 
ratio compared to the truncated isoforms. There were no detectable differences 
between APP FL levels or APPm/im ratio in cells transfected with TrkB T compared 
to TrkB SHC. TrkB FL also decreased the ratio of C99/C83 while TrkB T and SHC 
did not differ from each other. There is a trend in increased sAPP-α levels of TrkB 
FL compared to TrkB T.  Surprisingly TrkB SHC induced a significant decrease in 
Aβ40 levels compared to TrkB T while the Aβ40 levels decrease induced by TrkB FL 
was not significant.     
 
3.3.2 TrkB FL effects on APP metabolism are mainly mediated by the 
tyrosine kinase domain 
 
To determine the mechanism by which TrkB FL modulates APP levels, 
glycosylation and processing we investigated the roles of the tyrosine kinase and SHC 
domains of TrkB. We over-expressed two TrkB FL mutants, TrkB K571M and TrkB 
Y515F, that eliminate tyrosine kinase activity and SHC binding respectively (Atwal 
et al., 2000). Compared to TrkB FL, the tyrosine kinase inactive mutant K571M 
significantly decreased APP levels (p=0.0002) while the SHC binding site mutant 
Y515F had no effect compared to TrkB FL (Figure 3.4A, 3.4B and 3.4C). The levels 
of APP FL in TrkB K571M over-expressing cells were comparable to the ones 
observed in TrkB T or TrkB SHC over-expressing cells (Figure 3.4B).  
We observed that over-expression of the K571M mutant resulted in a 
significantly increased APPm/im ratio compared to TrkB FL (p<0.0001) while the 
Y515F mutant did not alter this ratio (Figure 3.4A, 3.4B & 3.4D). The APPm/im ratio 
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of cells transfected with the K571M mutant was comparable to the one of cells 
transfected with TrkB T or SHC isoforms.  
 We measured and calculated the C99/C83 ratio in cells transfected with these 
mutants (Figure 3.4A, 3.4B, and 3.4E). Again, the K571M mutant had different 
effects compared to TrkB FL over-expression, displaying a trend towards increased 
C99/C83 ratio (p = 0.07). The APPm/im ratio in TrkB K571M over-expressing cells 
is comparable to those observed with TrkB T and TrkB SHC over-expression. The 
TrkB Y515F mutant displayed no difference compared to TrkB FL over-expression. 
We measured sAPP and sAPP-α levels to understand the role of the functional 
domains on sAPP secretion (Figure 3.5A). Interestingly, we observed that the TrkB 
Y515F mutant increased sAPP levels (p=0.02) compared to TrkB FL while K571M 
had no effect (Figure 3.5A and 3.5B). On the other hand, sAPP-α levels were 
decreased in K571M over-expressing cells but not Y515F over-expressing cells, 
compared to TrkB FL (Figure 3.5A and 3.5C). The sAPP-α levels observed in 
K571M over-expressing cells were comparable to levels observed in TrkB T and 
TrkB SHC over-expressing cells. 
Finally, we measured secreted Aβ40 from cells transfected with these mutants 
(Figure 3.5D). We observed a significant decrease in Aβ40 levels upon TrkB Y515F 
over-expression (p=0.04) while TrkB K571M over-expression displayed a trend 
towards increased levels (p=0.10) compared to TrkB FL.  
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3.3.3 Impairment of γ-secretase activity increases sAPP and sAPP-α  levels 
independently of TrkB isoform or mutant 
 
Trafficking and cleavage of APP are intimately related because APP cleavage 
depends on it localization to the same cell compartments where the secretases are 
located. It has been shown that γ-secretase cleavage impairment also affects APP 
localization, increasing its cell surface retention (Kaether et al., 2002). APP retention 
at the cell surface increases sAPP-α production (Lichtenthaler, 2006). Our data 
suggest that TrkB FL and TrkB Y515F might be involved in increasing production of 
sAPP-α. Therefore we tested the hypothesis that both γ-secretase and TrkB 
FL/Y515F mediated increase in sAPP-α might occur through overlapping pathways. 
We then treated TrkB transfected cells with vehicle (DMSO) or L-685 (a γ-secretase 
inhibitor). We collected the conditioned media of these cells and quantified sAPP-α 
levels (Figure 3.6A and 3.6B). First, we checked if TrkB isoforms/mutants had an 
effect on sAPP-α levels in both treatments (Figure 3.6B). We found that both TrkB 
FL and TrkB Y515F showed a tendency to increase sAPP-α levels in DMSO treated 
cells compared to TrkB T (Figure 3.6B). Interestingly, TrkB FL did not show the 
same trend in cells treated with L-685 compared to TrkB T while TrkB Y515F 
displayed the same trend for both treatments (Figure 3.6B). Secondly, we wanted to 
assess if γ-secretase inhibition was effective in increasing sAPP-α levels 
independently of the TrkB isoform or mutant transfected in the cells. Therefore we 
normalized all sAPP-α values to the TrkB T DMSO treatment control and we 
compared the TrkB transfected DMSO treated cells with their corresponding L-685 
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transfections (Figure 3.6C). We found that in all cases γ-secretase inhibition increased 
sAPP-α levels compared to the DMSO treatment (p=0.00001, Figure 3.6C).        
 TrkB Y515F also showed a significant increase of sAPP total (sAPP-α+sAPP-β) 
levels compared to TrkB FL. We then assessed if the combination of TrkB isoforms 
and γ-secretase inhibition had different effects on sAPP total (Figure 3.7). In fact, γ-
secretase impairment increases APP surface retention of APP allowing for more α-
secretase cleavage. The remaining sAPP signal is attributable to sAPP-β. We 
compared TrkB isoforms and mutants within DMSO and L-685 treatments. We found 
that only TrkB Y515F showed a significant increase in sAPP compared to TrkB FL in 
DMSO (p=0.05, Figure 3.7A and 3/7B) and L-685 treatment (p=0.04, Figure 3.7B). 
The other TrkB isoforms did not alter sAPP total levels in either treatment. When we 
compared DMSO and L-685 treatment across the TrkB constructs we found that L-
685 treatment increased sAPP levels in all cases, including TrkB Y515F transfection 
(p=0.003, Figure 3.7C). This result suggests that the increase in sAPP observed with 
L-685 treatment is due only to the treatment and is probably attributable to sAPP-α. 
Instead, since TrkB Y515F has an additive effect to sAPP, the additional sAPP signal 
might be due to an unknown interaction of TrkB Y515F affecting APP cleavage.  
   
3.3.4 TrkB FL increases APP cell surface levels 
 
The increased sAPP-α levels upon TrkB FL transfection compared to the 
truncated isoforms and the fact that the Y515F and K571M mutants have opposite 
effects on sAPP-α levels, suggest differential roles for the SHC and tyrosine kinase 
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domains in modulating APP cleavage at the cell surface. Since sAPP-α is mainly 
generated at the cell surface (Lichtenthaler, 2006; Schobel et al., 2008), we tested 
whether the TrkB isoforms and the TrkB FL mutants modulated cell surface APP 
levels. Higher surface APP levels would explain the increased sAPP-α levels we 
observe upon TrkB FL and TrkB Y515F over-expression. Indeed, compared to TrkB 
T, over-expression of TrkB FL results in a modest increase in cell surface APP levels 
(p=0.06; Figure 3.8A and 3.8B), while over-expression of TrkB SHC does not alter 
these levels. These TrkB FL effects are due to the tyrosine kinase domain since, 
compared to TrkB FL over-expression, the K571M mutant significantly reduced cell 
surface APP levels (p=0.02) while the Y515F mutant did not alter these levels. We 
also noticed the appearance of a faint band of immature APP at the cell surface that 
was more prominent in when full length TrkB constructs were transfected (Figure 
3.8A).  
 
3.3.5 BDNF stimulation does not change TrkB FL effects on APP 
metabolism 
  
Since the experiments described so far were conducted using a cell line that does not 
produce BDNF and in absence of exogenous BDNF in HEK293 (Daniel et al., 2007) 
we wanted to determine if the presence of BDNF would alter the effects resulting 
from TrkB isoform over-expression. The tyrosine kinase activity seems essential to 
trigger TrkB FL effects on APP FL levels, APP glycosylation, sAPP levels and 
C99/C83 ratio, in fact these effects were not recapitulated by the tyrosine kinase 
inactive mutant TrkB K571M. TrkB FL tyrosine kinase activity is necessary to auto-
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phosphorylate the TrkB receptor after BDNF mediated dimerization in physiologic 
conditions (Reichardt, 2006). We hypothesized that addition of exogenous BDNF 
might trigger the activation of different pathways resulting in a different effect on 
APP metabolism. To test this hypothesis we transfected cells with the TrkB isoforms 
and TrkB FL mutants and then we exposed the cells to either 50 ng/ml BDNF or H2O 
for 24 hours (Figure 3.9A). We observed that the addition of BDNF did not change 
the effects that we had previously seen in its absence and that there was still a specific 
effect of the TrkB isoforms; that is TrkB T, SHC and the TrkB K571M mutant had no 
effect on APP full length levels and APP m/im ratio while TrkB FL and TrkB Y515F 
triggered almost exactly the same effects on APP in presence or absence of BDNF.  
 
3.3.6 TrkB FL is phosphorylated in absence of BDNF stimulation 
  
Since the tyrosine kinase activity of TrkB FL receptor was essential for 
mediating the observed effects on APP and BDNF did not change them, we 
hypothesized that in our experimental setting TrkB was able to auto-phosphorylate 
independently of BDNF exposure. There are in fact previous reports of BDNF 
independent phosphorylation of TrkB receptors (Rajagopal et al., 2004; Schecterson 
et al., 2010). We tested this hypothesis by using an antibody that recognizes the 
phosphorylated SHC binding site (tyrosine 515) of TrkB FL and TrkB SHC. We 
looked specifically at the phosphorylation state of the SHC binding site of the TrkB 
receptor. Over-expressing the TrkB isoforms in absence of BDNF, we observed that 
TrkB FL was phosphorylated while TrkB T and TrkB SHC were not phosphorylated 
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(Figure 3.9B). While TrkB SHC does not contain the tyrosine kinase domain, it does 
contain the Tyr 515 residue that is phosphorylated in the TrkB FL isoform. As 
expected, mutation of the Tyr 515 in the TrkB FL isoform abolished phosphorylation 
(Figure 3.9B). Also, inactivation of tyrosine kinase activity in the full-length isoform 
(TrkB K571M) abolished Tyr 515 phosphorylation (data not shown). The absence of 
phosphorylation on the SHC isoform and on the TrkB K571M mutant suggests that 
the tyrosine kinase activity of the receptor is necessary to transfer the phosphate 
group and that phosphorylation by other kinases does not take place, at least in this 
system. 
Since we found that TrkB FL was phosphorylated independently of BDNF we 
concluded that BDNF is not necessary to trigger TrkB receptor phosphorylation in 
this experimental setting. Moreover, TrkB FL and TrkB Y515F both had the same 
effects on APP m/im ratio and APP full-length levels suggesting that the 
phosphorylation of the SHC binding site is not crucial in determining these effects. 
 
3.3.7 Co-transfection of TrkB FL and truncated isoforms changes TrkB 
FL effects on APP metabolism 
 
In our experimental setting BDNF application did not change the effects on APP 
metabolism suggesting that spontaneous dimerization occurs and triggers auto-
phosphorylation of the receptors. We hypothesized that TrkB phosphorylation was 
mediated by the forced dimerization of the receptors that are over-expressed and 
aggregate spontaneously at the cell surface. Since we only transfected one isoform or  
mutant at a time the observed APP effects can only be a consequence of homo-
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dimerization. We reasoned that co-transfection of the TrkB FL with the dominant 
negative isoform, TrkB T (Haapasalo et al., 2001), should decrease TrkB FL 
activation and therefore reduce the extent of its downstream effects on APP 
metabolism. We tested this hypothesis by co-transfecting equimolar amounts of TrkB 
FL and TrkB T over-expression plasmids. To further investigate the regulatory role of 
TrkB SHC on TrkB FL, which is not very clear, we also co-expressed these two 
receptors. Finally, to elucidate the role of the intracellular functional domains on the 
TrkB FL receptor, we also co-expressed the wild type TrkB FL with its mutant TrkB 
K571M and TrkB Y515F.  
Since we co-transfected the TrkB receptors we used as a reference the 
transfection of TrkB FL only and we normalized the Western Blot quantifications to 
that value within each experiment. This way we can relate the results to the previous 
experiments where single isoforms/variants were over-expressed. After 
normalization, co-transfection of TrkB FL/T was compared to all the other co-
transfections.   
We observed that TrkB FL/TrkB T co-transfection (TrkB FL/T) resulted in lower 
APP FL levels than TrkB FL/FL (Figure 3.10A and 3.10B; p=0.001). Co-transfection 
of TrkB FL/SHC increased APP FL levels compared to TrkB FL/T (Figure 3.10B; 
p=0.008). This result is the first that differentiates the TrkB T and TrkB SHC 
isoforms effects on APP levels when measured in whole cell lysates and suggests a 
different regulatory role of the two truncated isoforms on TrkB FL. Co-transfection of 
TrkB FL/Y515F significantly increased APP FL levels similarly to TrkB FL/FL co-
transfection compared to TrkB FL/T co-transfection (p=0.006). While co-transfection 
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of TrkB FL with the tyrosine kinase inactive K571M mutant resulted in APP FL 
levels comparable to TrkB FL/T. 
The ratios of mature APP to immature APP were also altered by co-transfection 
of the TrkB constructs with TrkB FL (Figure 3.10C). As expected from single 
transfection results, TrkB FL/FL transfection lowered the APP m/im the most, all the 
values were normalized to these ratios. TrkB FL/T significantly increased the APP 
m/im ratio compared to TrkB FL/FL (p=0.05). TrkB FL/SHC decreased the APPm/im 
ratio when compared to TrkB FL/T (p=0.009). No significant difference was found 
between the TrkB FL/K571M co-transfection compared to TrkB FL/T. Surprisingly, 
no significant difference was detected between TrkB FL/Y515F co-transfection 
compared to TrkB FL/T. 
We then measured the C99/C83 ratios to see what effect the co-transfection of 
TrkB FL with the other isoforms and mutants would have on β versus α-secretase 
cleavage of APP (Figure 3.10A and 3.10D). Again, all values were normalized to the 
C99/C83 ratio observed in the transfection of TrkB FL only. TrkB FL/T co-
transfection compared to TrkB FL/FL co-transfection yielded a significantly higher 
C99/C83 ratio (p=0.036). TrkB FL/SHC co-transfection decreased the C99/C83 ratio 
compared to TrkB FL/T. Finally there was a trend towards decreased C99/C83 when 
either TrkB FL/Y515F (p=0.071) or TrkB FL/K571M (p=0.069) were co-expressed 
compared to TrkB FL/T.  
sAPP levels were determined in conditioned media of 293Swe cells co-transfected 
with TrkB FL and other TrkB isoforms/variants (Figure 3.10E). As in the single 
transfection experiments, there were no statistically significant differences between 
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sAPP levels from co-transfections of the TrkB FL with each of the isoforms (Figure 
3.10F). We also found no significant difference when we co-transfected TrkB FL 
with the TrkB FL mutants Y515F and K571M (Figure 3.10E and 3.10F). This result 
suggests that TrkB FL eliminates the TrkB FL Y515F mediated increase in sAPP that 
is detectable when TrkB Y515F is transfected by itself.  
Since co-transfecting TrkB FL and the isoforms/mutants had similar effects on 
APP metabolism compared to the single TrkB transfections we tested the hypothesis 
that in this more physiologic context, BDNF treatment might alter the effects. We 
then treated the co-transfected cells with 50 ng/ml BDNF or vehicle (Figure 3.11A).  
Again, BDNF treatment did not alter the effects observed on APP levels, suggesting 
that the APP effects observed are dependent on the TrkB over-expression and do not 
depend on BDNF stimulation. Therefore the effects observed in the co-expression 
experiments are due to the presence of the truncated isoforms or mutant.  
Since we have observed that auto-phosphorylation of the TrkB FL receptor is 
essential for triggering the effects on APP metabolism and that BDNF does not 
change the observed effects on APP, we hypothesized that co-transfection of TrkB FL 
with the isoforms lacking tyrosine kinase activity, or mutants in which this activity is 
disrupted, can reduce or eliminate TrkB FL phosphorylation thereby inhibiting 
intracellular signaling. Therefore we assessed the phosphorylation state of the TrkB 
FL receptor when co-transfected with the other TrkB isoforms/variants (Figure 
3.11B). We observed TrkB FL phosphorylation when TrkB FL was transfected alone 
or co-transfected with TrkB SHC. TrkB FL phosphorylation was greatly reduced 
when TrkB FL was co-transfected with TrkB T, TrkB Y515F or the TrkB K571M 
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mutant (Figure 3.11B). These results demonstrate that TrkB FL phosphorylation can 
be prevented by TrkB T but not by the TrkB SHC isoform.  
 
3.4 Discussion 
 
A variety of experimental evidence suggests that TrkB/BDNF signaling has an 
important role in AD pathogenesis. Genetic linkage and association studies (Blacker 
et al., 2003; Bertram et al., 2007a) as well as TrkB expression analysis in post-
mortem brain tissue (Ginsberg et al., 2006) implicate TrkB in AD. TrkB FL/BDNF 
signaling can activate several signaling pathways through its intracellular domains: a 
SHC binding domain, a tyrosine kinase domain and a PLC-γ binding domain 
(Middlemas et al., 1991). Some of these pathways have been shown to directly affect 
APP metabolism.  In vitro studies show a direct effect of TrkB FL on APP 
transcription and proteolytic processing (Ruiz-Leon and Pascual, 2001, 2004; 
Holback et al., 2005). TrkB FL can activate PLC-γ, which is upstream of PKC, an 
activator of ADAM10 (Yamada et al., 2002; Musumeci et al., 2009); and SHC, that 
binds to TrkB, has been shown to modulate BACE expression levels (Xie et al., 
2007).  In addition, Aβ42 has been shown to down-regulate TrkB /BDNF signaling in 
primary neurons (Tong et al., 2004; Poon et al., 2009), while activation of TrkB 
signaling reduces Aβ production (Rohe et al., 2009). All these results point to the 
existence of a dynamic relationship between APP metabolism and TrkB.  
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3.4.1 TrkB isoforms differentially affect APP metabolism 
 
The role of the truncated TrkB isoforms, TrkB T and TrkB SHC, on APP 
metabolism has not been investigated. All TrkB isoforms are co-expressed in neurons 
and glia (Armanini et al., 1995; Fryer et al., 1996; Fryer et al., 1997; Ohira et al., 
2005; Cheng et al., 2007; Ohira et al., 2007; Carim-Todd et al., 2009). TrkB T was 
initially thought to be the inactive version of TrkB FL (Haapasalo et al., 2001), 
however it can activate signaling pathways independently of TrkB FL (Rose et al., 
2003). Therefore it is important to determine if and how these truncated isoforms 
affect APP metabolism.  
To determine these effects we transfected HEK293 cells stably over-expressing 
APPSwe with over-expression plasmids for TrkB isoforms or mutants. HEK293 cells 
do not express endogeneous TrkB, unlike neuronal cell lines, allowing the study of 
single TrkB isoforms. These cells also do not express BDNF which activates TrkB 
signaling and differentially affects TrkB isoforms turnover (Daniel et al., 2007; 
Colley et al., 2009). In fact is known that TrkB FL is rapidly transported to the 
surface after BDNF stimulation and then degraded (Sommerfeld et al., 2000) while 
TrkB T expression remains constant (Rohe et al., 2009). We initially transiently over-
expressed individual TrkB isoforms under the hypothesis that each isoform 
differentially affects APP metabolism. We found that TrkB FL was able to modify 
APP levels, glycosylation and C99/C83 ratio. TrkB T and SHC did not differ from 
each other in the effects on APP metabolism. 
The two major effects that we observed were altered full-length APP (APP 
FL) levels and altered APP glycosylation, specifically the ratio of fully (mature, N + 
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O glycosylation) to partially glycosylated APP (immature, N glycosylation). We 
believe that these two findings are related. Increased APP FL levels cannot be due to 
a transcriptional effect of TrkB FL on the APP promoter. Even though increased 
transactivation of the endogenous APP promoter by TrkB FL has been previously 
demonstrated (Ruiz-Leon and Pascual, 2001, 2003). In our experimental setting, APP 
is expressed under the control of the CMV promoter therefore it cannot be 
physiologically regulated. The altered APP m/im ratio we observe is consistent with 
the recent finding that auto-activated TrkB receptor can alter glycosylation of proteins 
(Schecterson et al., 2010). We believe that the observed increase in APP FL in our 
experimental setting is due to an accumulation of APP in the pre-Golgi compartment 
that leads to decreased APP turnover thereby increasing steady state APP levels. This 
hypothesis is supported by the decreased ratio of APP m/im. In fact the majority of 
APP that is transported to the cell surface is fully glycosylated. After shedding, APP 
is endocytosed and degraded (Lichtenthaler, 2006). Therefore impaired glycosylation 
of the protein might prevent its transport to degradation compartments.  
APP glycosylation state can regulate APP proteolysis. In fact inhibition of O-
glycosylation, which occurs in the Golgi compartment, inhibits APP α and β 
processing (Tomita et al., 1998). Over-expression of TMEM59, a trans-membrane 
protein that is resident in the Golgi, results in APP retention in the Golgi (even if no 
direct interaction with APP was observed) and impaired N- and O-glycosylation 
(Ullrich et al., 2010). TMEM59 seems to act as a general inhibitor of glycosylation 
since it was also able to inhibit N-glycosylation of BACE1 and the prion protein. The 
authors do not describe any effects on C83/C99 production but observe a decrease in 
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α and β sAPP levels that was not due to loss of BACE1or ADAM10 activity (Ullrich 
et al., 2010).      
Since we do not observe major changes in C83 and/or C99 levels we do not 
have a reason to hypothesize that ADAM10 and BACE1, the two enzymes 
responsible for α and β secretase APP cleavage, are strongly affected by TrkB 
isoform over-expression. Glycosylation defects would impair ADAM10 activity 
(Escrevente et al., 2008) and could affect BACE activity even if BACE activity is 
largely independent of its glycosylation status (Huse et al., 2000; Benjannet et al., 
2001; Vanoni et al., 2008). We also do not observe a statistically significant 
difference in sAPP-α levels when TrkB isoforms and/or mutants are over-expressed. 
We only observed a slight increase in sAPP-α caused by TrkB FL over-expression, 
and a TrkB FL induced glycosylation defect is unlikely to increase ADAM10 activity. 
Since the secretase activity is not likely affected, we hypothesize that the significant 
decrease in C99/C83 ratio that we observe is due to altered APP trafficking. In fact, 
the production of C83 and C99 is influenced by the availability of APP to the 
secretases. That is why we did not normalize the levels of C99 and C83 (CTFs) to the 
total amounts of APP full-length. In fact, even if TrkB FL increases total APP FL 
levels, it might not necessarily increase the pool of APP that is available for cleavage. 
Therefore increases in APP levels do not necessarily correlate to a proportional 
increase in APP proteolytic products. Since the main pathologic mechanism in AD is 
the increased β-secretase cleavage of APP compared to α-secretase cleavage, we 
analyzed the ratio of C99 to C83 to assess if any of the TrkB isoforms displays 
preferential generation of the amyloidogenic fragment (C99) over the non-
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amyloidogenic fragment (C83).  Calculating the C99/C83 ratio normalizes the effects 
of altered APP FL levels and also addresses the question of the APP cleavage route 
that might be favored by the different TrkB isoforms. We found that tyrosine kinase 
active receptors significantly decreased the C99/C83 ratio compared to the 
truncated/TK inactive receptors. This suggests that the TrkB FL beneficial effects 
might be partially mediated by decreased β-secretase cleavage of APP. In agreement 
with this hypothesis is the reduced Aβ40 levels found in the media of cells transfected 
with TrkB FL and TrkB Y515F. The magnitude of the decrease of Aβ40 and 
C99/C83 ratio was modest. C83 and C99 can be generated in different intracellular 
compartments and at the cell surface (Muresan et al., 2009). Some compartments 
might be more subjected than others to TrkB mediated effects. When we measure 
protein levels in the whole cell lysate, we only monitor an average effect that might 
be less obvious that the net effect in specific compartments. This is most likely the 
reason we do not see a robust difference in C99/C83 ratios. The same consideration 
must be applied to secreted Aβ40 levels. 
A general experimental observation we made in the course of these 
experiments was TrkB FL expression levels were lower than the expression levels of 
the truncated counterparts. This is despite using equimolar amounts of DNA used for 
transfection and the identical vector containing the TrkB isoform cDNAs. This 
suggests that there is a regulation mechanism aimed at maintaining TrkB FL levels 
low. Tight regulation of TrkB FL levels after BDNF stimulation has been previously 
demonstrated (Sommerfeld et al., 2000) further underlining the importance of this 
receptor in the homeostasis of the cells.  
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3.4.2 The TrkB FL effects on APP metabolism depend on the tyrosine 
kinase domain but are BDNF independent 
 
Since over-expression of TrkB FL altered APP metabolism most significantly, 
we hypothesized that either the SHC binding domain, tyrosine kinase (TK) domain, 
or both must be responsible for these effects. We therefore mutated the functional 
residues within these domains to determine the relative contribution of these domains 
to the observed effects.  
Only full length TrkB variants with tyrosine kinase activity, FL and Y515F, 
were able to increase APP FL levels and decrease the APPm/im ratio suggesting that 
this is a tyrosine kinase dependent effect. The importance of an active tyrosine kinase 
domain on glycosylation of proteins has been documented by another study that 
extended the finding to all the tyrosine kinase family members: TrkB A, B and C. In 
this study the authors demonstrated how tyrosine kinase inactive receptors were 
unable to alter glycosylation of other proteins (Schecterson et al., 2010). While this 
might seem a rather unspecific effect of intracellular receptor auto-activation, the 
same authors found that TrkB does not have the same effect as the others Trks on 
NOTCH1 (Schecterson et al., 2010). While TrkA and C increase NOTCH1 levels and 
alter its glycosylation, compared to the control cells, TrkB does not. On the contrary, 
TrkB, TrkC and TrkA similarly affect other proteins such as NHR2 and TNFR2 
(Schecterson et al., 2010). NOTCH1 and APP are generally compared since they have 
a similar metabolism and it is interesting to observe that while TrkB FL over-
expression had little effect on NOTCH1 glycosylation it has a considerable effect on 
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APP. This suggests that TrkB effects on APP might be specifically related to this 
neurotrophin receptor and therefore merit through investigation. 
We found similar effects of TrkB over-expression on the glycosylation of the 
TrkB receptor itself: in fact we observed two distinct bands (Figure 3.4A and 3.4B) 
when we over-expressed the tyrosine kinase active receptors (TrkB FL or Y515F, 
Figure 3.4A) and not when we expressed the kinase dead (K571M) receptor (Figure 
3.4B). These two bands represent glycosylated receptor and non-glycosylated or 
partially glycosylated receptor as previously described (Schecterson et al., 2010). 
Similarly we consistently observed the formation of intermediate glycosylation forms 
of APP that migrate between the immature APP and the fully glycosylated APP 
(Figure 3.4A/B, 3.2A, 3.8A, 3.9A, 3.10A, 3.11A). These glycosylation effects have 
been related to modifications of Golgi trafficking mediated by proteins such as Trks 
or TMEM59 (Schecterson et al., 2010; Ullrich et al., 2010).       
sAPP levels were unchanged among all the TrkB isoforms and the TrkB FL 
K571M variant while TrkB Y515F significantly increased sAPP levels. There was no 
significant difference in sAPP-α levels among TrkB isoforms even if both TrkB FL 
and TrkB Y515F displayed a tendency to increase them. The tendency to increase 
sAPP-α of both TrkB FL and TrkB Y515F mutant is consistent with the decreased 
C99/C83 ratio that these constructs yield in whole cell lysates compared to TrkB 
truncated isoforms. It is also consistent with the observed decrease in Aβ 1-40 levels 
detected in conditioned media.  
The TrkB Y515F variant displayed significantly higher sAPP levels compared 
to the other isoforms. This effect is likely not due to an increased sAPP-α level since 
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both TrkB FL and TrkB Y515F showed similar sAPP-α levels. β-secretase cleavage 
also seems unlikely to be increased by TrkB Y515F transfection given the decreased 
C99/C83 ratio and decreased Aβ40 levels. It is possible, though, that mutation of the 
SHC binding site affects the secretion of sAPP-β and that the stability of this 
fragment in the extra-cellular media allows for detection of differences that are not 
evident with other TrkB isoforms and mutants.   
 TrkB FL and Y515F both showed a tendency to increase sAPP-α levels. 
Since sAPP-α levels are thought to be directly proportional to the amount of cell 
surface APP (Lichtenthaler, 2006), we investigated TrkB effects on APP transport to 
the cell surface. We found that tyrosine kinase active TrkB (FL receptor and Y515F) 
increased APP cell surface levels while decreasing TrkB surface levels. TrkB FL 
effects were not significantly altered upon mutation of the SHC binding site (Y515F) 
despite SHC binding has been shown to be important for trafficking of proteins 
(Colley et al., 2009).  Since we attribute the observed APP effects to trafficking 
alteration, we expected that SHC binding would play some important role. Especially 
considering that SHC binds to both TrkB and APP (Tarr et al., 2002). EndophilinA3 
was found to strongly up-regulate α-secretase APP cleavage by inhibiting its 
endocytosis (Schobel et al., 2008). Endophilin has a SH3 domain that can bind the 
SHC adaptor protein like the TrkB receptor. It is hypothesized that interaction of APP 
with proteins favoring its endocytosis reduces α-secretase cleavage and favors β-
secretase cleavage (Lichtenthaler, 2006). Despite this, SHC binding does not seem to 
be the main factor contributing to sAPP-α generation in our experimental setting.  
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We also observed different surface levels of the receptors: TrkB FL and 
Y515F surface levels were lower than the truncated isoforms and the TrkB K571M 
mutant. The altered transport of tyrosine kinase active TrkB receptors might be due to 
the effect that auto-activated TrkB receptors have on the Golgi compartment. This 
would also explain why we did not observe reduced cell surface levels of TrkB 
K571M (Schecterson et al., 2010). Tight regulation of the TrkB receptor surface 
expression has been previously described and the findings agree with what we 
observed: TrkB receptors that have tyrosine kinase activity also display lower surface 
expression levels than TrkB receptors that are tyrosine kinase inactive (Haapasalo et 
al., 2002).        
Interestingly we also observed that TrkB FL and TrkB Y515F (both TK active 
receptors) had a similar effect on the C99/C83 ratio. This effect, even if more modest, 
seemed to be related to the effects described earlier (APP FL and APP m/im ratio). 
We initially hypothesized that TK active receptors would increase C83 production 
through PLC-γ and PKC/ADAM10 activation. In fact it has been previously 
demonstrated that BDNF mediated activation of TrkB FL increases α-secretase 
cleavage of APP (Holback et al., 2005). Surprisingly we did not observe a significant 
increase in C83 suggesting that α-secretase processing is not significantly affected in 
our experimental setting. There are many ways in which SHC binding to TrkB could 
modulate APP trafficking/intracellular processing leading to altered C99/C83 ratios. 
First, TrkB FL binds SHC adaptor proteins and engages ERKs which can decrease 
APP β-secretase processing by increasing transcription of the gene sortin protein 
mediated receptor A (SORLA1)(Rohe et al., 2009). SORLA mediates transport of 
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APP in the trans-Golgi network and early endosomes (Rohe et al., 2009). Secondly, 
siRNA mediated knock-down of Fe65 was able to reduce Aβ production without 
affecting BACE1 levels but altering APP trafficking (Xie et al., 2007). Similarly, 
siRNA mediated SHC knock-down reduces Aβ 40/42 levels but also reduces BACE 
levels. The authors conclude that both Fe65 and SHC might affect APP trafficking 
(Xie et al., 2007).We could then speculate that the decrease in C83/C99 ratio that we 
observe when over-expressing TrkB FL, might result from the increased SORL1 
transcription while in the case of TrkB Y515F by a mechanism mimicking SHC 
knock-down. It is possible that C99/C83 ratio reduction is achieved through different 
but parallel pathways: reduced endocytosis from the cell surface, SORLA1 gene 
expression and maybe other unknown mechanisms that are also TrkB mediated. The 
existence of these multiple pathways complicates the attribution of effects to a 
specific mechanism. Consistently, with the decreased C99/C83 ratio we observed 
reduced Aβ levels when TrkB FL and TrkB Y515F are over-expressed. This Aβ 
effect can also be partially explained with the SHC mediated signaling described 
above. TrkB FL binding SHC can mediate decreased Aβ production via the SORLA 
protein while the TrkB Y515F mutant can act on APP trafficking.  
Finally the SHC binding might play some other role in APP metabolism 
regulation since TrkB Y515F seems to increase APP FL levels less than TrkB FL and 
also to cause less accumulation of immature APP (Figure 3.4A).   
Importantly all these isoform-specific changes in APP levels, glycosylation 
and processing are independent of BDNF binding. Over-expression of TrkB FL alone 
is sufficient to cause phosphorylation of the intracellular domain in the absence of 
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BDNF. BDNF binding does not change the effects on APP metabolism of any of the 
isoforms suggesting that the intracellular signaling triggered by BDNF independent 
TrkB activation is the same. These results suggest that BDNF just mediates 
dimerization of the receptors and this event is what causes the auto-phosphorylation 
(activation) of the receptors and the downstream signaling pathways. When the 
receptors are over-expressed they spontaneously aggregate and can trigger 
intracellular signaling.  
 
3.4.3 Truncated TrkB isoforms suppress TrkB FL mediated effects on 
APP metabolism. 
 
TrkB signaling is achieved by BDNF induced dimerization of the receptors 
that triggers auto-phosphorylation of the intracellular domain on TrkB FL. This 
initiates intracelluar signaling by the binding of the adaptor protein SHC and of PLC-
γ to the TrkB phosphorylated residues (Reichardt, 2006; Minichiello, 2009). The 
three TrkB isoforms, studied here, are co-expressed on the surface of neurons and 
form hetero-dimers (Ohira et al., 2001). Co-expression of TrkB T with TrkB FL 
inhibits TrkB FL mediated intracellular signaling (Ninkina et al., 1996; Haapasalo et 
al., 2001). It has been shown that, in a mouse model of Down Syndrome (where there 
are three copies of the APP gene) down-regulation of TrkB T reduces neuronal death 
re-establishing TrkB FL signaling (Dorsey et al., 2006). The effect of TrkB SHC co-
expression on TrkB FL signaling has not, until now, been investigated.  
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Co-transfection of TrkB FL with TrkB T or TrkB K571M (the tyrosine kinase 
inactive variant) decreases APP FL, increases APPm/im ratio and increases the 
C99/C83 ratio compared to TrkB FL transfection. These two receptors (TrkB T and 
TrkB K571M) act in a dominant negative fashion on TrkB FL. Co-transfection of 
TrkB SHC with TrkB FL, instead, significantly increases APP FL and also 
significantly decreases APPm/im ratio and the C99/C83 ratio compared to TrkB FL/T 
co-transfection. TrkB FL/Y515F co-transfection had the same effects as TrkB FL 
transfection compared to TrkB FL/T co-transfection, suggesting, once again, that the 
tyrosine kinase domain has a pivotal role in determining the effects on APP while the 
SHC binding site on the receptor is a minor contributor. 
 Importantly co-transfection of TrkB FL and SHC also increases sAPP-α 
underlining the importance of further investigating the role of this isoform. In fact, 
while stimulation of TrkB FL signaling for therapeutic purposes might be too 
aggressive since TrkB FL releases Ca2+ from intracellular storage via PLC-γ 
activation. This is not advisable since increased Ca2+ signaling has many adverse 
effects in AD context (Mattson and Chan, 2003). TrkB SHC, instead, lacking the 
PLC-γ binding site, might attenuate the Ca2+ response but still promote α-secretase 
processing of APP by promoting its transport to the cell surface.  
An intriguing open question of TrkB signaling regulation by dimerization is if 
there is a preference of the receptors for homo-dimerization or hetero-dimerization 
and in this second case if one isoform is preferred over the other. In our experimental 
setting we co-transfected equimolar quantities of TrkB receptors and we cannot 
assess whether homo or hetero dimerization is preferred. Our results suggest that 
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hetero-dimerization is probably the cause of the elimination of the TrkB FL mediated 
effects on APP. Supporting this hypothesis, co-transfection of TrkB FL and TrkB T at 
different ratios induced a dose dependent decrease in TrkB FL mediated survival of 
primary neurons when the amount of TrkB T plasmid was increased (Ninkina et al., 
1996). This work would suggest that the hetero-dimerization is mainly driven by 
relative amounts of the receptors at the cell surface. Another intriguing possibility is 
that homo-dimerization of TrkB FL and TrkB T occurs at the same time and activates 
signaling pathways that are interfering with each other. TrkB T has been shown 
before to be able to generate Ca2+ intracellular currents in glial cells independently of 
TrkB FL (Rose et al., 2003). It is known that the domains regulating dimerization of 
Trk receptors are located in the extra-cellular region. There are both domains that 
favor dimerization and domains that inhibit it (Arevalo et al., 2000; Arevalo et al., 
2001). It has been shown that in macaque brains the extent of formation of homo or 
hetero-dimers is directly proportional to BDNF concentration and the composition of 
the dimers changes during development (Ohira et al., 2001). These authors elegantly 
describe the formation of the TrkB dimers by cross-linking the receptors but do not 
show the levels of the TrkB FL receptor versus the TrkB T receptor in the tissues 
under investigation (Ohira et al., 2001). Therefore it remains to be determined if the 
composition of the dimers is solely dependent on the relative concentration of the 
TrkB isoforms or there are other mechanisms involved. This question is particularly 
important since the composition of the dimers can have such different effects on APP 
metabolism. It would be crucial to be able to modulate TrkB signaling with small 
molecules that can be effectively used as drugs in the central nervous system. It has 
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already been shown that engineered BDNF can induce Trk receptors dimerization 
(Ibanez et al., 1993) and that small molecules can be easily synthesized and used as 
agonists to promote TrkB receptor dimerization and activation (O'Leary and Hughes, 
2003; Jang et al., 2009). This drug development approach will become more effective 
once we gain a better molecular understanding of how these different TrkB isoforms 
interaction with each other and modulate signaling.  
 
In conclusion, TrkB truncated isoforms and TrkB FL have different effects on 
APP metabolism. These specific differences are important in AD and have to be 
considered when designing BDNF based therapies. Our results suggest that BDNF 
treatment might be ineffective in AD patients that do not express TrkB FL at high 
levels. In fact BDNF treatment could cause more damage. We also show that co-
expression of the TrkB FL receptor with the truncated isoforms could modulate its 
effect on APP. This result is very important since the three isoforms are co-expressed 
on both neuronal and non-neuronal cells. The relative expression levels of the three 
isoforms in AD are determined by alternative splicing that can be altered by 
polymorphisms in the gene. Studying the relationship between the splicing regulation 
and the TrkB isoforms protein levels might give insight in one more genetic risk 
factor for LOAD. 
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3.5 Figure Legends: 
 
Figure 3.1: Schematic representation of the TrkB human isoforms. Modified from 
Stoilov et al.   
 
Figure 3.2: TrkB isoforms differentially affect APP full-length levels, glycosylation 
(APPm/im) and C99/C83 ratio. (A) Representative western blot of whole cell lysate 
showing TrkB signal and the corresponding APP signal with actin as a loading 
control. (B) APP full-length levels are increased by TrkB FL transfection and not by 
TrkB T or SHC transfection (p=0.01). (C) The ratio of mature to immature APP is 
decreased by TrkB FL transfection but not by TrkB T or SHC transfection (p=0.002). 
(D) TrkB FL significantly decreases the C99/C83 ratio compared to TrkB T 
(p=0.010). (n=6-7).  
 
Figure 3.3: TrkB isoforms effects on total sAPP and sAPP-α levels. (A) 
Representative Western blot showing total sAPP and sAPP-α levels in conditioned 
media from HEK239-APPswe cells transfected with TrkB isoforms. (B) TrkB isoforms 
do not alter total sAPP levels. (C) TrkB FL displays a non-significant increase in 
sAPP-α compared to TrkB T and TrkB SHC. (D) TrkB SHC displays a trend in 
decreased Aβ40 levels compared to TrkB T (p=0.077). Values represent arbitrary 
luminescence units (ALU) and are divided by the protein concentration of the 
corresponding cell lysate. (n=4-5). 
 
 - 131 - 
Figure 3.4: TrkB FL mutants effect on APP full-length, glycosylation (APPm/im) 
and C99/C83 ratio. (A) and (B) representative Western blots showing whole cell 
lysate probed for TrkB, APP, C99, C83 and actin as a loading control. The transfected 
TrkB isoforms/mutants are indicated above each lane. Note that TrkB FL and TrkB 
Y515F show two bands corresponding to different glycosylated receptors while the 
TrkB T, the TrkB SHC isoforms and TrkB K571M migrate as a single band. (C) 
TrkB K571M causes a significant decrease in APP levels when compared to TrkB FL 
wild type (n=3; p=0.0002); there is no significant difference in APP levels between 
TrkB FL and TrkB Y515F mutant (n=7, p=0.5). (D) TrkB K571M significantly 
increases the APP m/im ratio when compared to TrkB FL (n= 4, p=0.006); the TrkB 
Y515F mutant does not alter the APPm/im ratio compared to TrkB FL (n=5). (E) 
TrkB K571M shows a trend in increasing the C99/C83 ratio compared to TrkB FL 
(p=0.07, n=3), TrkB Y515F does not affect the C99/C83 ratio compared to TrkB FL.   
 
Figure 3.5: Total sAPP, sAPP-α, Aβ40 levels in conditioned media of HEK293-
APPswe cells transfected with TrkB isoforms or TrkB FL mutants. (A) Representative 
Western blot of conditioned media probed for sAPP total and sAPP-α. The 
transfected TrkB constructs are indicated above each lane. (B) Total sAPP levels are 
significantly increased by transfection of TrkB Y515F compared to TrkB FL (p=0.02) 
but not by transfection of TrkB FL K571M. (C) TrkB Y515F does not significantly 
affect sAPP-α levels and TrkB K571M decreases non significantly sAPP-α compared 
to TrkB FL. (D) TrkB Y515F significantly decreased Aβ1-40 levels compared to 
TrkB FL (p=0.05) while TrkB K571M showed a non significant increase.     
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Figure 3.6: Impairment of γ-secretase cleavage increases sAPP-α levels 
independently of TrkB transfected construct. (A) Representative Western blot 
showing sAPP-α levels in cells transfected with TrkB isoforms and mutants and 
treated with DMSO or L-685. (B) sAPP-α levels were normalized to the values 
detected in TrkB T transfected cells within treatments. TrkB FL and TrkB Y515F 
show a tendency to increase sAPP-α in DMSO treated cells compared to TrkB T but 
this increase is not significant. Only TrkB Y515F displays the tendency to further 
increase sAPP-α levels compared to TrkB T in L-685 treated cells. TrkB FL 
Transfected cells treated with L-685 display the same sAPP-α levels of TrkB T 
transfected cells and L-685 treated. (C) L-685 treatment significantly increases sAPP-
α levels independently of TrkB construct transfected (p=0.0001).  
 
Figure 3.7: Impairment of γ-secretase cleavage increases sAPP levels independently 
of TrkB transfected construct but does not alter the effects of the TrkB isoforms. (A) 
Representative Western blot showing sAPP levels in cells transfected with TrkB 
isoforms and mutants and treated with DMSO or L-685. (B) sAPP levels were 
normalized to the values detected in TrkB T transfected cells within treatments. TrkB 
Y515F shows increased sAPP in DMSO treated cells compared to TrkB T (p=0.05) 
and in L-685 treated cells (p=0.04). (C) L-685 treatment significantly increases sAPP-
levels independently of TrkB construct transfected (p=0.0001) even if the TrkB 
Y515F levels are higher compared to other TrkB constructs.      
 
 - 133 - 
Figure 3.8: Cell surface APP levels in cells transfected with TrkB isoforms and TrkB 
FL mutants. (A) Representative Western blot of whole cell lysates from cells 
transfected with different TrkB construct and the corresponding biotinylated surface 
protein. Note that the APP detected at the cell surface is mainly fully glycosylated 
APP. A low level of immature and intermediately glycosylated APP is more 
prominent in the TrkB FL and TrkB Y515F transfected cells. (B) APP glycosylated 
surface levels are higher in TrkB FL and TrkB Y515F transfected cells, there is no 
statistically significant difference between TrkB FL and TrkB T. There is a 
statistically significant difference between TrkB FL and TrkB K571M transfected 
cells (n=3; p=0.02).  
 
Figure 3.9: TrkB mediated effects on APP metabolism are BDNF independent and 
TrkB FL is phosphorylated in absence of BDNF stimulation. (A) Treatment of TrkB 
transfected cells with BDNF (50 ng/ml) does not alter the isoform/mutant specific 
effects on APP levels and/or glycosylation. (B) TrkB FL auto-phosphorylates when 
over-expressed in HEK293-APPswe without BDNF treatment. A Y515 phospho-
specific antibody was used to detect TrkB FL phosphorylated at tyrosine 515. Note 
that TrkB T, TrkB SHC and the full-length Y515F mutant are not phosphorylated.  
 
Figure 3.10: TrkB FL co-transfection with TrkB isoforms and TrkB FL mutants.  
(A) Representative Western blot of whole cell lysates from HEK293-APPswe co-
transfected with TrkB FL and truncated isoforms or mutants. Note the several bands 
corresponding to the molecular weight of the different isoforms transfected, when 
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only TrkB FL is transfected the bands are reduced to two or one. (B) APP full-length 
levels are increased in cells co-transfected with TrkB FL/SHC compared to TrkB 
FL/T (p= 0.008); TrkB FL/Y515F co-transfection also increases APP full-length 
levels compared to TrkB FL/T (p= 0.006); TrkB FL/K571M APP full-length levels 
are not statistically significantly different from TrkB FL/T. (C) APPm/im ratios are 
decreased by co-transfection of TrkB FL/SHC compared to TrkB FL/T (p=0.009); 
surprisingly no significant difference was found between TrkB FL/Y515F compared 
to TrkB FL/T. As expected there was no significant difference between co-
transfection of TrkB FL/K571M compared to TrkB FL/T (n=6-8). (D) TrkB FL/SHC 
co-transfection decreases the C99/C83 ratio compared to TrkB FL/T (p=0.036); TrkB 
FL/Y515F co-transfection shows a trend in decreased C99/C83 ratio compared to 
TrkB FL/T (p=0.07). There is no significant difference between TrkB FL/K571M co-
transfection and TrkB FL/T co-transfection. (E) Representative Western blot of total 
sAPP in conditioned media of TrkB co-transfected cells. (F) There is no difference in 
sAPP total levels in conditioned media from cells co-transfected with TrkB FL and 
the other TrkB isoforms or mutants.  
 
Figure 3.11: BDNF treatment of cells co-transfected with TrkB FL and TrkB 
isoforms/mutants. (A) Treatment with BDNF does not change the effects of TrkB FL 
co-transfection with isoforms/mutants on APP full-length or APP glycosylation. (B) 
Phosphorylation on the SHC binding site of the TrkB FL receptor is detectable when 
TrkB FL is co-transfected with TrkB FL or TrkB SHC. No detectable 
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phosphorylation is evident in TrkB FL/T, TrkB FL/Y515F and TrkB FL/K571M co-
transfections. 
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4. CHAPTER 4: TrkB mediates endogenous 
APP metabolism, BACE endogenous levels and 
NFAT mediated transcriptional activity 
 
Abstract 
 
TrkB isoforms differentially affect APP levels and processing in SH-SY5Y 
APP Gal4 cells and HEK293 APPSwe cells. These two cell lines over-express APP 
and are used as a model for several reasons. SH-SY5Y APP Gal4 cells are a 
neuroblastoma cell line that had been modified to allow AICD levels detection 
through a luciferase reporter system. HEK293 APPSwe cells over-express an APP 
mutant that causes early onset Alzheimer’s disease in patients. These cell lines cannot 
be used to investigate the effects of TrkB isoforms on endogenous APP.  
We therefore investigated the effects of TrkB FL and TrkB T to test the 
hypothesis that TrkB might have different effects in the two corresponding naive cell 
lines. Because we have observed TrkB isoforms effects on APP processing, we also 
tested the hypothesis that TrkB FL might affect endogenous ADAM10 activity and 
BACE1 levels in HEK293 cells.  
We find that TrkB FL increases APP endogenous levels in both HEK293 and 
SH-SY5Y naïve cells. We do not find an increase in ADAM10 activity in HEK293 
cells but an increase in BACE1 levels. We also find that TrkB FL is able to increase 
NFAT mediated transcriptional activity and we suggest that this might be the 
mechanism of transcriptional activation of the BACE1 promoter that causes increased 
BACE1 levels.    
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4. 1 Introduction 
 
We have found that TrkB mediated signaling can affect the processing and the 
expression levels of over-expressed APP in two different cell lines: SH-SY5Y and 
HEK293 cells. Interestingly, we found that in SH-SY5Y cells APP full-length levels 
were increased and the TrkB FL receptor increased APP mature levels. In HEK293 
cells APP full-length levels were also increased but APP mature levels were 
decreased (the glycosylation of APP was impaired). This result suggests that there are 
specific regulation mechanisms dependent on the cell line used. We therefore wanted 
to test if TrkB FL and TrkB T had different effects on endogenously expressed APP 
in these two different cell lines.  
TrkB FL also had an effect on APP processing that was dependent on the 
tyrosine kinase activity of the receptor. This was evident in both cell lines. In SH-
SY5Y APP Gal4 cells, TrkB FL increased AICD mediated transcriptional activity and 
AICD-Gal4 levels. Previous experimental evidence suggested increased ADAM 
activity in SH-SY5Y cells stimulated by RA that induces up-regulation of TrkB 
(Holback et al., 2005). These studies did not investigate if RA was able to increase 
ADAM activity or levels but only measured the products of APP α-secretase 
cleavage, sAPP-α as indirect evidence of increased ADAM activity. First we 
demonstrated that RA treatment of SH-SY5Y cells specifically increases ADAM 
activity and levels. We observed a slight increase in sAPP-α levels upon transfection 
of TrkB FL in HEK293 APPSwe cells. We then tested the hypothesis that TrkB FL can 
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directly affect ADAM activity in HEK293 APPSwe cells in a BDNF independent 
manner.   
In HEK293 APPSwe cells, TrkB FL decreased the C99/C83 levels but did not alter 
C83 levels, suggesting a specific effect on β-secretase cleavage of APP. BACE1 is 
responsible for β-secretase cleavage of APP and its levels are influenced by SHC 
levels and by NFAT mediated transcription (Groth and Mermelstein, 2003; Xie et al., 
2007). Since both SHC and NFAT are mediators of TrkB FL signaling pathways, we 
tested the hypothesis that TrkB FL auto-activation in HEK293 cells might modulate 
BACE1 levels via NFAT mediated transcriptional regulation. 
We found that, in both SH-SY5Y and HEK293 cells, TrkB FL over-
expression increases endogenous levels of APP. Moreover, TrkB FL specifically 
increases NFAT mediated transcription in both cell lines. We also found that in 
HEK293 APPSwe cells endogenous BACE levels were increased by TrkB FL over-
expression.  
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4.2 Materials and Methods 
 
4.2.1 Cell lines and stable populations 
 
SH-SY5Y Naïve and 293HEK cells were maintained in DMEM medium (Gibco) 
with 10% FBS (Gibco) with penicillin streptomycin. SH-SY5Y APP-Gal-4 cells were 
maintained in the same media but added with 200 µg/ml of G418 (Gibco).  
We also obtained stable cell populations expressing farnesylated GFP, TrkB T and 
TrkB FL both GFP tagged. The transfected cells were selected with 400 µg/ml G418 
from 48 hours after transfection up to one month. Liquid nitrogen stocks were 
obtained. Expression of the constructs was verified by fluorescence microscopy.      
For ADAM activity assays cells treated with 10µM in 0.5% DMSO of the ADAM10 
agonist PMA (phorbol 12-myristate 13-acetate, Sigma) for 10 hours or DMSO 
control.  
We also treated cells with 20 µM of all trans retinoic acid (ATRA or RA, Sigma) in 
0.5% DMSO for 48 hours before collection, when this treatment was performed, 
control cells were treated 48 hours with 0.5% DMSO. 
 
4.2.2 ADAM10 Assay 
 
Cell lysates were collected in extraction buffer provided with the R&D Systems 
ADAM activity kit and centrifuged at 4 °C. The supernatant was saved and combined 
with reaction buffer and substrate in a 96-well plate. The plate was incubated at 37 °C 
 - 151 - 
in the dark for 2 hours and then placed in a Tecan Infinite 200 plate reader controlled 
by the commercial software Magellan. The plate reader was set at 355nm excitation 
wavelength and absorption was read at 510nm, the gain was automatically optimized 
and the integration time was set at 80 µS. Each well was read only once. As a positive 
control we used lysates from PMA treated cells. Each lysate was run in duplicates and 
readings were averaged. Background readings from wells containing reagents and 
substrate were divided by the experimental values and positive controls so that the 
ADAM10 activity is expressed in fold increase over background. The experiment was 
repeated twice independently for the cell lines and three times independently for the 
stable population of HEK293 cells transfected with TrkB constructs or GFP-F 
controls. Statistical analysis was conducted using the student t-test.  
 
4.2.3 Western blotting procedure and antibodies 
 
Cells were collected 48 hours after all transfection procedures Whole cell lysates 
were prepared by lysing cells in the plate with ice cold radio immuno-precipitation 
buffer (150mM NaCl, 1% NP40, 0.5% DOC, 1% SDS, 50mM Tris, pH 8.0) 
supplemented with Halt cocktail of protease and phosphatase inhibitors 
(ThermoFisher). Cell lysates were sonicated in an ice-cold water bath sonicator for 6 
minutes then centrifuged 20 minutes at 4 °C at 14,000 rpm. The resulting 
supernatants were collected and protein concentration measured with the BCA protein 
concentration kit (Pierce) according to manufacturer’s instructions. Western blot 
samples were prepared at a final concentration of 1-2 µg/µl in 4X reducing loading 
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buffer (InVitrogen) and heated at 70 °C for 10 minutes. 15-25 µg of total protein/well 
from the cell lysates were separated on 4-12% Tris-Glycine midi gels (InVitrogen) in 
MES-SDS running buffer (InVitrogen) and run at 190 mVolts for 45 minutes. The 
separated proteins were transferred to PVDF FL membranes (Millipore) using a 
Semi-Dry transfer apparatus (AA Hoefer TE77X) for 3 hours at 125 mAmp per gel. 
Membranes were blocked one hour at room temperature using Licor blocking buffer 
then probed overnight with primary antibodies diluted in Licor blocking buffer at 4-
25 °C. Membranes were then washed for 5 minutes 4 times with 0.1% Tween 
(Sigma) in PBS. After washing, membranes were incubated in the dark with the 
appropriate secondary antibody IRDye (Licor) diluted in Licor blocking buffer for 
one hour. Again membranes were washed as above and finally rinsed with PBS. 
Membranes were scanned on an Odyssey InfraRed scanner (Licor) at appropriate 
intensities and images acquired at 159 µm resolution. Band intensities were 
quantified with the provided built-in software (Licor) and always normalized to the 
actin loading control.  
APP was detected using a rabbit antibody A8717 (Sigma) at 1:2000 dilution; TrkB 
GFP tagged proteins were detected using a mouse GFP antibody (Clontech) at 1:500 
dilution; TrkB was also detected with a pan-TrkB rabbit antibody (Santa Cruz 
Biotechnology); BACE1 was detected using a rabbit antibody ab2077 (Abcam) at 
1:1000 dilution; ADAM10 was detected using a rabbit antibody (Chemicon); actin 
was detected using a mouse antibody (Sigma) at 1:15,000 dilution. Secondary IRDye 
antibodies (anti rabbit IR800 and anti mouse IR700) were purchased from Licor and 
used at 1:15,000 dilution.    
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4.2.4 Transfection and luciferase reporter assays 
 
Cells were transfected at approximately 50-60% confluency in 96-well plates using 
Arrest-In transfection reagent (OpenBiosystems) according to manufacturer’s 
protocol. For the reporter experiments TrkB plasmids, the GFP-F (negative control, 
Clontech) and the NFAT3-GFP plasmids (positive control, a gift of Dr. Chris Norris) 
were co-transfected with the NFAT luciferase reporter (Promega) or the pGL3 
luciferase reporter (Promega). Experimental or control plasmids were transfected in 
1:1 molar ratio with the luciferase reporter plasmids. In all transfections a renilla 
luciferase reporter (pRLSV40 or pRLTK, Promega) was used as a transfection 
normalization control at a molar ratio of 1:40 to the luciferase plasmid.   
Cells were collected in Dual Glo Lysis Buffer (E2920, Promega) 48 hours post 
transfection and the assay was carried out as per manufacturer’s instructions. Plates 
were read in a plate reader luciferase signal was normalized to renilla and data was 
analyzed using t-tests with Bonferroni correction for multiple comparisons.         
 
4.3 Results 
 
4.3.1 Effects of TrkB T and TrkB FL transfection on endogenous APP in 
HEK293 and SH-SY5Y cells 
 
TrkB FL has been reported to increase transcription of the APP promoter via 
IP3K and Akt mediated pathways in SH-SY5Y cells (Ruiz-Leon and Pascual, 2004). 
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Our previously employed cell models utilized cells that over-express APP under the 
CMV promoter and therefore impede the assessment of the effects of TrkB on 
endogenous APP. We hypothesized that, in both HEK293 naive cells and SH-SY5Y 
naive cells, TrkB FL transfection increases APP transcription. In fact, the signaling 
pathways triggered by TrkB FL engage molecules that are ubiquitously expressed in 
all cell lines.  
We transiently transfected GFP-F, TrkB T and TrkB FL in HEK293 cells and 
measured APP levels 48 hours post-transfection. APP detection was difficult in this 
naïve cell line. We found that TrkB FL transfection significantly increased APP 
levels compared to GFP-F or TrkB T transfection (Figure 4.1A and 4.1B). The extent 
of the increase, though, was modest. We then measured APP in a stable population of 
cells that had been selected for TrkB or GFP-F control expression with antibiotic 
treatment for at least one month. We found that cells expressing TrkB FL displayed 
higher levels of APP compared to GFP-F and TrkB T expressing cells (Figure 4.1C).  
We transiently transfected TrkB T, TrkB FL and the GFP-F plasmid control in 
SH-SY5Y naïve cells and found similar results (Figure 4.2A and 4.2B).    
We conclude that TrkB FL expression increases endogenous APP full-length 
levels in two different cell lines while TrkB T does not.    
 
4.3.2 ADAM10 activity does not differ in 293HEK cells stably transfected 
with TrkB T or TrkB FL 
 
TrkB FL has been shown to increase APP promoter transcription but also to 
increase sAPPα levels in the media of SH-SY5Y cells (Holback et al., 2005). We 
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hypothesized that this increase might be due to TrkB FL mediated PLC-γ activation 
that produces DAG, an ADAM activity stimulator. Therefore we employed an 
ADAM activity assay to measure ADAM activity in cells that had been transfected 
with TrkB T or FL.    
We initially checked for the assay reliability and the baseline ADAM activity 
of three different cell lines. A neuroblastoma cell line SH-SY5Y and the same cell 
line stably expressing APP fused to Gal4. We also used HEK293 cells. We collected 
lysates of cells treated with vehicle (DMSO) or PMA and read the fluorescence signal 
emitted at 510 nm. PMA is a phorbol ester that mimics DAG activity. 
SH-SY5Y cells showed a higher ADAM basal activity compared to 293HEK 
cells. PMA was able to increase the ADAM activity signal in all cell lines (Figure 
4.3A). SH-SY5Y cells have been shown to display accumulation of sAPP-α when 
treated with retinoic acid (Holback et al., 2005). The ADAM10 promoter contains 
RARE, so we hypothesized that this increased sAPP-α release is mediated by an 
increased transcription and maybe activity of ADAM10 in this cell line. To verify 
this, we treated SH-SY5Y cells for 48 hours with 20 µM RA or DMSO and measured 
ADAM activity in the cell lysates. We also treated cells for 10 hours with PMA as a 
positive control. Both RA and PMA treatments induced a detectable increase in 
ADAM10 activity, the increase induced by PMA was higher (Figure 4.3B). To verify 
if the increase in ADAM activity observed after RA treatment, was due to an increase 
in ADAM levels, we performed a Western blot analysis on the same cell lysates used 
for the ADAM activity assay. We found that there was an increase in ADAM10 
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levels in the cells treated with RA compared to the cells treated with vehicle only 
(DMSO) (Figure 4.3C and 4.3D). 
These experiments show that the ADAM10 assay is able to detect differences in 
ADAM activity and validate its use in our in vitro system.  
We then applied this assay to test the hypothesis that TrkB FL activates 
ADAM when transfected in cells. We obtained populations of 293HEK cells stably 
transfected with a control farnesylated GFP plasmid, TrkB T or TrkB FL. We 
measured ADAM10 activity of both untreated cells or PMA treated cells and 
compared them (Figure 4.3). Only the GFP transfected cells showed a small, non 
significant, increase in ADAM activity when treated with PMA, while both TrkB T or 
TrkB FL transfected cells displayed the same ADAM activity levels with or without 
PMA treatment (Figure 4.3). There was no statistical difference between the ADAM 
activity levels detected in TrkB FL or TrkB T transfected cells (Figure 4.3).  
 
4.3.3 BACE1 levels are increased by TrkB FL transfection in 293Swe cells 
but not by TrkB T or TrkB SHC 
 
We did not observe altered ADAM activity when transfecting TrkB FL or 
TrkB T in HEK293 cells. ADAMs are responsible for C83 generation. We did 
observe alteration of C83/C99 ratios when transfecting TrkB FL, TrkB T, TrkB SHC 
or the TrkB FL mutants. Therefore we hypothesize that BACE1, responsible for C99 
production, levels might be decreased upon TrkB transfection. To test this hypothesis 
we measured BACE1 levels in cells transfected with the TrkB isoforms and mutants 
(Figure 4.5A). 
 - 157 - 
Surprisingly, we found that TrkB FL significantly increased BACE1 levels 
compared to TrkB T while TrkB SHC did not. Also TrkB FL Y515F did decreased 
BACE1 levels compared to TrkB FL, while the tyrosine kinase inactive mutant did 
not affect BACE1 levels compared to TrkB FL (Figure 4.5B). 
 
4.3.4 TrkB FL activates NFAT3 mediated transcription 
 
We observed an increase in BACE1 levels upon TrkB FL transfection. 
BACE1 levels have been shown to be modulated by the Ca2+ activated transcription 
factor NFAT1 but not by NFAT4 (Cho et al., 2008). Because TrkB FL can activate 
NFATc4, also referred to as NFAT3, the neuronal specific form of NFAT, we 
hypothesized that TrkB FL might mediate activation of NFATc4 and thus increase 
BACE1 transcription. To test whether TrkB FL transfection was able to activate 
NFATc4 we transfected a NFAT luciferase reporter construct together with TrkB FL 
or TrkB T. We used a GFP tagged NFAT3 over-expression construct as a positive 
control and a renilla luciferase reporter to normalize transfection efficiency. In both 
SH-SY5Y Naïve and HEK293 Naïve cells, we found that TrkB FL transfection 
increased NFAT mediated luciferase activity compared to TrkB T and GFP-F control 
but not compared to the NFAT3 over-expression construct (Figure 4.6A and 4.6B).   
TrkB FL can activate signaling pathways that increase release of Ca2+ from 
intracellular storage, therefore the effects that we observe might be due to Ca2+ 
mediated unspecific increase in transcription. To rule out this possibility we co-
transfected the TrkB constructs, the control constructs and the NFAT3 construct 
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together with a pGL3 luciferase reporter that does not respond to NFAT specific 
activation but would be subjected to general increases in transcription activity within 
the cells. We did not observe any differences in luciferase activity between TrkB T 
and TrkB FL when utilizing pGL3 as a reporter construct (Figure 4.6C and 4.6D) in 
both cell lines. This demonstrates that TrkB transcriptional effects are specific to 
NFAT. The increase in luciferase activity observed when transfecting NFAT3 and 
pGL3 luciferase is due to the fact that NFAT binds to the SV40 promoter enhancing 
its transcription (Manley et al., 2008).    
 
4.4 Discussion 
 
We have here investigated the TrkB mediated modulation of endogenous APP 
and of the APP processing enzymes ADAM10 and BACE1.  
APP levels are increased by TrkB FL auto-activation and the increase is more 
dramatic in the HEK293 cells line than in the SH-SY5Y cell line. This might be due 
to the presence of all TrkB isoforms and BDNF in the latter cell line that might 
contribute to regulate levels of the TrkB FL/T exogenously expressed. APP promoter 
activation mediated by TrkB FL had been previously shown through reporter assays 
in SH-SY5Y cells, here we show that APP protein levels are increased by TrkB FL 
transfection compared to TrkB T and that this increase is apparent even in absence of 
exogenous BDNF. We observe the same increase in APP levels in HEK293 cells that 
do not express BDNF/TrkB endogenously. Therefore, over-expression of the TrkB 
FL receptor probably causes auto-activation and signaling through of the IP3K 
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pathway that has been shown to mediate APP transcription (Ruiz-Leon and Pascual, 
2001).  
The fact that we observe a TrkB FL mediated increase in APP levels in both cell lines 
suggests that the pathways engaged are common among the two. Interestingly, TrkB 
FL/BDNF signaling is associated with beneficial effects in the context of AD while 
any factor that increases APP levels is generally associated with worse degeneration. 
This apparent contradiction can be solved by several considerations. First, increased 
APP levels are not necessarily associated with more degeneration since APP is 
important in cell-matrix interaction and cell-cell interactions, is expressed on 
dendritic spines and plays important roles in synaptic regulation (Kamenetz et al., 
2003; Hoe et al., 2009). Secondly, increased APP levels do not necessarily correlate 
to increased production of neurotoxic fragments. The outcome of APP proteolytic 
cleavage is central for the pathogenesis. If APP is cleaved by α-secretases, it 
generates fragments that have growth factor like characteristics, such as sAPP-α 
(Caille et al., 2004). Finally, TrkB activates many signaling pathways that are anti-
apoptotic and favor synaptic transmission and LTP (Minichiello, 2009). In the 
broader context of all these interactions and balance, TrkB FL beneficial effects can 
be associated even with over-all increased APP levels. 
The hypothesis that TrkB FL might favor α-secretase cleavage of APP has 
been marginally addressed before. In previously performed experiments RA treatment 
of cells had been showed to promote accumulation of sAPP-α. Even is the authors 
show that BDNF stimulation of the cells increases sAPP-α accumulation, it is 
difficult to unequivocally determine if this effect is only, or at least mainly, mediated 
 - 160 - 
by TrkB. In fact RA can activate ADAM10 transcription TrkB independently. The 
authors also do not use the TrkB T isoform to check if the effect was specifically due 
to the tyrosine kinase activity of the full-length receptor. Here we show that 
ADAM10 levels are increased in SH-SY5Y cells after RA stimulation and that 
ADAM activity is also increased. We could not detect an ADAM activity increase in 
HEK293 cells transfected with TrkB T or TrkB FL. There could be several reasons 
for this. We found that the assay employed was sensitive to the GFP fluorescence 
emission. Our TrkB constructs are GFP positive. This might have altered the readings 
introducing an unknown factor in the quantification. A reading of the samples at 
540nm, the optimal emission wavelength of GFP, did not highlight differences in 
signal among lysates obtained from different stable populations (transfected with 
different constructs).  While this would suggest that the GFP signal, constant across 
samples, would not contribute to the reading of the experimental samples, we cannot 
exclude that, at 510nm, the optimal wavelength for ADAM activity readings, the 
emission spectra of GFP interferes with the quantification. It must also be noted that 
HEK293 cells show a lower baseline value of ADAM activity, lowering the 
sensitivity and dynamic range of the assay for this particular cell line. Experimental 
issues aside, we could also speculate that auto-activation of the TrkB FL receptor, 
shown to differ from the BDNF dependent activation, is not efficient at mediating 
PLC-γ binding and therefore at increasing ADAM activity. We performed the 
experiment in HEK293 cells because that was the cell line where we observed a 
decrease in C83/C99 ratio and this cell line lacks BDNF and endogenous TrkB 
expression, it might therefore lack specific mediators of TrkB signaling that are 
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necessary to engage ADAMs. Another explanation is that TrkB FL does not mediate 
ADAM activation. To investigate all these possibilities more experiments are needed. 
TrkB FL over-expression could be employed in SH-SY5Y cells in combination with 
its isoforms and mutants to determine if there is an ADAM activity effect and if the 
PLC-γ binding site is mediating this effect. Moreover BDNF stimulation of 
exogenously expressed TrkB FL could be employed to investigate whether an ADAM 
activity effect can be recapitulated even in the HEK293 cell line.  
ADAMs are mediators of α-secretase cleavage of APP and we did not find 
any evidence for altered ADAM activity in HEK293 APPSwe cells. BACE1 is 
responsible for the β-secretase cleavage of APP that generates the toxic fragment Aβ. 
We observed that TrkB FL was able to reduce the C83/C99 ratio in HEK293 APPSwe 
cells, therefore we tested if BACE1 levels were decreased by TrkB FL or its isoforms. 
We found that BACE1 levels were increased by TrkB FL but not by its tyrosine 
kinase inactive mutants or truncated isoforms. SHC knock-down has been shown to 
decrease BACE1 levels and therefore Aβ production (Xie et al., 2007). SHC mediates 
downstream signaling of TrkB FL. Moreover, NFAT1 activation has been shown to 
increase BACE1 levels, while NFAT4 does not mediate the same effect (Cho et al., 
2008). NFAT3 is activated by TrkB FL/BDNF signaling (Groth and Mermelstein, 
2003). We then suggest a mechanism for BACE1 transcriptional regulation mediated 
by TrkB FL/SHC and NFAT.  
In conclusion we find that TrkB FL over-expression increases APP levels 
even in absence of exogenous BDNF, suggesting that auto-activation of the receptor 
can mediate APP transcription. We also find that BACE1 levels are increased by 
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TrkB FL auto-activation in HEK293 APPSwe. We speculate that altered trafficking of 
APP and/or BACE1 is responsible for decreased C83/C99 levels in HEK293 APPSwe. 
We finally identify NFAT mediated transcriptional activation as a possible 
mechanism of BACE1 transcription up-regulation.  
                    
4.5 Figure Legends: 
 
Figure 4.1: TrkB FL transfection increases endogenous APP full-length levels in 
HEK293 cells. (A) Transient transfection of TrkB FL induces an increase in APP full-
length levels while TrkB T does not affect APP levels compared to GFP-F control. 
(B) Stable transfection of TrkB FL also induces an increase in APP full-length levels 
compared to both TrkB T and GFP-F stably transfected cells. (C) Quantification of 
APP FL levels in cells transfected with TrkB FL shows a statistically significant 
increase in APP levels over both TrkB T and GFP-F.  
Error bars represent STDEV; *=p<0.025 after t-test, Bonferroni corrected for 
multiple comparisons.  
 
Figure 4.2: TrkB FL transfection increases endogenous APP full-length levels in SH-
SY5Y Naïve cells. (A) Representative Western blot of SH-Sy5Y Naïve cells lysates 
transiently transfected with TrkB T or FL. (B) TrkB FL transfection induces an 
increase in APP full-length levels compared to TrkB T transfection. 
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Figure 4.3: ADAM10 activity/expression in cell lines treated with PMA or stably 
transfected with TrkB. (A) PMA treatment of three different cell lines induces a 
significant increase in ADAM activity compared to the vehicle treated controls. (B) 
RA treatment of SH-SY5Y cells induces an increase in ADAM activity compared to 
vehicle control treated cells but not compared to PMA treated cells. (C) 
Representative Western blot for detection of ADAM10 levels in RA treated SH-
SY5Y and SH-SY5Y-APP-Gal4 cells. (D) Quantification of the Western blot in (C) 
showing that ADAM10 levels are increased by RA treatment of the SH-SY5Y 
neuroblastoma cell line.       
 
Figure 4.4: TrkB FL and TrkB T stable transfection does not increase ADAM 
activity compared to GFP-F transfected cells. PMA treatment also does not affect 
ADAM activity in these cell lines. 
N=3; t-test with Bonferroni correction for multiple comparisons.  
 
Figure 4.5: TrkB transfection affects BACE1 levels in HEK293 APPSwe cells. (A) 
Representatives Western blots of BACE1 in cells transfected with TrkB isoforms and 
mutants. (B) Quantification of at least two independent experiments. TrkB FL 
significantly increases BACE1 levels compared to TrkB T (p=0.01) while TrkB SHC 
does not. Transfection of the mutant on the SHC binding site of TrkB FL, Y515F, 
decreases BACE1 levels compared to TrkB FL. 
Error bars: SEM; n=6 for TrkB T, FL, SHC; n=4 for TrkB Y515F; n=2 for K571M. 
Statistical analysis: paired t-test with Bonferroni correction.    
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Figure 4.6: TrkB FL increases NFAT mediated transcription. (A) TrkB FL and TrkB 
T were transfected in SH-SY5Y Naïve cells with a NFAT luciferase reporter 
constructs. TrkB FL significantly increased NFAT mediated luciferase compared to 
TrkB T (p=0.02). GFP-F was used as a negative control while NFAT3 GFP tagged 
was used as a positive control. (B) TrkB FL and TrkB T were transfected in HEK293 
Naïve cells with a NFAT luciferase reporter constructs. TrkB FL significantly 
increased NFAT mediated luciferase compared to TrkB T (p=0.0001). (C) TrkB FL 
did not increase transcription of a pGL3 reporter construct co-transfected in SH-
SY5Y Naïve cells. NFAT3 increased transcription of pGL3 because it can bind to its 
SV40 viral promoter. (D) TrkB FL did not increase transcription of a pGL3 reporter 
construct co-transfected in HEK293 Naïve cells. NFAT3 increased transcription of 
pGL3 because it can bind to its SV40 viral promoter. 
N=3 for SH-SY5Y cells with 6 replicates, n=2 for HEK293 cells with 6 replicates; 
error bars represent STDEV; statistical analysis: student t-test. 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4 
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Figure 4.5 
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Figure 4.6 
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5. SUMMARY AND FUTURE DIRECTIONS 
 
5.1 Summary of findings 
 
TrkB is an important neurotrophic receptor expressed on neurons and 
implicated in synapses formation, neuronal survival/differentiation and long-term 
potentiation. TrkB levels are developmentally regulated and are affected in 
Alzheimer’s neurodegeneration and other conditions such as depression.  
TrkB is expressed in three different splicing isoforms, TrkB full length (FL), TrkB 
truncated (T) and TrkB SHC, that share a common extracellular domain that binds 
brain derived neurotrophic factor (BDNF) and differ in their intracellular domain. The 
intracellular domain of TrkB can activate different signaling pathways and bind to the 
adaptor protein SHC and to the enzyme PLC-γ. TrkB FL has been shown to affect 
APP transcription and processing, moreover, some studies associated single 
nucleotide polymorphisms of NTRK2, the gene encoding for TrkB, to Alzheimer’s 
disease. NTRK2 is located on chromosome 9p22, a region with a high likelihood of 
disease score.  
We hypothesized that TrkB isoforms differentially modulate APP metabolism 
and tested this hypothesis in different cell lines. Initially we employed the SH-SY5Y 
neuroblastoma cell line that expresses basal levels of TrkB and BDNF and has been 
used before to investigate TrkB mediated signaling pathways. Then we employed 
HEK293 APPSwe cells that provide a TrkB/BDNF free model system that simplifies 
data interpretation. This cell line also over-expresses APPSwe that causes early onset 
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Alzheimer’s disease (AD) in humans and is a commonly used in vitro AD model. 
Finally we determined TrkB mediated effects on APP endogenous in both SH-SY5Y 
and HEK293 cells. We also investigated TrkB effects on endogenous ADAM10 and 
BACE1.  
In SH-SY5Y APP Gal4 cells, we found that APP levels are increased by TrkB 
FL over-expression but are not affected by TrkB T and TrkB SHC. Knock-down of 
the TrkB receptors causes decreased levels of APP and knock-down of TrkB FL and 
TrkB SHC only causes cell death, suggesting that TrkB T might impair cell survival.  
We found that TrkB FL increases AICD mediated transcriptional activity and that this 
effect is mediated by the tyrosine kinase activity of the receptor and by the PLC-γ 
binding activity. AICD mediated transcriptional activity is not affected by TrkB T but 
is decreased by TrkB SHC through its SHC binding site. Therefore we demonstrate 
that TrkB isoforms can affect APP levels and processing.  
 We then investigated the role of the TrkB isoforms in APPSwe metabolism. We 
hypothesized that BDNF independent signaling of TrkB can affect APP and we tested 
this hypothesis on APPSwe that causes early onset AD in humans. We found that TrkB 
FL auto-activates in HEK293 APPSwe cells and that it impairs APPSwe glycosylation 
and decreases the C99/C83 ratio. TrkB T and TrkB SHC do not affect APPSwe 
glycosylation or processing. These effects are mainly mediated by the tyrosine kinase 
activity of the receptor and not by its SHC or PLC-γ binding. We also found that co-
transfection of the TrkB truncated isoforms regulates TrkB FL effects on APP. In 
particular, TrkB T acts as a dominant negative, while TrkB SHC shows the same 
effects as TrkB FL. In agreement with this finding, TrkB FL was not phosphorylated 
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when co-transfected with TrkB T but was phosphorylated when co-transfected with 
TrkB SHC. This demonstrates, for the first time, that TrkB truncated isoforms have a 
different regulatory role on TrkB FL.  
 While TrkB had different effects on the metabolism of exogenously expressed 
APP in the two cell lines employed, we found that it increases endogenous APP 
levels in both without affecting APP glycosylation. This demonstrates that TrkB 
affects APP levels through mechanisms that are common between the two cell lines.  
TrkB does not affect endogenous ADAM10 activity in HEK293 cells but increases 
BACE1 levels. We speculate that BACE1 levels increase is due to TrkB FL mediated 
increased NFAT transcriptional activity.  
 TrkB FL had different effects on APP over-expressed in two different cell 
lines. We speculate that this difference is due to the mechanism of activation of the 
receptor: BDNF dependent, in SH-SY5Y cells, or BDNF independent, in HEK293 
cells. In SH-SY5Y cells, BDNF binding to the TrkB FL receptor causes 
internalization of the receptor in activated endocytic vesicles and its rapid degradation 
in endosomal compartments. This physiologic route of activation does not affect APP 
glycosylation but only its processing. In HEK293 cells, BDNF is not present therefore 
TrkB FL auto-activation occurs in intracellular vesicles in the trans-Golgi network 
impairing protein glycosylation and trafficking. The fact that TrkB FL activation can 
be prevented in both cell lines by co-transfection of TrkB T but not by TrkB SHC 
suggests that TrkB FL regulation through the truncated isoforms is conserved and 
probably occurs through similar mechanisms.    
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5.2 Future Directions 
 
The aforementioned findings are relevant in AD context for several reasons. 
TrkB FL/BDNF signaling pathways are associated with beneficial effects and BDNF 
agonists are being investigated as potential therapies. The demonstration that TrkB 
isoforms have different effects on APP metabolism suggests that these therapeutic 
approaches might be effective only in patients that express TrkB FL at higher levels 
than the truncated isoforms. In patients where TrkB FL levels are reduced relative to 
TrkB T/SHC, BDNF, or its agonists, would be scavenged by these isoforms. Binding 
of TrkB truncated isoforms to BDNF would negatively regulate TrkB FL signaling 
and maybe activate pathways that increase neurodegeneration rather than 
ameliorating it. The fact that TrkB can modulate APP metabolism but also is 
subjected to APP mediated regulation suggests the presence of a self-sustaining loop 
of interactions between the two proteins in AD. If Aβ down-regulates TrkB 
FL/BDNF signaling, it is unlikely that BDNF agonists will be an effective therapy in 
patients that already have a high Aβ load. On the contrary, if TrkB FL/BDNF 
signaling pathways can promote α-secretase processing and neuronal survival, they 
might be valuable drug targets during the early stages of AD. Given the regulatory 
role of the truncated isoforms on TrkB FL, these can also be considered as drug 
targets. Instead of triggering TrkB FL signaling, an alternative approach could be 
TrkB T down-regulation or TrkB SHC up-regulation. Therefore, RNAi therapeutic 
strategies targeting TrkB T specifically or targeting the splicing mechanism of the 
TrkB gene to increase production of TrkB SHC/FL could also be investigated.  
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The design of effective therapies targeting TrkB will benefit from a more 
through investigation of its role in regulating APP metabolism and as a target of APP 
regulation. In particular, based on our findings, we think necessary to perform 
additional experiments to address important outstanding questions. 
The experiments conducted on SH-SY5Y APP Gal4 and HEK293 APPSwe   
cells suggest that BDNF dependent or independent TrkB activation might have 
different effects on over-expressed APP metabolism. Moreover we find that TrkB 
truncated isoforms can regulate TrkB FL effects in both cell lines. Further 
characterization of the TrkB mediated effects in these cell lines should address the 
questions: 
 
1. What are the intracellular levels of Aβ in HEK293 APPSwe cells after 
TrkB isoform transfection? Do levels of sAPP-β correlate with these? 
Based on the Aβ extracellular levels, the C83/C99 ratio and the sAPP-α 
quantifications, we hypothesize that TrkB FL would lower these levels. 
TrkB Y515F might also decrease Aβ and sAPP-β products.  
2. Since BACE1 levels are increased by TrkB FL transfection, based on the 
results of Aβ quantification, it would be essential to investigate how APP 
cleavage is modified by TrkB isoforms. Co-localization and cellular 
fractionation experiments aimed at detecting the location of the secretases 
and APP in the cells upon transfection of the TrkB isoforms could be 
employed. We hypothesize that trafficking of these proteins is altered 
causing the altered processing.  
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3. Aβ, sAPP-β and BACE1 expression levels should also be checked in SH-
SY5Y APP Gal4 cells and possibly in the same cell line expressing 
APPSwe .  
4. Characterization of the TrkB SHC Y515F mutant should be performed in 
both aforementioned cell lines since it might help uncover the mechanism 
of its lack of inhibition of AICD-mediated transcription.  
  
It can be hypothesized that basal expression of TrkB FL followed by BDNF 
stimulation of the receptor in HEK293 APPSwe cells, will be able to recapitulate the 
effects seen in SH-SY5Y APP Gal4. Specifically, lower levels of expression of TrkB 
FL should avoid intracellular auto-activation of the receptor and BDNF application 
would trigger a physiologic activation of the receptor at the cell surface. 
 
1. Titration experiments to determine TrkB FL amounts that transfected 
avoid intracellular auto-activation. 
2. Investigation of the mechanism of TrkB SHC mediated TrkB FL 
activation. We hypothesize that this isoform, co-localizing with TrkB FL, 
helps the crowding of this receptor intracellularly promoting its auto-
activation. 
3. Co-transfection experiments aimed at dissecting the optimal ratios of 
TrkB FL inhibition by TrkB T and exogenous BDNF application 
experiments to check for the role of BDNF in promoting TrkB 
dimerization. The question of isoform homo/hetero dimerization 
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preference can also be addressed in this system by performing chemical 
cross-linking of the receptors.        
  
Finally, our experiments employed cell lines over-expressing APP as a model 
for this initial characterization of the TrkB effects on APP metabolism. Cell lines are 
valuable models for molecular and cellular biology investigations but have limited 
relevance to the physiologic situation. Therefore investigation of the same problems 
in primary neurons and animal models is needed.  
 
1. Primary neurons express all the TrkB isoforms but nobody has performed an 
exact characterization of the relative levels of the TrkB isoforms. Primary 
neuronal cultures should be obtained and mRNA of the TrkB isoforms as well 
as protein levels should be measured. It would be interesting to see if cultures 
display different TrkB ratio at different days in vitro. 
2. Investigation of the effects of a specific isoform at a time can be performed by 
using shRNA mediated knock-down of the other isoforms. This approach is 
easy to implement because the mRNA of the isoforms are different. Over-
expression of the isoforms/mutants, using lower efficiency promoters can also 
be employed to this end. 
3. Investigation of the TrkB SHC isoform will be difficult in mouse/rat neuronal 
cultures because these animals do not express this isoform. Alternatively, 
human neuronal stem cell lines could be employed after performing 
characterization experiments (see point 1).   
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After the work in primary neurons, if the findings are promising in light of 
future applicable therapeutic strategies, animal models can be used. These models 
could include TrkB or BDNF knock-outs and AD models.  
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6. APPENDIX I: Brefeldin A inhibits APP 
glycosylation and inhibits APP cleavage in SH-
SY5Y APP Gal4 cells 
 
We have observed that TrkB FL over-expression in HEK293 APPSwe cells 
decreases APP glycosylation. We hypothesized that this effect is due to disruption of 
the Golgi apparatus caused by the auto-activated TrkB FL receptors as it has been 
shown previously (Schecterson et al., 2010). We also hypothesize that the impaired 
glycosylation of APP causes its decreased processing as measured by the decreased 
C83/C99 ratio that we observe. We do not observe the same effect in SH-SY5Y APP-
Gal4 cells and we hypothesize that this is due to the different regulation of TrkB FL 
signaling in this cell line that expresses BDNF and TrkB endogenous. We speculate 
that in SH-SY5Y APP Gal4 cells, APP glycosylation is not affected because TrkB 
activation and regulation is different and therefore activation of the TrkB FL does not 
affect the Golgi apparatus/protein glycosylation. If APP impaired glycosylation is 
causing the decreased APP processing observed in HEK293 APPSwe cells, we should 
be able to recapitulate the same effect in SH-SY5Y APP Gal4 cells. Therefore we 
hypothesize that inhibiting APP glycosylation in SH-SY5Y APP Gal4 cells will 
inhibit APP processing. To test this hypothesis we treated with Brefeldin A SH-SY5Y 
APP-Gal4. Brefeldin A (BFA) is a drug commonly used to impair protein 
glycosylation.   
BFA is lactame antibiotic that affects the Golgi compartment. It impedes the 
trafficking of proteins from the ER to the Golgi thus inhibiting post-translational 
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modification of proteins. These trafficking changes do not alter transferrin and iron 
transport from the cell surface to the intracellular compartment and vice versa. 
Therefore normal membrane trafficking is not completely compromised (Klausner et 
al., 1992). BFA also inhibits the delivery of proteins from the early endosomal 
compartment to lysosomes (Klausner et al., 1992).  
We initially demonstrated decreased APP processing through an AICD-
mediated luciferase activity assay (Figure 6.1). AICD mediated luciferase activity 
decreased about 30% in BFA treated cells compared to vehicle control. Parallel L-685 
treatment as a positive control showed a luciferase decrease of about 50% (Figure 
6.1). 
APP processing is mainly mediated by α-secretase activity. We therefore 
tested the hypothesis that ADAM10 levels could be decreased by BFA treatment. In 
particular, we thought that BFA would affect ADAM10 maturation and that we 
would find higher levels of immature pro-enzyme ADAM10. We quantified 
ADAM10 levels in lysates treated with BFA or controls and we did not detect a 
significant difference in total ADAM10 levels. Furthermore, we could not detect a 
shift in molecular weight of ADAM10 that would suggest an impaired ADAM10 
maturation in treated cells (Figure 6.2).   
APP glycosylation was impaired by BFA treatment as demonstrated by an 
accumulation of an intermediate glycosylated form of APP (Figure 6.3). We also 
observed an increase in APP total when treating cells with BFA for 4 hours (Figure 
6.3 and 6.4A). This accumulation is probably due to BFA mediated inhibition of 
mature endosomes formation. APP does not get degraded and the time period of the 
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treatment is enough to cause APP accumulation. In fact APP half-life is 
approximately 1.5 hours. Even if total APP levels were increased by BA treatment, 
we found that BFA treatment decreases CTFs levels, hence APP processing (Figure 
6.3).   
 C83 levels in lysates of SH-SY5Y APP Gal4 cells treated for 4 hours with 
BFA were very low, almost below Western blot detection limit (Figure 6.3 and 6.4B). 
Combined BFA and L-685 treatment showed accumulation of the CTFs to the same 
extent as non-treated cells (Figure 6.4B). This suggests that APP processing by both 
α and β secretases, but not γ-secretase, is inhibited by BFA. 3 hour treatment with 
BFA followed by one hour incubation with L-685 lead to significant accumulation of 
CTFs compared to the vehicle control. This suggests that BFA inhibition of APP α 
and β processing is quickly reversible.  
We conclude that BFA mediated APP impaired glycosylation can inhibit APP 
processing in SH-SY5Y APP Gal4. BFA does not affect ADAM10 levels or 
maturation. Decreased APP processing is therefore probably due to the impaired 
trafficking of APP between the endoplasmic reticulum and the Golgi. 
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Figures: 
 
Figure 6.1: BFA treatment of cells decreases AICD-mediated luciferase activity in 
SH-SY5Y APP Gal4 cells. Cells were treated with L-685, a γ-secretase inhibitor that 
inhibits formation of AICD as a positive control. DMSO treated cells were the 
negative control for γ-secretase treated cells. Cells were treated with BFA for 4 hours 
and control cells were treated 4 hours with ethanol only (BFA vehicle). Statistical 
analysis was performed with Student’s t test. Error bars represent SEM. N=2 with 
replication of 6.  
 
Figure 6.2: ADAM10 levels are not affected by BFA treatment. (A) Representative 
Western blot analysis of cells treated with BFA only or BFA and L-685 in different 
combinations. Each “+” represents one hour of treatment with the indicated drug, 
each “-” represents one hour of treatment with vehicle only. No symbol means that no 
treatment was applied. Lane 1 represents 3 hours of BFA treatment and one hour of 
L-685 treatment while lane 3 represents contemporary treatment of BFA and L-685 
for 4 hours. Actin was used as a loading control. (B) Quantification of ADAM10 
levels in cells treated as reported above. The levels of ADAM10 for each treatment 
were normalized to the corresponding vehicle control. There was no significant 
difference in ADAM10 levels between treatments and corresponding controls. N=2 
with replication of two. Statistical analysis was performed with Student’s t-test. 
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Figure 6.3: BFA treatment causes an increase in APP immature levels and a decrease 
in APP processing. Representative Western blot analysis of cells treated with BFA 
only or BFA and L-685 in different combinations. Each “+” represents one hour of 
treatment with the indicated drug, each “-” represents one hour of treatment with 
vehicle only. No symbol means that no treatment was applied. Lane 1 represents 3 
hours of BFA treatment and one hour of L-685 treatment while lane 3 represents 
contemporary treatment of BFA and L-685 for 4 hours. Actin was used as a loading 
control.  
 
Figure 6.4: BFA treatment causes an increase in APP levels but a decrease in C83 
levels. (A) Quantification of APP total levels in BFA treated as in figure 6.3 or 
control cells. (B) Quantification of C83 levels in cells treated as reported in Figure 
6.3. There was no statistical difference between C83 levels in cells treated with BFA 
for 3 hours and then with L-685 and vehicle only control. Each treatment was 
normalized to the corresponding vehicle control. N=2 with replication of two. 
Statistical analysis was performed with Student’s t-test. 
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Figure 6.2 
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Figure 6.3 
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Figure 6.4 
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7. APPENDIX II: TrkB isoforms and APP 
localization in HEK293 cells 
 
We have noticed effects of TrkB isoforms on APP metabolism and we 
hypothesize that some of these effects are due to a different trafficking of APP that 
leads to altered processing. For example BACE1 levels were increased by 
transfection of TrkB FL in HEK293 APPSwe cells but the C83/C99 ratio was 
decreased. This would suggest that APP in TrkB FL transfected cells is not available 
to BACE1 for cleavage probably due to a different intracellular localization. 
We performed preliminary fluorescence microscopy experiments to test the 
hypothesis that APP localization is different when TrkB isoforms are transfected into 
the cells.  
We employed TrkB constructs GFP tagged and an APP-RFP tagged construct 
and co-transfected them in equimolar ratios in HEK293 cells cultured on glass 
coverslips. 48 hours post-transfection, cells were fixed in paraformaldheyde and 
mounted on glass slides for confocal microscopy observation. Magnification and laser 
intensity of the appropriate excitation wavelengths were kept constant through all 
image acquisitions. Single cells in the acquired images were scored for:  
1. TrkB pattern of distribution (diffused fluorescence; clustered puncta; Golgi 
accumulation).  
2.  APP distribution.  
3. Co-localization of APP and GFP, estimated based on extent of yellow 
signal in the images.  
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All these assessments are highly qualitative and preliminary as subcellular 
organelles markers were not employed and 3D imaging also was not employed to 
verify accurate co-localization. Images were quantified blindly for all the 
aforementioned characteristics and scored at three levels: 1, 2 and 3 as measures of 
appearance of each characteristic. The arbitrary scores were then averaged for the 
number of cells counted and finally associated to the transfected constructs for data 
analysis and discussion.  
In Figure 7.1 we show three representative confocal images of TrkB/APP 
transfected HEK293 cells. We noticed that the truncated constructs tended to 
highlight more the rim of the cells suggesting an association with lamellipodia and 
the cell membrane (Figure 7.1). This characteristic was annotated but not quantified 
with the scoring system and is in agreement with previous published findings 
(Haapasalo et al., 2002). TrkB FL Y515F receptors seemed to be more aggregated in 
puncta compared to the wild type TrkB FL while the TrkB SHC isoform displayed a 
more even distribution patter. We could speculate that this phenomenon is partially 
due to SHC association to the intracellular domain and possible interactions with 
other membrane proteins.  
TrkB T was less associated with “Golgi-like” accumulation suggesting that 
the potential of this receptor to disrupt protein glycosylation is lower than the tyrosine 
kinase counterparts. Surprisingly, even the TrkB SHC isoform was found to be 
accumulated in the Golgi more than initially expected from a superficial observation. 
We have to remember that transfection of this isoform alone did not cause any 
glycosylation effects on APP.  APP signal seemed to be evenly distributed in cells 
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independently of TrkB transfected construct. Finally TrkB FL and TrkB SHC 
isoforms and the TrkB Y515F mutant seemed to co-localize to a lesser extent with 
APP than the TrkB T isoform.      
In conclusion our preliminary data suggests that TrkB have different cellular 
localizations and different effects on Golgi structure. Also the co-localization of the 
TrkB isoforms with APP seems to differ among isoforms. Further experiments are 
needed to identify the specific subcellular organelles affected and to explore the 
biological significance of TrkB and APP residence in the same cellular 
compartments.     
 
Figure 7.1: Fluorescence microscopy images of HEK293 cells transfected with TrkB 
GFP tagged constructs and APP-RFP. The transfecetd TrkB construct is indicated in 
the panels in the top left corner. The table reports arbitrary assigned scores for the 
indicated characteristics. N is the number of cells that were scored and which scores 
were averaged to get the values reported in the table.  
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Figure 7.1 
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8. APPENDIX III 
 
This appendix is a published paper that provides a streamlined method to subclone 
shRNA constructs in lentiviral vectors. This method is very useful in creating RNAi 
tools that are suitable for use in neuronal primary cultures and in vivo.  
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ABSTRACT 
 
RNA interference (RNAi) is a widely used molecular biology technique to investigate the importance of 
specific genes in molecular pathways. Since mammalian cells are equipped with endogenous RNAi 
processing machinery, it has become common practice to transfect constructs that encode for short hairpin 
RNAs that are then cleaved to form the active RNAi sequences that bind to target mRNAs. Given the profit 
potential of this research approach, companies have developed retroviral libraries of shRNA constructs 
targeting the majority of the human genes. Recent technologic advances have allowed the rapid improvement 
of the vectors carrying the shRNA constructs while the silencing sequences remain the same. Therefore, sub-
cloning of shRNA sequences from more obsolete vectors to newer vectors is a straightforward way to take 
advantage of newer delivery technologies. We describe here a streamlined procedure to transfer shRNA 
sequences from the pSM2 retroviral vector to a newer pGIPZ vector that is more stable, contains a GFP 
cassette and allows the preparation of high titer viral particles for transduction of cells and in vivo use. We 
demonstrate that our protocol provides a cost-effective and fast method to successfully sub-clone shRNA 
from a pSM2 retroviral vector to a pGIPZ lentiviral vector making it a useful tool for the investigators that 
have purchased pSM2 vectors in the past and wish now to upgrade their constructs by inserting them in more 
versatile vectors. 
 
KEYWORDS: Sub-cloning, shRNA, RNA interference, lentivirus, retrovirus, pSM2, pGIPZ, pTRIPZ 
 
 
 
INTRODUCTION 
 
RNA interference (RNAi) is an endogenous system that 
regulates gene expression. Since its discovery (Fire et al, 
1998) it has been exploited to silence specific genes and 
has become an important experimental method utilized in 
cellular and in vivo studies. RNAi based therapies are in 
development (Castanotto and Rossi, 2009). Given this 
promise and utility, many current investigations aim at 
better understanding the molecular mechanisms of RNAi 
and to find effective delivery methods for RNAi 
reagents. 
 
There are several approaches to introduce silencing RNAs 
into cells. One of them is to directly introduce short 
interfering RNAs, 21-23 nucleotide duplexes targeting 
specific mRNAs, into the cells or tissue under 
investigation (Elbashir et al, 2001). The disadvantage of 
this approach is that silencing is dependent on the amount 
of siRNA administered. A sustained silencing requires a 
constant and expensive siRNA supply. This shortcoming is 
eliminated when vectors containing sequences encoding 
short hairpin RNAs (shRNAs) are utilized (Paddison et al, 
2002). shRNAs are processed in the cells to produce 
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siRNA. Cells transfected with these vectors can sustain 
RNAi-mediated gene silencing for 48 hours or longer 
under antibiotic selection. 
 
The first large library of shRNA constructs targeting 
human and mouse genes was created in a retroviral vector, 
pShagMagic2 (pSM2) (Paddison et al, 2004). This vector 
is subject to frequent recombination, does not contain a 
GFP marker and has inefficient viral packaging that limits 
the use in hard to transfect cells and in vivo.  
 
Aware of these problems, companies have transferred the 
shRNAs into more stable GFP-tagged lentiviral vectors 
that produce high-titer viruses (Moffat et al, 2006). 
Lentiviruses are suitable for transduction of hard to 
transfect cell lines, primary cells and in vivo applications. 
The latest generation of lentiviral constructs includes 
inducible shRNA production (TRIPZ Lentiviral Inducible 
shRNAmir Library®, www.openbiosystems.com). 
 
All the researchers who purchased the now outdated 
retroviral libraries cannot take advantage of these 
improvements. It is very expensive for laboratories to buy 
a complete lentiviral library, and the single lentiviral 
constructs range from $209 to $428. One inexpensive way 
to “upgrade” the shRNA without purchasing new ones is 
to sub-clone them to an appropriate lentiviral vector. Open 
Biosystems® provides a protocol for sub-cloning shRNA 
constructs from pSM2 into the lentiviral vector pGIPZ but 
it requires expensive kits and multiple steps. Therefore, if 
an investigator wants to sub-clone a high number of 
shRNA constructs, it may be cheaper and more convenient 
to just purchase the constructs. 
 
We developed a protocol that greatly simplifies the 
transfer of shRNA sequences from the retroviral pSM2 
vector into the pGIPZ lentiviral vector. The improvements 
in the protocol are reported in Table 1. This sub-cloning 
protocol can be applied to sub-clone shRNA from pSM2 
to newer lentiviral vectors and possibly to sub-cloning 
schemes that involve plasmids and fragments of the same 
sizes reported here. 
 
 
MATERIALS AND METHODS 
 
Vector preparation and restriction digestion 
pSM2 and pGIPZ plasmids were purified with Qiagen 
Miniprep kits and DNA concentration was measured 
spectrophotometrically. All the restriction enzymes, the T4 
DNA ligase and the molecular weight markers were 
purchased from New England Biolabs. The Open 
Biosystems protocols were followed for bacterial culture 
growth and for recombination checks. 
 
pGIPZ vector (5-10μg) was digested with Mlu I/Xho I (1-
2U/μl) and the 13,087kb band was gel purified 
(QIAquick® gel extraction kit, Qiagen). The elution step 
was performed with 50μl HPLC water. The purified vector 
was used immediately after heat-inactivation, or stored 
frozen at -20oC until further use. The pSM2 vector (4μg) 
containing the shRNA of choice was also digested with 
Mlu I/Xho I (1-2U/μl) to generate a ~350bp fragment 
containing the shRNA, in a 20μl reaction volume (final 
insert concentration of 200ng/μl). After heat-inactivation 
(65°C for 20min) the cut pSM2 was used directly in 
ligation without purification. 
 
 
Table 1. Comparison between the Open Biosystems® and the proposed streamlined sub-cloning protocols for insert preparation. 
Cost- and time-savings are detailed for steps in insert preparation that are significantly different and are estimated for the smallest 
sized kit/reagent. In summary, an investigator with pSM2 vectors available can sub-clone a single construct for $631 using the Open 
Biosystems® protocol or $256 using our streamlined protocol. For both protocols there is an additional one-time expense of 
purchasing the empty pGIPZ vector ($321). In summary, our simplified procedure provides approximately 60% cost savings 
compared to the protocol provided by Open Biosystems® and is faster. Alternatively, an investigator can purchase the pGIPZ shRNA 
clones for $209 each, as well as the required pGIPZ control shRNAs ($428 each). 
 
Original Open Biosystems® Protocol Streamlined Protocol 
Step  
  Materials / Reagents 
 
Time 
 
Cost 
Step  
  Materials / Reagents 
 
Time
 
Cost
Primers for pSM2 shRNA PCR:                                             
pSM2 forward - 5' aagccctttgtacaccctaagcct 3'                            
pSM2 reverse - 5' actggtgaaactcacccagggatt 3’ 
 
 
1-3d 
 
 
 $14 
Not required   
 
4 PCR amplifications per shRNA to be sub-cloned             
       KOD Hot start Polymerase Kit®, Novagen® 
 
 
2-3hr 
 
 
 $50 
Not required   
 
Restriction digest Mlu I/Xho I 3hr $121 Restriction digest Mlu I/Xho I 3 hr  $121 
 
Agarose gel Electrophoresis  45min   Not Required     
 
Gel purification/quantitate fragment concentration        
     Wizard SV Gel /PCR Clean-up System column, Promega®        30min  $83  Not required     
 
Ligation (250ng destination vector) 3hr  $63 Ligation (100 ng destination vector) 3hr  $63 
 
Transformation                                                                 
      Prime+ competent E. coli, Gentaur®  $300 
Transformation  
     DH5-alpha E. coli, InVitrogen®     $72 
 
TOTAL COSTS   $631   $256  
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Ligation and transformation 
Experimental and control ligation mixes were set up in 
10μl final volume using 1:1 molar ratios of the destination 
vector:insert (100ng vector and 2.6ng insert). 100ng of the 
uncut pGIPZ vector was used as a positive control diluted 
in ligation buffer, 100ng of the Xho I/Mlu I pGIPZ cut 
vector without ligase was used to control for cutting 
efficiency of both enzymes and 100ng of the Xho I/Mlu I 
pGIPZ cut vector with 1μl of ligase were used to control 
for re-ligation of partially cut pGIPZ vector. In addition 
we had a ligation reaction without DNA added to control 
for DNA contamination in our reagents.    
 
Ligation was performed at room temperature for 3hr to 
overnight and was followed by heat-inactivation at 65oC 
for 20min. 1μl of ligation mix was transformed in DH5α 
cells (InVitrogen). 300μl of the bacterial suspension were 
plated onto LB-ampicillin plates. Plates were incubated 
over night at 37oC. The next morning, colonies on the 
plates were counted to verify successful ligation. Typical 
observed colony counts were as follows: More than 100 
colonies on the pGIPZ positive control and 20-100 
colonies on the experimental ligation or ligations. The 
pGIPZ vector cut without ligase had generally 0-10 
colonies while the pGIPZ cut vector added with ligase had 
0-20 colonies. 
 
Clone selection and verification 
The ratio between the number of colonies on the 
experimental plates and the control plate (cut pGIPZ 
vector with ligase) was calculated and multiplied by three, 
the resulting number of colonies was selected for 
screening to validate our method. Each colony picked was 
dissolved in 10μl sterile HPLC water. 5μl of this 
suspension were used to inoculate a 5ml liquid culture of 
LB-ampicillin, 2μl were dotted on a master LB-Amp plate, 
and 2μl used as template for  PCR to confirm shRNA 
insertion. The PCR amplification products are 600bp if the 
shRNA sequence is present and 500bp if it is not. The 
following PCR parameters were used: 5min at 94oC; then 
30 cycles of, 94oC for 15sec, 56oC for 30sec, 72oC for 
25sec. The pGIPZ-specific primers used were: 
 
X76 Forward: 5'ACGTCGAGGTGCCCGAAGGA 
 
M100 Reverse: 5'AAGCAGCGTATCCACATAGCGT 
 
This PCR reaction only amplifies shRNA in pGIPZ vectors. 
 
In addition to the PCR check, the pGIPZ vectors 
containing the sub-cloned shRNA were also digested to 
check for recombination of the vectors and successful 
insertion of the shRNA sequence. Sac II digestion was 
used to test for recombination of the pGIPZ vectors 
containing the sub-cloned shRNAs (expected bands: 
7927bp, 2502bp and 1259bp). Successful ligation of the 
shRNA sequence was verified by excising it from the 
recipient pGIPZ vector using Mlu I/Xho I double digestion 
(expected bands: 350bp and ~10Kb).  
 
Knock-down and western blotting procedure 
SH-SY5Y cells over-expressing APP-Gal4 were 
transiently transfected or transduced as previously 
described (Zhang et al, 2007). Transfection was performed 
with pSM2 plasmids targeting APP or a non-silencing 
control (Open Biosystems), and with pGIPZ plasmids 
containing the same shRNA sequences as the pSM2 
vectors that were sub-cloned following our protocol. 
Transfection was performed with Arrrest-In® (Open 
Biosystems®) transfection reagent. Whole cell lysates were 
prepared in ice-cold radio immuno-precipitation buffer 
(150mM NaCl, 1%, v/v, NP40, 0.5%, v/v, DOC, 1%, w/v, 
SDS, 50mM Tris, pH 8.0) supplemented with Halt cocktail 
of protease and phosphatase inhibitors (ThermoFisher). 
The western blotting procedure has been previously 
described (Zhang et al, 2007). We used anti-APP antibody 
clone A8717 (Sigma) and anti-actin antibody (Sigma) at 
1:2000 and 1:15,000 dilution, respectively. The same cell 
line was transduced with viruses obtained following the 
packaging protocol provided by Open Biosystems® but 
using the same sub-cloned pGIPZ vectors previously 
employed for the transfection. 
 
RESULTS AND DISCUSSION 
 
Our protocol was successfully used to sub-clone shRNA 
constructs into pGIPZ vectors. As an example, one 
experimental transformation plate had approximately fifty 
colonies, the control cut pGIPZ vector with ligase had 6 
colonies so the ratio of clones containing the insert to the 
empty ones was 50/6=8.3. Twenty-five colonies were 
screened with PCR using pGIPZ specific primers that 
amplify the shRNA sequence. In Figure 1A we show 16 of 
the 25 PCR reactions with the appropriate controls run on 
an agarose gel stained with ethidium bromide. Two clones 
did not show amplification (not shown), one clone resulted 
empty (Figure 1A; lane 4) and three clones showed sub-
optimal amplification (Figure 1A; lanes 13, 14, 15). All 
the remaining clones showed the correct band size with 
efficient amplification. In summary, out of the 25 colonies 
screened, only 3 did not show correct amplification 
confirming a ratio of 25/3=8.3 clones containing insert to 
the false positive ones. Following PCR we checked the 
recipient vectors for both recombination and the presence 
of the insert. In Figure 1B we show the results of Sac II 
restriction digestion of 16 clones that showed the correct 
amplicon following PCR. These 16 clones did not show 
signs of recombination. After checking for recombination 
of the recipient plasmid, we also checked for correct 
ligation of the shRNA sequence. In Figure 1C we used 
restriction digestion to excise the inserted shRNA from the 
clones and we confirmed the correct ligation in the new 
vector. All the clones that showed the correct PCR 
amplicon also showed correct restriction patterns making 
restriction digest unnecessary. Insertion of the shRNA 
sequences was also verified by sequencing. 
 
In order to ensure that our sub-cloned constructs main-
tained silencing activity, comparable to the original pSM2 
plasmids, we transfected, using the same procedure, both 
vectors in the same cell line. Moreover, we assessed if viral 
transduction of the cells also showed effective silencing. 
Figure 2 shows the detection of Amyloid Precursor Protein 
(APP) by western blotting in SH-SY5Y APP-Gal4 cells 
following transfection of shRNA constructs in pSM2 or 
pGIPZ vectors or transduction with pGIPZ containing viral 
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B: 
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Figure 1. Gel electrophoresis analysis of PCR and restriction 
endonuclease-digested products of the putative clones. A. 
Successful subcloning was assessed by colony PCR, using 
pGIPZ specific PCR primers. 16 putative clones were picked 
from a transformation plate. The last two samples are a positive 
control (+) (a pGIPZ vector containing a shRNA sequence that 
had been previously verified by nucleotide sequencing) and the 
pGIPZ empty vector (E). Clone 4 does not contain the insert 
while clones 13, 14 and but showed inefficient PCR 
amplification. These PCR results confirm that the shRNA is 
inserted in the pGIPZ destination vector.  B. Sac II restriction 
endonuclease digest of positive clones identified in panel (A) 
shows no signs of pGIPZ recombination. We observe the 
expected bands: 7927bp, 2502bp and 1259bp. C. Mlu I/Xho I 
restriction digest shows the inserted 350bp band corresponding to 
the shRNA excised from the destination pGIPZ vector. 
 
 
 
   A:   B:   C: 
 
Lentivirusdelivered 
pGIPZ‐shRNA
APP CTRL
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Figure 2. Western blot analysis of cells transfected or transduced 
with shRNA constructs in different vectors. Knock-down of the 
Amyloid Precursor Protein (APP) is assessed in the human 
neuroblastoma cell line SH-SY5Y. APP is over-expressed in this 
cell line and is detected as two bands that are fully-glycosylated 
(top migrating band) and partially-glycosylated (lower migrating 
band) states of APP, respectively. The anti-human APP antibody 
A8717 was used. Actin levels were used as a loading control. A 
and B. Transfection of either pSM2 vectors (A) containing the 
shRNA targeting APP or pGIPZ vectors (B), containing the same 
shRNA construct, efficiently decreases APP total levels 
compared to non silencing control shRNA. C. APP levels are 
also efficiently decreased through transduction of the cells with 
viral particles obtained with the subcloned shRNA pGIPZ 
vectors. APP: Amyloid Precursor Protein; CTRL: non-silencing 
shRNA. 
particles. The silencing efficiency of the shRNA constructs 
in their original pSM2 vectors (Figure 2A) is comparable 
with the one of the shRNA subcloned in the pGIPZ vector 
(Figure 2B) showing that the construct was successfully 
inserted and does not loose targeting ability. Finally, we 
show that the pGIPZ construct can also efficiently 
decrease APP levels when delivered via viral particles 
(Figure 2C). 
 
CONCLUSIONS 
 
The RNAi Resource Center at Drexel University 
purchased from Open Biosystems the pSM2 retroviral 
library targeting ~65,000 human genes. Our sub-cloning 
method has been applied successfully to ~100 shRNA 
sequences of interest that were transferred from the pSM2 
vector into the pGIPZ empty vector. The protocol proved 
successful in the hands of different operators and 80% of 
the shRNA constructs were sub-cloned successfully on the 
first attempt. Unsuccessful sub-cloning was largely due to 
the presence of recombination in the pSM2 donor vectors.  
 
pGIPZ vectors containing shRNAs obtained from our 
subcloning procedure produced high titer viruses (106 
infectious units/ml) that were used to transduce hard-to-
transfect cell lines and primary neurons. We believe that 
our protocol will be helpful to all the investigators who 
have invested in the now outdated pSM2 libraries allowing 
them to efficiently upgrading their shRNA sequences into 
the new lentiviral vectors. Given the simplicity of the steps 
involved, it would probably be possible to implement high 
throughput methods to automate the rapid transfer of many 
shRNA simultaneously. This procedure offers 
approximately 60% cost savings and substantial time 
savings compared to the suggested protocol. 
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ORGANIZATIONAL INVOLVEMENT/PERSONAL DEVELOPMENT 
2008/2009  
• President of the Graduate Student Association, Drexel University. 
  - 212 - 
212 
o Obtained Health Insurance coverage for all PhD students. 
o Increased Graduate Student Association budget by ~30%. 
• Chair of the Mentor Award Committee, Drexel University. 
• Member, Student Health Advisory Committee, Drexel University. 
• Member, Committee for Teaching Assistant Awards, Drexel University. 
• Advanced training for leadership excellence based on Dr. John Maxwell’s book “The 21 
Irrefutable Laws Of Leadership”. 
2007/2008  
• President, Biology Graduate Student Association, Drexel University. 
• Member, Student Health Advisory Committee, Drexel University. 
• Member, Committee for Teaching Assistant Awards and preparation course. 
• Personal Leadership Certificate, Creating Excellent Organizations Program for development 
of personal and professional skills, Drexel University. 
• Professional Development Workshops: “Delegating for Results” by UNISYS, “Political 
Savvy”, Frank Perras, Career Concepts consulting company.    
2006/2007   
• Secretary, Biology Graduate Student Association, Drexel University.  
2005/2006  
• Social Chair, Biology Graduate Student Association, Drexel University.  
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